<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="55288"><DrugName>trametinib</DrugName><DrugNamesKey><Name id="43011338">Mekinist</Name><Name id="42955580">trametinib</Name><Name id="42955577">trametinib dimethyl sulfoxide</Name></DrugNamesKey><DrugSynonyms><Name><Value>MEK inhibitor (cancer, inflammation), GlaxoSmithKline</Value></Name><Name><Value>Erk inhibitor (cancer, inflammation), Japan Tobacco/GlaxoSmithKline</Value></Name><Name><Value>Mark inhibitor (cancer, inflammation), Japan Tobacco/GlaxoSmithKline</Value></Name><Name><Value>GSK-1120212</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MEK inhibitor (oral, cancer), GlaxoSmithKline</Value></Name><Name><Value>JTP-74057 DMSO</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GSK-1120212B</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GSK-212</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>trametinib DMSO</Value></Name><Name><Value>trametinib dimethyl sulfoxide</Value><Types><Type>USAN</Type></Types></Name><Name><Value>trametinib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>Mekinist</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>NSC-763093</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TMT-212</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1187431-43-1</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>871700-17-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17327">Japan Tobacco Inc</CompanyOriginator><CompaniesPrimary><Company id="23137">Novartis AG</Company></CompaniesPrimary><CompaniesSecondary><Company id="17327">Japan Tobacco Inc</Company><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="55288" type="Drug"><TargetEntity id="447139" type="siDrug"></TargetEntity><TargetEntity id="415494" type="siDrug">Trametinib dimethyl sulfoxide</TargetEntity></SourceEntity><SourceEntity id="17327" type="Company"><TargetEntity id="4295879109" type="organizationId">Japan Tobacco Inc</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"></TargetEntity><TargetEntity id="D005910" type="MeSH"></TargetEntity><TargetEntity id="-1503483999" type="omicsDisease"></TargetEntity><TargetEntity id="680" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1134" type="ciIndication"><TargetEntity id="C73" type="ICD10"></TargetEntity><TargetEntity id="193" type="ICD9"></TargetEntity><TargetEntity id="10066474" type="MEDDRA"></TargetEntity><TargetEntity id="D013964" type="MeSH"></TargetEntity><TargetEntity id="-845587053" type="omicsDisease"></TargetEntity><TargetEntity id="649" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1516" type="ciIndication"><TargetEntity id="10055111" type="MEDDRA"></TargetEntity><TargetEntity id="D001661" type="MeSH"></TargetEntity><TargetEntity id="-1032913655" type="omicsDisease"></TargetEntity><TargetEntity id="577" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1736" type="ciIndication"><TargetEntity id="C91.4" type="ICD10"></TargetEntity><TargetEntity id="10019053" type="MEDDRA"></TargetEntity><TargetEntity id="D007943" type="MeSH"></TargetEntity><TargetEntity id="58017" type="ORPHANET"></TargetEntity><TargetEntity id="-1237098648" type="omicsDisease"></TargetEntity><TargetEntity id="693" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="199" type="ciIndication"><TargetEntity id="10024288" type="MEDDRA"></TargetEntity><TargetEntity id="D007938" type="MeSH"></TargetEntity><TargetEntity id="-609576380" type="omicsDisease"></TargetEntity><TargetEntity id="683" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"></TargetEntity><TargetEntity id="D008223" type="MeSH"></TargetEntity><TargetEntity id="-386134440" type="omicsDisease"></TargetEntity><TargetEntity id="698" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2399" type="ciIndication"><TargetEntity id="10001141" type="MEDDRA"></TargetEntity><TargetEntity id="D000230" type="MeSH"></TargetEntity><TargetEntity id="-1620546969" type="omicsDisease"></TargetEntity><TargetEntity id="656" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3205" type="ciIndication"><TargetEntity id="10051066" type="MEDDRA"></TargetEntity><TargetEntity id="D046152" type="MeSH"></TargetEntity><TargetEntity id="44890" type="ORPHANET"></TargetEntity><TargetEntity id="-1743085733" type="omicsDisease"></TargetEntity><TargetEntity id="668" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3256" type="ciIndication"><TargetEntity id="10025670" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="3257" type="ciIndication"><TargetEntity id="10027480" type="MEDDRA"></TargetEntity><TargetEntity id="708" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3521" type="ciIndication"><TargetEntity id="Q85.01" type="ICD10"></TargetEntity><TargetEntity id="D009456" type="MeSH"></TargetEntity><TargetEntity id="636" type="ORPHANET"></TargetEntity><TargetEntity id="-1668622175" type="omicsDisease"></TargetEntity><TargetEntity id="2661" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3658" type="ciIndication"><TargetEntity id="10052358" type="MEDDRA"></TargetEntity><TargetEntity id="595" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3664" type="ciIndication"><TargetEntity id="10036909" type="MEDDRA"></TargetEntity><TargetEntity id="639" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"></TargetEntity><TargetEntity id="613" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3671" type="ciIndication"><TargetEntity id="10055097" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="3672" type="ciIndication"><TargetEntity id="10055114" type="MEDDRA"></TargetEntity><TargetEntity id="2341" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3737" type="ciIndication"><TargetEntity id="D009373" type="MeSH"></TargetEntity><TargetEntity id="-720598874" type="omicsDisease"></TargetEntity><TargetEntity id="603" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3769" type="ciIndication"><TargetEntity id="142" type="ORPHANET"></TargetEntity><TargetEntity id="-757359232" type="omicsDisease"></TargetEntity><TargetEntity id="1936" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="427" type="ciIndication"><TargetEntity id="C53" type="ICD10"></TargetEntity><TargetEntity id="10008342" type="MEDDRA"></TargetEntity><TargetEntity id="D002583" type="MeSH"></TargetEntity><TargetEntity id="-837567682" type="omicsDisease"></TargetEntity><TargetEntity id="590" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"></TargetEntity><TargetEntity id="D015179" type="MeSH"></TargetEntity><TargetEntity id="-1280257855" type="omicsDisease"></TargetEntity><TargetEntity id="594" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="4764" type="Action"><TargetEntity id="1227" type="Mechanism">Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2; MEK2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4762" type="Action"><TargetEntity id="1226" type="Mechanism">Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01286" type="ciTarget"><TargetEntity id="128149047456043" type="siTarget">Dual specificity mitogen-activated protein kinase kinase 1</TargetEntity><TargetEntity id="486" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01287" type="ciTarget"><TargetEntity id="53991183556053" type="siTarget">Dual specificity mitogen-activated protein kinase kinase 2</TargetEntity><TargetEntity id="487" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Stage IV melanoma - US - Jul-2013</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1108">Glioma</Indication><Indication id="1134">Thyroid tumor</Indication><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="1516">Biliary cancer</Indication><Indication id="1736">Hairy cell leukemia</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="199">Leukemia</Indication><Indication id="205">Melanoma</Indication><Indication id="2399">Adenocarcinoma</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="3205">Gastrointestinal stromal tumor</Indication><Indication id="3256">Stage III melanoma</Indication><Indication id="3257">Stage IV melanoma</Indication><Indication id="3521">Neurofibromatosis type I</Indication><Indication id="3658">Metastatic colorectal cancer</Indication><Indication id="3664">Metastatic prostate cancer</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="3671">Metastatic rectal cancer</Indication><Indication id="3672">Metastatic colon cancer</Indication><Indication id="3737">Germ cell and embryonic cancer</Indication><Indication id="3769">Anaplastic thyroid cancer</Indication><Indication id="427">Uterine cervix tumor</Indication><Indication id="725">Solid tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="203">Lymphoma</Indication><Indication id="651">Cancer</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="4764">MEK-2 protein kinase inhibitor</Action><Action id="4762">MEK-1 protein kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="7293">Synergist</Action><Action id="1545">Anticancer</Action><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="751">Film coating</Technology><Technology id="595">Tablet formulation</Technology></Technologies><LastModificationDate>2019-07-02T06:02:49.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>2006-04-21T11:38:41.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed  and launched by &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; (GSK) (under license from &lt;ulink linkID="17327" linkType="Company"&gt;Japan Tobacco&lt;/ulink&gt;), and now marketed by  &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; following its acquisition of GSK's oncology products,   trametinib DMSO (GSK-1120212; JTP-74057 DMSO solvate; NSC-763093; Mekinist), is a MEK (Erk/Mark) -1 and -2 protein kinase inhibitor [&lt;ulink linkID="1514229" linkType="Reference"&gt;1514229&lt;/ulink&gt;]. The product is indicated in the US as a single agent or in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; (Tafinlar) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. It is also indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection, for the treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test, and for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options [&lt;ulink linkID="1430654" linkType="Reference"&gt;1430654&lt;/ulink&gt;].      In the EU, the drug is indicated as a single agent or in combination with dabrafenib for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation, and in combination with dabrafenib for BRAF V600-positive advanced or metastatic NSCLC as detected by an FDA-approved test  [&lt;ulink linkID="1575306" linkType="Reference"&gt;1575306&lt;/ulink&gt;], [&lt;ulink linkID="1913566" linkType="Reference"&gt;1913566&lt;/ulink&gt;]. In Japan, trametinib is indicated in combination with dabrafenib for the treatment of BRAF V600-positive malignant melanoma and BRAF V600-positive advanced or metastatic NSCLC and as postoperative adjuvant therapy for BRAF mutation-positive malignant melanoma     [&lt;ulink linkID="2103111" linkType="Reference"&gt;2103111&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By July 2013, the drug had been launched as a single agent in the US for BRAF V600E or V600K mutated unresectable or metastatic melanoma [&lt;ulink linkID="1456076" linkType="Reference"&gt;1456076&lt;/ulink&gt;]. In June 2014, the EC approved the drug as a monotherapy for unresectable or metastatic melanoma with a BRAF V600 mutation [&lt;ulink linkID="1575306" linkType="Reference"&gt;1575306&lt;/ulink&gt;], [&lt;ulink linkID="1576533" linkType="Reference"&gt;1576533&lt;/ulink&gt;]; the drug was presumably launched shortly after approval.&lt;/para&gt;&lt;para&gt;In January 2014, combination use of   trametinib plus &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; was granted accelerated approval by the FDA  for unresectable  or metastatic melanoma with BRAF V600E/K mutations as detected by an FDA-approved test [&lt;ulink linkID="1514072" linkType="Reference"&gt;1514072&lt;/ulink&gt;], [&lt;ulink linkID="1514730" linkType="Reference"&gt;1514730&lt;/ulink&gt;]; in November 2015, the FDA granted full approval [&lt;ulink linkID="1514072" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1715252" linkType="Reference"&gt;1715252&lt;/ulink&gt;]. In August 2015, the EMA approved the combination use of dabrafenib plus trametinib for unresectable or metastatic melanoma with a BRAF V600 mutation [&lt;ulink linkID="1690501" linkType="Reference"&gt;1690501&lt;/ulink&gt;], [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]. In May 2016, trametinib was launched in Japan in combination with dabrafenib for the treatment of BRAF V600 mutation-positive malignant melanoma [&lt;ulink linkID="1767636" linkType="Reference"&gt;1767636&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, trametinib in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; was approved in the US for the adjuvant treatment of stage III melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection [&lt;ulink linkID="2029260" linkType="Reference"&gt;2029260&lt;/ulink&gt;]. In July 2018, the combination of dabrafenib with trametinib was approved in Japan as a postoperative adjuvant therapy for BRAF mutation-positive malignant melanoma [&lt;ulink linkID="2050817" linkType="Reference"&gt;2050817&lt;/ulink&gt;]. In August 2018,  the drug in combination with dabrafenib was approved in the EU for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection [&lt;ulink linkID="2067367" linkType="Reference"&gt;2067367&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, the EC approved &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; in combination with trametinib for the treatment of BRAF V600-positive advanced or metastatic NSCLC [&lt;ulink linkID="1913566" linkType="Reference"&gt;1913566&lt;/ulink&gt;]. In June 2017, the FDA approved dabrafenib in combination with trametinib for the treatment of BRAF V600-positive advanced or metastatic NSCLC [&lt;ulink linkID="1940133" linkType="Reference"&gt;1940133&lt;/ulink&gt;]. In March 2018, dabrafenib in combination with trametinib was approved for the treatment of BRAF V600-positive advanced or metastatic NSCLC in Japan [&lt;ulink linkID="2016801" linkType="Reference"&gt;2016801&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2018, the FDA approved trametinib in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for the treatment of BRAF V600E mutation-positive ATC that cannot be removed by surgery or is metastatic [&lt;ulink linkID="2030753" linkType="Reference"&gt;2030753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development in other cancers is ongoing.  In July 2009, a phase II trial in a range of leukemias was initiated [&lt;ulink linkID="1045072" linkType="Reference"&gt;1045072&lt;/ulink&gt;]; in May 2011, a phase II rollover trial was initiated to allow patients with solid tumors or leukemias who were participating in a clinical trial and benefiting from the drug continued access [&lt;ulink linkID="2097299" linkType="Reference"&gt;2097299&lt;/ulink&gt;]. In September 2010, a phase II trial in first-line pancreatic cancer began [&lt;ulink linkID="1141173" linkType="Reference"&gt;1141173&lt;/ulink&gt;]; in April 2016, a phase II trial in advanced pancreatic cancer was initiated [&lt;ulink linkID="1655393" linkType="Reference"&gt;1655393&lt;/ulink&gt;]. In January 2015, a phase II trial in combination with &lt;ulink linkID="43738" linkType="Drug"&gt;pazopanib&lt;/ulink&gt;, in advanced gastrointestinal stromal tumors (GIST) was planned to be initiated in March 2015 [&lt;ulink linkID="1635892" linkType="Reference"&gt;1635892&lt;/ulink&gt;]. However, in March 2017, the trial was withdrawn prior to enrollment [&lt;ulink linkID="1635892" linkType="Reference"&gt;1635892&lt;/ulink&gt;]. In February 2014, a phase II trial was initiated in cervical cancer patients [&lt;ulink linkID="1503966" linkType="Reference"&gt;1503966&lt;/ulink&gt;]; however, in June 2015, recruitment was suspended  due to drug supply [&lt;ulink linkID="1503966" linkType="Reference"&gt;1503966&lt;/ulink&gt;], and by August 2016, recruitment to the trial had been terminated  [&lt;ulink linkID="1666045" linkType="Reference"&gt;1666045&lt;/ulink&gt;];  in November 2017,  the trial  completed. In December 2017, a compassionate use trial was initiated in  patients with progressive metastatic castrate resistant prostate cancer (mCRPC) [&lt;ulink linkID="1995660" linkType="Reference"&gt;1995660&lt;/ulink&gt;]. In March 2018, an investigator-initiated, company-sponsored phase II trial of trametinib in combination with &lt;ulink linkID="81193" linkType="Drug"&gt;durvalumab&lt;/ulink&gt; was initiated in patients with microsatellite stable (MSS) metastatic colon and colorectal cancer [&lt;ulink linkID="2049230" linkType="Reference"&gt;2049230&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug was previously being developed in other cancer settings as combinations. In March 2013, a phase I/II trial in colorectal cancer  was initiated [&lt;ulink linkID="1387848" linkType="Reference"&gt;1387848&lt;/ulink&gt;]; in January 2017,  phase II development was ongoing and filings for  trametinib plus dabrafenib for colorectal cancer were expected in 2020 [&lt;ulink linkID="1895140" linkType="Reference"&gt;1895140&lt;/ulink&gt;], [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]; in June 2017, a phase I/II trial of trametinib was planned in combination with  &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; and &lt;ulink linkID="36630" linkType="Drug"&gt;ipilimumab&lt;/ulink&gt;  in patients with metastatic colorectal cancer with MSS tumors  where the tumors were proficient in mismatch repair (MSS mCRC pMMR) [&lt;ulink linkID="1934696" linkType="Reference"&gt;1934696&lt;/ulink&gt;], [&lt;ulink linkID="1934528" linkType="Reference"&gt;1934528&lt;/ulink&gt;]; however, in January 2018, Novartis noted that development of the combination in the BRAF V600-positive colorectal cancer had been discontinued [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;GSK was previously also investigating trametinib DMSO in inflammation [&lt;ulink linkID="662918" linkType="Reference"&gt;662918&lt;/ulink&gt;]; however, this indication was not listed on the February 2009 pipeline [&lt;ulink linkID="989587" linkType="Reference"&gt;989587&lt;/ulink&gt;] and development  is presumed to have been discontinued. In July 2008, a phase I trial was initiated in lymphoma [&lt;ulink linkID="945050" linkType="Reference"&gt;945050&lt;/ulink&gt;]; no further development was reported in this setting. A phase I/II trial evaluating efficacy in solid tumors and multiple myeloma began in November 2011 [&lt;ulink linkID="1352404" linkType="Reference"&gt;1352404&lt;/ulink&gt;]. In June 2013, data were presented [&lt;ulink linkID="1425047" linkType="Reference"&gt;1425047&lt;/ulink&gt;]; however, no further development was reported for multiple myeloma.&lt;/para&gt;&lt;para&gt;Novartis is also investigating a &lt;ulink linkID="104644" linkType="Drug"&gt;Captisol-enabled oral liquid formulation of trametinib&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;Trametinib has Orange Book-listed patent coverage in the US to 2025 (&lt;ulink linkID="PA3076630" linkType="Patent"&gt;US-7378423&lt;/ulink&gt;). In January 2016, Novartis stated that in the US, the compound patent will expire in 2025 (with pending patent term extension in 2027), a patent on the method of use in 2025, a patent on the formulation in 2032, regulatory exclusivity to 2018 and orphan drug exclusivity to 2020. For the combination of &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; plus trametinib, a patent covering the use of the combination will expire in 2030, regulatory exclusivity in 2017 and orphan drug exclusivity in 2021 [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]. In January 2017, Novartis noted that there was no generic competition either for trametinib nor for the combination of dabrafenib plus trametinib [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]; in January 2018, that was still the case. At that time, Novartis noted that two additional US formulation patents covering the single agent and expiring in 2032 are in force. US regulatory exclusivities for the combination with dabrafenib on melanoma and NSCLC are to expire in 2018 and 2020, respectively, and orphan drug exclusivities on melanoma with certain mutations and on NSCLC expire in 2021 and 2024 [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]. By January 2019, the US patent term extension to 2027 of the compound patent had been granted [&lt;ulink linkID="2116311" linkType="Reference"&gt;2116311&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In January 2016, Novartis stated that in the EU, patents on the compound and method of use will expire in 2025 (with SPC in 2029) and regulatory exclusivity in 2025. For the combination of &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; plus trametinib, regulatory exclusivity of the combination will expire in 2025 [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]. In January 2017, Novartis noted that there was no generic competition either for trametinib nor for the combination of dabrafenib plus trametinib [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]; in January 2018, that was still the case.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In January 2016, Novartis stated that in Japan, the compound patent will expire in 2025, a patent on the method of use in 2025 and a patent on the formulation in 2031. For the combination of &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; plus trametinib, a patent covering the use of the combination will expire in 2030 [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]. In January 2017, Novartis noted that there was no generic competition either for trametinib nor for the combination of dabrafenib plus trametinib [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]; in January 2018, that was still the case.&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Melanoma&lt;/subtitle&gt;By  December 2017, an sNDA had been filed for &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; in combination with trametinib for the adjuvant treatment of stage III melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, following complete resection; at that time,  the US FDA  accepted the filing for Priority Review. The filing was based on results from the COMBI-AD trial    [&lt;ulink linkID="1993442" linkType="Reference"&gt;1993442&lt;/ulink&gt;]. In October 2017, the  FDA granted Breakthrough Therapy designation for dabrafenib in combination with trametinib for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection; the designation  was granted based on the results from the  COMBI-AD trial  [&lt;ulink linkID="1973359" linkType="Reference"&gt;1973359&lt;/ulink&gt;], [&lt;ulink linkID="1973328" linkType="Reference"&gt;1973328&lt;/ulink&gt;], [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]. In April 2018, dabrafenib in combination with trametinib was approved in that setting  [&lt;ulink linkID="2029260" linkType="Reference"&gt;2029260&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2013, the company submitted an  sNDA to the FDA for the use of trametinib in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 E or K mutation [&lt;ulink linkID="1449851" linkType="Reference"&gt;1449851&lt;/ulink&gt;]. In September 2013, the FDA granted Priority Review designation [&lt;ulink linkID="1477518" linkType="Reference"&gt;1477518&lt;/ulink&gt;], [&lt;ulink linkID="1695812" linkType="Reference"&gt;1695812&lt;/ulink&gt;]. In January 2014, the combination of trametinib plus dabrafenib was granted accelerated approval for the treatment of unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations; approval was contingent on data from the ongoing Combi-D trial  [&lt;ulink linkID="1514072" linkType="Reference"&gt;1514072&lt;/ulink&gt;], [&lt;ulink linkID="1514730" linkType="Reference"&gt;1514730&lt;/ulink&gt;]. In February 2015, final positive survival data from the COMBI-d trial were reported; the data were to be submitted to regulatory authorities for review in the coming months [&lt;ulink linkID="1631873" linkType="Reference"&gt;1631873&lt;/ulink&gt;]; by July 2015, a November 2015 PDUFA date had been set for conversion to full approval following review of the COMBI-d data [&lt;ulink linkID="1680469" linkType="Reference"&gt;1680469&lt;/ulink&gt;]. In November 2015, combination use of   trametinib plus dabrafenib was granted full approval by the FDA  for unresectable  or metastatic melanoma with BRAF V600E/K mutations as detected by an FDA-approved test [&lt;ulink linkID="1514072" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1715252" linkType="Reference"&gt;1715252&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2012, GSK filed for US approval of trametinib for unresectable or metastatic melanoma with BRAF-V600 mutations [&lt;ulink linkID="1313077" linkType="Reference"&gt;1313077&lt;/ulink&gt;], [&lt;ulink linkID="1313498" linkType="Reference"&gt;1313498&lt;/ulink&gt;]; in May 2013, the PDUFA goal date was extended by 3 months to September 13, 2013 to allow sufficient time for the FDA to review additional manufacturing data submitted to the FDA  [&lt;ulink linkID="1414016" linkType="Reference"&gt;1414016&lt;/ulink&gt;]. In May 2013, trametinib was approved for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations [&lt;ulink linkID="1430300" linkType="Reference"&gt;1430300&lt;/ulink&gt;], [&lt;ulink linkID="1430654" linkType="Reference"&gt;1430654&lt;/ulink&gt;], [&lt;ulink linkID="1430684" linkType="Reference"&gt;1430684&lt;/ulink&gt;],  [&lt;ulink linkID="1431652" linkType="Reference"&gt;1431652&lt;/ulink&gt;]. By July 2013, the drug had been launched in the US [&lt;ulink linkID="1456076" linkType="Reference"&gt;1456076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, the FDA granted trametinib Orphan Drug designation for the treatment of stage IIb to stage IV melanoma [&lt;ulink linkID="1334884" linkType="Reference"&gt;1334884&lt;/ulink&gt;]. In September 2012, Orphan designation was granted to trametinib plus dabrafenib for stage IIb to IV melanoma [&lt;ulink linkID="1334880" linkType="Reference"&gt;1334880&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In 3Q16, a filing was submitted in the US for &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; + trametinib for BRAF V600E mutation-positive NSCLC [&lt;ulink linkID="1866715" linkType="Reference"&gt;1866715&lt;/ulink&gt;]; in November 2016, the FDA granted Priority Review for that indication as detected by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy [&lt;ulink linkID="1895140" linkType="Reference"&gt;1895140&lt;/ulink&gt;], [&lt;ulink linkID="1903463" linkType="Reference"&gt;1903463&lt;/ulink&gt;], [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]. In June 2017, the FDA approved dabrafenib in combination with dabrafenib for the treatment of BRAF V600-positive advanced or metastatic NSCLC [&lt;ulink linkID="1940133" linkType="Reference"&gt;1940133&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2015, the FDA granted the combination regimen of &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; and trametinib Breakthrough Therapy status for BRAF V600E mutation-positive NSCLC [&lt;ulink linkID="1678993" linkType="Reference"&gt;1678993&lt;/ulink&gt;]. In October 2015, the FDA granted a combination of dabrafenib and trametinib Orphan designation for the treatment of BRAF mutation-positive NSCLC [&lt;ulink linkID="1709328" linkType="Reference"&gt;1709328&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In January 2016,  filings for  trametinib plus &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for colorectal cancer were expected in 2020 or later [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]; in January 2017, filings were expected in 2020 [&lt;ulink linkID="1895140" linkType="Reference"&gt;1895140&lt;/ulink&gt;], [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]; however, in January 2018, Novartis noted that development of the combination in the BRAF V600-positive colorectal cancer had been discontinued [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Thyroid cancer&lt;/subtitle&gt;By May 2018, the FDA had granted Priority Review and Breakthrough therapy designation for the combination of &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; and trametinib  for the treatment of BRAF V600E mutation-positive ATC that cannot be removed by surgery or is metastatic. Later that month, the FDA approved  the combination therapy in that setting. The approval was based on data from an open-label clinical trial [&lt;ulink linkID="2030753" linkType="Reference"&gt;2030753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, the FDA granted the combination of  trametinib and dabrafenib Orphan designation for the treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation [&lt;ulink linkID="1796564" linkType="Reference"&gt;1796564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Melanoma&lt;/subtitle&gt;In 4Q17, a filing for adjuvant treatment of high-risk BRAF V600+ melanoma were submitted in the EU [&lt;ulink linkID="1999482" linkType="Reference"&gt;1999482&lt;/ulink&gt;]. In July 2018, the EMA's CHMP granted a positive opinion for the approval of the drug in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection. The recommendation was based on the results of the COMBI-AD study [&lt;ulink linkID="2057887" linkType="Reference"&gt;2057887&lt;/ulink&gt;], [&lt;ulink linkID="2058243" linkType="Reference"&gt;2058243&lt;/ulink&gt;]. In August 2018,  the drug in combination with dabrafenib was approved in the EU for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection [&lt;ulink linkID="2067367" linkType="Reference"&gt;2067367&lt;/ulink&gt;]. At that time, the drug was also approved, and presumably launched, in Switzerland in that setting [&lt;ulink linkID="2073891" linkType="Reference"&gt;2073891&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2015, the CHMP of the EMA recommended approval of the &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; plus trametinib regime for adult patients with unresectable or metastatic melanoma with a BRAF V600 	mutation; the EC's final decision was expected within 3 months [&lt;ulink linkID="1680469" linkType="Reference"&gt;1680469&lt;/ulink&gt;], [&lt;ulink linkID="1680288" linkType="Reference"&gt;1680288&lt;/ulink&gt;]. In August 2015, the combination was approved by the EMA [&lt;ulink linkID="1690501" linkType="Reference"&gt;1690501&lt;/ulink&gt;], [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]. In August 2018, the drug was approved, and presumably launched, in Switzerland in that setting [&lt;ulink linkID="2073891" linkType="Reference"&gt;2073891&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2013, an MAA was submitted in the EU for trametinib use as monotherapy or in combination with dabrafenib, for the treatment of adults with unresectable or metastatic melanoma which express BRAF-V600 mutations. The filing was granted accelerated assessment by the EMA's CHMP [&lt;ulink linkID="1368381" linkType="Reference"&gt;1368381&lt;/ulink&gt;]. In May 2013, GSK stated that new manufacturing information submitted to the FDA would also be shared with the EMA [&lt;ulink linkID="1414016" linkType="Reference"&gt;1414016&lt;/ulink&gt;]. However, in March 2014, the MAA for the trametinib plus dabrafenib combination was withdrawn after the EMA's review indicated that the data  were insufficient to determine a positive benefit-risk balance of the combination. At that time, the MAA for trametinib use as monotherapy remained under review, and GSK planned to resubmit the MAA for the combination when additional data from the phase III program became available [&lt;ulink linkID="1539380" linkType="Reference"&gt;1539380&lt;/ulink&gt;]. In April 2014, a positive opinion was issued by the EMA's CHMP, which recommended marketing authorization for trametinib as monotherapy [&lt;ulink linkID="1550746" linkType="Reference"&gt;1550746&lt;/ulink&gt;]. In June 2014, the EC approved the drug as monotherapy for treating adults with unresectable or metastatic melanoma with a BRAF V600 mutation [&lt;ulink linkID="1575306" linkType="Reference"&gt;1575306&lt;/ulink&gt;], [&lt;ulink linkID="1576533" linkType="Reference"&gt;1576533&lt;/ulink&gt;]; the drug was presumably launched shortly after approval. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In 3Q16, a filing was submitted in the EU for &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; + trametinib for BRAF V600E mutation-positive NSCLC [&lt;ulink linkID="1866715" linkType="Reference"&gt;1866715&lt;/ulink&gt;]; in February 2017, the EMA's CHMP recommended approval in that setting  [&lt;ulink linkID="1903463" linkType="Reference"&gt;1903463&lt;/ulink&gt;]. In April 2017, the combination was approved in the EU, Iceland and Norway for BRAF V600-positive advanced or metastatic NSCLC, and presumably launched at that time [&lt;ulink linkID="1913566" linkType="Reference"&gt;1913566&lt;/ulink&gt;], [&lt;ulink linkID="2136525" linkType="Reference"&gt;2136525&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 3Q16, a filing was submitted in Switzerland for &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; + trametinib for BRAF V600E mutation-positive NSCLC [&lt;ulink linkID="1866715" linkType="Reference"&gt;1866715&lt;/ulink&gt;]. In August 2018, the was  approved, and presumably launched, in Switzerland in that setting [&lt;ulink linkID="2073891" linkType="Reference"&gt;2073891&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In January 2016,  filings for  trametinib plus &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for colorectal cancer were expected in 2020 or later [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]; in January 2017, filings were expected in 2020 [&lt;ulink linkID="1895140" linkType="Reference"&gt;1895140&lt;/ulink&gt;], [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]; however, in January 2018, Novartis noted that development of the combination in the BRAF V600-positive colorectal cancer had been discontinued [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Melanoma&lt;/subtitle&gt;In 4Q17, a filing for adjuvant treatment of high-risk BRAF V600+ melanoma was submitted in Japan [&lt;ulink linkID="1999482" linkType="Reference"&gt;1999482&lt;/ulink&gt;]; in May 2018, The Ministry of Health, Labour and Welfare's second committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council (PAFSC) recommended approval of trametinib for for postoperative adjuvant therapy of malignant melanoma, in combination with dabrafenib [&lt;ulink linkID="2038307" linkType="Reference"&gt;2038307&lt;/ulink&gt;].  In July 2018, the combination therapy was approved in Japan for that indication, based on data from the global phase III COMBI-AD trial [&lt;ulink linkID="2050817" linkType="Reference"&gt;2050817&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, trametinib was filed for approval in Japan for the treatment of BRAF V600 mutation-positive malignant melanoma [&lt;ulink linkID="1654583" linkType="Reference"&gt;1654583&lt;/ulink&gt;]. In February 2016, Japan's Pharmaceutical Affairs and Food Sanitation Council's Second Committee recommended approval of trametinib for that indication [&lt;ulink linkID="1734166" linkType="Reference"&gt;1734166&lt;/ulink&gt;]. In March 2016, trametinib was granted approval in Japan in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for the treatment of BRAF V600 mutation-positive malignant melanoma [&lt;ulink linkID="1746725" linkType="Reference"&gt;1746725&lt;/ulink&gt;]. In May 2016, launch occurred in Japan [&lt;ulink linkID="1767636" linkType="Reference"&gt;1767636&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, the PAFSC Second Committee on Drugs granted the drug Orphan status for malignant melanoma with BRAF-V600 mutation; in April 2015, the Orphan designation was transferred to Novartis [&lt;ulink linkID="1479034" linkType="Reference"&gt;1479034&lt;/ulink&gt;], [&lt;ulink linkID="1654850" linkType="Reference"&gt;1654850&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In December 2016, an application was filed in Japan for &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; +  trametinib  for BRAF V600 mutation-positive NSCLC [&lt;ulink linkID="1883178" linkType="Reference"&gt;1883178&lt;/ulink&gt;]; in March 2018, dabrafenib in combination with trametinib was approved for the treatment of BRAF V600-positive advanced or metastatic NSCLC in Japan. The approval was based on results from the phase II E2201 trial [&lt;ulink linkID="2016801" linkType="Reference"&gt;2016801&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, the PAFSC  Second Committee on Drugs recommended Orphan drug designation for the drug in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for  BRAF-positive unresectable advanced or recurrent NSCLC [&lt;ulink linkID="1804290" linkType="Reference"&gt;1804290&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ChinaMelanoma&lt;/subtitle&gt;In January 2019, a filing for approval was submitted in China presumably for melanoma [&lt;ulink linkID="2107483" linkType="Reference"&gt;2107483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In July 2013, the product (0.5- and 2.0-mg tablets) was approved in Canada as a monotherapy for unresectable or metastatic melanoma in adults with the BRAF V600 mutation [&lt;ulink linkID="1456078" linkType="Reference"&gt;1456078&lt;/ulink&gt;]. It was launched in August 2013 [&lt;ulink linkID="1736666" linkType="Reference"&gt;1736666&lt;/ulink&gt;]. By July 2015, Health Canada has approved the use of &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; in combination with trametinib for the treatment of  unresectable or metastatic melanoma with a BRAF V600 mutation [&lt;ulink linkID="1938418" linkType="Reference"&gt;1938418&lt;/ulink&gt;], [&lt;ulink linkID="1938420" linkType="Reference"&gt;1938420&lt;/ulink&gt;]. In November 2018, Health Canada approved the adjuvant use of trametinib either as  monotherapy or in combination with  &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt;   for the treatment of patients with unresectable or metastatic melanoma with a  BRAF V600 mutation  and involvement of lymph nodes, following complete resection [&lt;ulink linkID="2089955" linkType="Reference"&gt;2089955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, Health Canada approved the use of &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; in combination with trametinib for the treatment of metastatic NSCLC with a BRAF V600 mutation that has progressed following systemic therapy [&lt;ulink linkID="1938335" linkType="Reference"&gt;1938335&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In January 2016, the drug was approved in Brazil for the treatment of unresectable or metastatic melanoma with BRAF V600E  mutation [&lt;ulink linkID="2056935" linkType="Reference"&gt;2056935&lt;/ulink&gt;]; launch was presumed to have occurred shortly after approval.&lt;/para&gt;&lt;para&gt;In June 2014, the product was approved in Argentina, presumably for unresectable (Stage III) or metastatic (Stage IV) melanoma with BRAF V600E  mutation [&lt;ulink linkID="2073879" linkType="Reference"&gt;2073879&lt;/ulink&gt;]; launch was presumed to have occurred shortly after approval.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;In July 2013, dabrafenib was filed for approval in Israel. In March 2014, approval was granted for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation and  in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for the treatment of adult patients with advanced NSCLC with a BRAF V600 mutation [&lt;ulink linkID="2073830" linkType="Reference"&gt;2073830&lt;/ulink&gt;]; launch was presumed to have occurred shortly after approval.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In July 2016, the product (as Mekinist) was approved in Taiwan for BRAF-V600E/K mutation-positive unresectable or metastatic melanoma [&lt;ulink linkID="1792698" linkType="Reference"&gt;1792698&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, the MFDS approved the drug (as Mekinist) in Korea [&lt;ulink linkID="1714087" linkType="Reference"&gt;1714087&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, a regulatory filing was submitted in New Zealand. In June 2014, dabrafenib was approved for the  treatment of patients with BRAF V600 mutation-positive unresectable Stage III or metastatic (Stage IV) melanoma, and in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation [&lt;ulink linkID="2073870" linkType="Reference"&gt;2073870&lt;/ulink&gt;]; launch was presumed to have occurred shortly after approval.&lt;/para&gt;&lt;para&gt;In June 2012, Australia's Therapeutic Goods Administration (TGA) granted trametinib Orphan designation for BRAF-V600 mutation-positive unresectable or metastatic (stage IV) melanoma [&lt;ulink linkID="1337011" linkType="Reference"&gt;1337011&lt;/ulink&gt;]. In February 2014, the drug (as Mekinist) was approved in Australia as monotherapy and in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for the treatment of patients with BRAF-V600 mutation-positive unresectable or metastatic stage IV melanoma [&lt;ulink linkID="1550746" linkType="Reference"&gt;1550746&lt;/ulink&gt;], [&lt;ulink linkID="1585451" linkType="Reference"&gt;1585451&lt;/ulink&gt;]. In December 2017, the TGA granted trametinib (Mekinist) priority review designation for use in combination with dabrafenib for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation, following complete resection; the designation would lapse in June 2018 [&lt;ulink linkID="2010290" linkType="Reference"&gt;2010290&lt;/ulink&gt;]. By January 2018, the drug had been launched in Australia [&lt;ulink linkID="2136526" linkType="Reference"&gt;2136526&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;POSTMARKETING STUDIESPhase IV&lt;/subtitle&gt;In June 2019, an open-lable, multi-center, single-group assignment, roll-over, phase IV study (&lt;ulink linkID="383339" linkType="Protocol"&gt;NCT03975829&lt;/ulink&gt;; CDRB436G2401; 2018-004459-19) was planned to initiate in August 2019, to assess long-term effect in pediatric patients (expected n = 250) treated with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; and/or trametinib. The primary end point was the number of participants with adverse events and serious adverse events. At that time, the trial was expected to complete in May 29, 2026 [&lt;ulink linkID="2161005" linkType="Reference"&gt;2161005&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Melanoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In April 2018, data from double-blind, randomized, placebo-controlled, phase III COMBI-i study (NCT02967692) which evaluated the efficacy, safety and biomarker findings of spartalizumab in combination with dabrafenib + trametinib, in treatment-naive patients with BRAF V600–mutant metastatic melanoma was presented at 109th AACR Annual Meeting in Chicago, IL. Patients (n = 23) received spartalizumab (400 mg q4w) + dabrafenib (150 mg bid) + trametinib 2 mg qd. In patients treated with spartalizumab + dabrafenib + trametinib, any grade adverse events (AEs) were reported by 91% of patients; and grade 3/4 were reported by 22% of patients. In patients treated with spartalizumab + dabrafenib + trametinib for 2 to 3 weeks showed a substantial increase in intratumoral CD8+ cells [&lt;ulink linkID="2025868" linkType="Reference"&gt;2025868&lt;/ulink&gt;]. In June 2019, further data were presented at the 55th ASCO Annual Meeting in Chicago, IL. Complete response (CR) was achieved in 42% of patients treated with spartalizumab + dabrafenib + trametinib with median follow-up of 19.9 months. In patients with PFS event in first 12 months, significantly lower tumor mutation burden/T-cell-inflamed gene expression signature levels and increased immunosuppressive tumor microenvironment (TME) signatures (cancer-associated fibroblasts) were observed; increase in MAPK pathway activity score (MPAS) per the 8- to 12-week biopsy samples was observed [&lt;ulink linkID="2156160" linkType="Reference"&gt;2156160&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, a randomized, double-blind, phase III study (&lt;ulink linkID="91126" linkType="Protocol"&gt;NCT01682083&lt;/ulink&gt;; 115532; COMBI-AD) began to evaluate  trametinib in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; versus two placebos in the adjuvant treatment of patients (n = 852) with BRAF V600E/K mutation-positive stage III melanoma after surgical resection. In April 2015, the trial was ongoing and expected to complete in July 2018 [&lt;ulink linkID="1660056" linkType="Reference"&gt;1660056&lt;/ulink&gt;]. In September 2017, positive data were presented from the study in 870 patients at ESMO 2017 Congress in Madrid, Spain, demonstrating that the trial met its primary endpoints.  In patients, dabrafenib + trametinib treatment significantly reduced the risk of disease recurrence or death by 53% versus placebo with hazard ratio 0.47, at the time of the data cut off for the primary analysis (June 30, 2017; median follow-up, 2.8 years; median not reached versus 16.6 months, respectively; p&amp;lt;0.001). The relapse-free survival benefit was observed across all patient subgroups, including stage III A, B and C, in the combination arm  [&lt;ulink linkID="1960415" linkType="Reference"&gt;1960415&lt;/ulink&gt;], [&lt;ulink linkID="1961936" linkType="Reference"&gt;1961936&lt;/ulink&gt;], [&lt;ulink linkID="1960108" linkType="Reference"&gt;1960108&lt;/ulink&gt;]. In October 2017, these data were published [&lt;ulink linkID="2007675" linkType="Reference"&gt;2007675&lt;/ulink&gt;].  In June 2018, further data were presented at the 54th ASCO Annual Meeting in Chicago, IL. Treatment discontinuations were observed due to consent withdrawal, deaths, investigator discretion and lost to follow-up. Adverse events (AEs; includes pyrexia, nausea, headache, chills, diarrhea, vomiting, arthralgia and rash) were not associated with a clinically meaningful decrease in health-related quality of life during the treatment phase, and visual analogue scale (VAS) score was improved over time for patients who had experienced each of the most common adverse events. Mean changes observed in VAS (−6.02 and −6.84, p = 0.003 and &amp;lt; 0.001) and utility scores (-0.626 and -0.748, p &amp;lt;0.001 and 0.001) showed a significant reduction in dabrafenib+trametinib and placebo arms, respectively, following before versus after disease recurrence [&lt;ulink linkID="2039666" linkType="Reference"&gt;2039666&lt;/ulink&gt;]. Further data were presented at the same conference. At year-three, in dabrafenib plus trametinib versus placebo groups, RFS rates based on AJCC8 (American Joint Committee on Cancer for describing the extent of disease progression in cancer patients) were 83 versus 70, 63 versus 43 and 52 versus 33% in patients with stage IIIA, IIIB and IIIC disease, respectively [&lt;ulink linkID="2040112" linkType="Reference"&gt;2040112&lt;/ulink&gt;]. In October 2018, results from an additional analysis of safety from the primary analysis were presented at 2018 ESMO Congress in Munich, Germany. Pyrexia (63%) was the most commonly reported AE reported by patients who received dabrafenib + trametinib. Common AEs reported by &amp;gt;/= 15% of patients were pyrexia, fatigue, nausea, headache, chills, diarrhea, vomiting, arthralgia, rash, cough, myalgia, ALT increase and influenza-like illness. The most frequent AE resulting in dabrafenib + trametinib treatment discontinuation was pyrexia/chills (12.4%). During the first 3 months of therapy in the dabrafenib + trametinib group, exposure-adjusted AE incidence rate per patient was 6.14 events/patient/3 months of exposure, with the AE occurrences reducing considerably with increased duration of treatment [&lt;ulink linkID="2084630" linkType="Reference"&gt;2084630&lt;/ulink&gt;]. At the same conference, further RFS results were presented. Median follow-up, estimated cure rate and relapsed rate was 44 versus 42 months, 54 versus 37% and 41 versus 59%, respectively, for dabrafenib + trametinib versus placebo. Median RFS was not reached with dabrafenib + trametinib arm versus 16.6 months with placebo (hazard ratio = 0.49) [&lt;ulink linkID="2084840" linkType="Reference"&gt;2084840&lt;/ulink&gt;], [&lt;ulink linkID="2085412" linkType="Reference"&gt;2085412&lt;/ulink&gt;]. At the same conference, results from an analysis that explored the baseline factors were presented. In the analysis of baseline covariates using a stratified multivariate Cox regression model, analysis of sex indicated that female patients might be related to a better prognosis whereas male patients might be slightly predictive for treatment: HR value was 1.30 for male versus female in the placebo group and was 1.08 in the dabrafenib + trametinib. In the analyses of T stage, tumor thickness was prognostic for and favored lower stages [&lt;ulink linkID="2084513" linkType="Reference"&gt;2084513&lt;/ulink&gt;]. In June 2019, further data were presented at the 55th ASCO Annual Meeting in Chicago, IL. In patients with tumor (T) stage 1, median RFS was not reached in dabrafenib + trametinib or placebo arms (HR: 0.42); with T2, median RFS was not reached in dabrafenib + trametinib versus 22.1 months in placebo arm (HR: 0.51); with T3, median RFS was 44.5 versus 16.6 months (HR: 0.55) in dabrafenib + trametinib versus placebo arm and with T4, median RFS was 40.9 versus 8.6 months (HR: 0.42) in dabrafenib + trametinib versus placebo arm, respectively [&lt;ulink linkID="2156348" linkType="Reference"&gt;2156348&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, a randomized, open-label, phase III trial (&lt;ulink linkID="87403" linkType="Protocol"&gt;NCT01597908&lt;/ulink&gt;; MEK116513; COMBI-v) began in the US, Argentina, Australia, Brazil, Canada, Israel, Korea, New Zealand,  Taiwan and  Europe to assess   trametinib plus dabrafenib versus &lt;ulink linkID="54469" linkType="Drug"&gt;vemurafenib&lt;/ulink&gt; alone in patients (expected n = 694) with unresectable or metastatic BRAF V600E/K cutaneous melanoma. The primary endpoint was overall survival at 20 months. At that time, the trial was expected to complete in June 2015 [&lt;ulink linkID="1518688" linkType="Reference"&gt;1518688&lt;/ulink&gt;]. In July 2014, data from an interim analysis were reported. An overall survival benefit was observed for trametinib plus dabrafenib therapy compared with vemurafenib that crossed the pre-specified efficacy stopping boundary. At that time, the Independent Data Monitoring Committee recommended that trial be stopped early based on the results. Analysis of the data was ongoing [&lt;ulink linkID="1578115" linkType="Reference"&gt;1578115&lt;/ulink&gt;]. In September 2014, further data were presented at the 39th European Society for Medical Oncology congress in Madrid, Spain.  The median overall survival was 17.2 months in the vemurafenib arm, while survival data for the combination were not mature. The median progression-free survival duration was 11.4 and 7.3 months and median duration of response was 13.8 and 7.5 months in the dabrafenib plus trametinib- and vemurafenib-treated patients, respectively [&lt;ulink linkID="1596145" linkType="Reference"&gt;1596145&lt;/ulink&gt;]. In November 2014, the final analysis after termination of the 704-patient trial was published. Patients treated with trametinib+dabrafenib had a 31% decreased risk of death compared with those treated with vemurafenib. At 12 months, the overall survival rates were 72 and 65% in  the dabrafenib+trametinib and vemurafenib arms, respectively. Overall, there was a 44% decrease in the risk of disease progression or death in patients treated with the combination compared with vemurafenib. The objective response rates were 64  and  51% in  the two groups, respectively, and the complete response rates were 13 and 8% in  the two groups, respectively [&lt;ulink linkID="1612800" linkType="Reference"&gt;1612800&lt;/ulink&gt;], [&lt;ulink linkID="1613161" linkType="Reference"&gt;1613161&lt;/ulink&gt;]. In September 2015, further data were presented at the 2015 European Cancer Congress in Vienna, Austria. There were significant and clinically meaningful improvements observed on most aspects of health-related quality of life (global health and physical, role, social functioning) and symptoms (pain, insomnia, appetite loss and fatigue), thermometer and health utility scores and melanoma subscale score with dabrafenib + trametinib when compared with vemurafenib [&lt;ulink linkID="1698117" linkType="Reference"&gt;1698117&lt;/ulink&gt;] [&lt;ulink linkID="1697951" linkType="Reference"&gt;1697951&lt;/ulink&gt;]. In October 2016, 3-year follow-up data from a phase III study, presumably this trial, of the combination of dabrafenib + trametinib versus vemurafenib in patients with BRAF V600E/K mutation-positive advanced melanoma were presented at the ESMO 2016 Congress in Amsterdam, the Netherlands, showing an overall survival benefit for dabrafenib + trametinib at 3 years, with an estimated 3-year survival rate of 45% for patients receiving combination therapy versus 31% for patients receiving vemurafenib [&lt;ulink linkID="1866715" linkType="Reference"&gt;1866715&lt;/ulink&gt;]. Further data were presented at the same conference.  When compared with SD/PD patients, patients with CR/PR had greater mean MI in the global health dimension (7.1 and 12.9, respectively), and all functional domains like role (8.3 and 9.7, respectively), social (6.8 and 10.1, respectively), emotional (10.3 and 16.1, respectively), physical (4 and 6.8, respectively), and cognitive (3.1 and 5.1, respectively) and in most symptom scores [&lt;ulink linkID="1805943" linkType="Reference"&gt;1805943&lt;/ulink&gt;]. Further clinical data were presented at the same conference. The completion rates of EORTC quality of life questionnaire-core 36 at week-40 and at disease progression was &amp;gt; 85 and &amp;gt;/= 70%, respectively [&lt;ulink linkID="1806116" linkType="Reference"&gt;1806116&lt;/ulink&gt;]. Further clinical data in 704 patients were presented at the same conference. Overall, 45 and 32% patients achieved three year overall survival in dabrafenib + trametinib  and vemurafenib treated arms, respectively, and three year progression free survival was achieved in 25 and 11%, respectively [&lt;ulink linkID="1805953" linkType="Reference"&gt;1805953&lt;/ulink&gt;], [&lt;ulink linkID="1805462" linkType="Reference"&gt;1805462&lt;/ulink&gt;]. In June 2017, further results were presented at the 53rd ASCO meeting in Chicago, IL. Out of 352 patients who received dabrafenib + trametinib in the COMBI-v study, biopsies from 74 patients were assessed for expression of PD-L1 and CD8 and 54 patients had PD-L1-positive tumors. There was a positive trend between PD-L1 and CD8 expression. In patients who received dabrafenib + trametinib, PD-L1 positivity had no association with overall response rate, duration of response, tumor shrinkage, PFS and OS [&lt;ulink linkID="1931685" linkType="Reference"&gt;1931685&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, a two-arm, double-blind, randomized phase III trial (&lt;ulink linkID="86827" linkType="Protocol"&gt;NCT01584648&lt;/ulink&gt;; 115306; MEK115306; Combi-D) was initiated in patients (expected n  = 340) with first-line unresectable (stage III) or metastatic (stage IV) BRAF V600E/K  mutation-positive cutaneous melanoma, to compare trametinib and dabrafenib combination therapy to dabrafenib monotherapy alone. The trial was expected to be completed by January 2015 [&lt;ulink linkID="1440503" linkType="Reference"&gt;1440503&lt;/ulink&gt;]. In January 2014, the trial met its primary endpoint of progression free survival (PFS), although the difference in PFS between the treatment arms was more modest that seen with previous trials; the combination resulted in a 25% reduction in the risk of disease progression and/or death compared to dabrafenib alone  and the median PFS was 9.3 months for the combination compared to 8.8 months with dabrafenib alone. The 423 randomized patients would continue to be followed for overall  survival  [&lt;ulink linkID="1518360" linkType="Reference"&gt;1518360&lt;/ulink&gt;]. In June 2014, further data were presented at the  50th ASCO meeting in Chicago, IL. Median PFS for dabrafenib + trametinib was 9.3 months, with 70% of patients achieving PFS. These values for dabrafenib + placebo were 8.8 months and 57%, respectively.  The most common Grade 3 adverse events (AEs) included pyrexia, fatigue and hypertension, and these affected 6, 2 and 4% of patients in the dabrafenib + trametinib group and 2, &amp;lt; 1, and 5% of the dabrafenib + placebo group. Rates of AEs leading to dose interruption, dose reduction or permanent discontinuation were 49, 25 and 9% for the dabrafenib + trametinib group and 33, 13 and 5% for the dabrafenib + placebo group [&lt;ulink linkID="1561022" linkType="Reference"&gt;1561022&lt;/ulink&gt;], [&lt;ulink linkID="1564483" linkType="Reference"&gt;1564483&lt;/ulink&gt;]. In September 2014, further data were presented at the 39th European Society for Medical Oncology congress in Madrid, Spain. In the dabrafenib + trametinib arm, the overall quality of life was consistently better compared with dabrafenib monotherapy; these results were significant at weeks 8, 16 and 24. Patients treated with the combination therapy had improvement in four out of five functional domains and also significant improvements in pain scores were observed [&lt;ulink linkID="1596158" linkType="Reference"&gt;1596158&lt;/ulink&gt;]. In February 2015, survival data were reported. There was a significant reduction in the risk of death with the combination compared with dabrafenib alone (HR = 0.71) [&lt;ulink linkID="1631873" linkType="Reference"&gt;1631873&lt;/ulink&gt;]. In May 2015, further clinical data were presented at the 51st ASCO meeting in Chicago, IL. The median overall survival was 25.1 and 18.7 months with dabrafenib + trametinib and dabrafenib, respectively; PFS was 11 versus 8.8 months. The respective overall survival rates at  one and two years were 74 and 51% in the dabrafenib + trametinib group and were 68 and 42% in the dabrafenib group. No new or unexpected safety signals were noted during the additional 17-month follow-up period [&lt;ulink linkID="1661523" linkType="Reference"&gt;1661523&lt;/ulink&gt;], [&lt;ulink linkID="1665002" linkType="Reference"&gt;1665002&lt;/ulink&gt;]. In November 2015, further data were reported at the Society for Melanoma Research Congress in San Francisco, CA; from the largest pooled data analysis conducted of 617 patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma, data showed that patients experienced longer PFS and OS when baseline lactate dehydrogenase (LDH) levels were normal as compared to those with elevated LDH levels [&lt;ulink linkID="1730053" linkType="Reference"&gt;1730053&lt;/ulink&gt;]. In June 2016, further 3-year follow-up data were presented at ASCO in Chicago, IL. Dabrafenib + trametinib improved OS versus dabrafenib alone (mOS 25.1 months vs. 18.7 months, HR=0.71). Two-year OS was 52% for the combination vs 43% for dabrafenib alone and 3-year OS was 44% and 32% respectively. Best 3-year outcome for the combination was observed in patients with normal LDH and &amp;lt;3 disease sites (3-year OS 62%, 3-year PFS 38%). The combination also showed a significant improvement in PFS, with mPFS of 11.0 vs 8.8 months for dabrafenib alone (HR=0.67). Two-year PFS was 30% for the combination vs 16% for Tafinlar alone and three-year PFS was 22% vs 12%  [&lt;ulink linkID="1769762" linkType="Reference"&gt;1769762&lt;/ulink&gt;],  [&lt;ulink linkID="1769929" linkType="Reference"&gt;1769929&lt;/ulink&gt;].  In October 2016, further data were presented at the ESMO 2016 Congress in Copenhagen, Denmark. When compared with stable disease (SD)/progressive disease (PD)  patients, patients with complete response (CR)/partial response (PR) showed greater mean maximum improvement (MI) in health-related quality of life in the global health dimension (7.5 versus 13.8, respectively), and all functional domains like role (7.9 versus 10.2, respectively), social (6.2 versus 10.3, respectively), emotional (10.3 versus 15.4, respectively), physical (5.3 versus 6, respectively); cognitive (1.9 versus 4.9, respectively) and in most symptom scores including &amp;gt; 5-point improvements in pain and insomnia [&lt;ulink linkID="1805943" linkType="Reference"&gt;1805943&lt;/ulink&gt;], [&lt;ulink linkID="1806116" linkType="Reference"&gt;1806116&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2010, a two-arm, open-label, randomized phase III trial (&lt;ulink linkID="72448" linkType="Protocol"&gt;NCT01245062&lt;/ulink&gt;; METRIC; 114267) was initiated in North America, Europe and Australia to evaluate the safety and efficacy of trametinib DMSO compared with chemotherapy (either dacarbazine or &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt;) in patients (estimated n = 297) with stage IIIc or IV BRAF-mutation-positive malignant cutaneous melanoma who had received one previous regimen of chemotherapy. The primary endpoint was progression-free survival. At that time, the trial was expected to complete in September 2012  [&lt;ulink linkID="1161630" linkType="Reference"&gt;1161630&lt;/ulink&gt;], [&lt;ulink linkID="1162994" linkType="Reference"&gt;1162994&lt;/ulink&gt;]. In June 2012, data were presented at the 48th ASCO meeting in Chicago, IL. Median PFS in patients with BRAF V600E-mutant disease and  no prior brain metastases (the primary endpoint) was 4.8 months in the trametinib DMSO arm compared  with 1.4 months in the chemotherapy arm (p &amp;lt; 0.0001). At 6 months, the rate of overall survival was 81% in the trametinib group and 67% for chemotherapy [&lt;ulink linkID="1299347" linkType="Reference"&gt;1299347&lt;/ulink&gt;], [&lt;ulink linkID="1534494" linkType="Reference"&gt;1534494&lt;/ulink&gt;]. In November 2012, recruitment was completed [&lt;ulink linkID="1161630" linkType="Reference"&gt;1161630&lt;/ulink&gt;]. In June 2013, further data were presented at the 49th ASCO meeting in Chicago, IL. The median overall survival had not yet been reached. Adjustment for crossover showed  more beneficial treatment effect for trametinib when compared with that estimated without adjustment in primary efficacy population [&lt;ulink linkID="1425023" linkType="Reference"&gt;1425023&lt;/ulink&gt;]. In June 2016, the trial was planned to initiate in the US, Argentina, Austria, Belgium, Canada, Czech Republic, France, Germany, Greece, Italy, New Zealand, Norway, Poland, Russian Federation, Sweden, Switzerland, Ukraine and UK [&lt;ulink linkID="1161630" linkType="Reference"&gt;1161630&lt;/ulink&gt;]. In September 2017, five-year efficacy and safety data were presented at the ESMO 2017 Congress in Madrid, Spain. In trametinib and chemotherapy groups in the intent-to-treat population, ORR (CR + PR) was 40 and 14%, respectively. In cross-over population (n = 70), ORR was 44%. In trametinib and chemotherapy groups in safety population (n = 211 and 99, respectively), any grade AE was experienced by all patients; and grade 4 AE 14 was experienced by 14 and 5 patients, respectively. In cross-over population, 69 patients experienced any grade AE; and grade 4 AEs were experienced by 5 patients [&lt;ulink linkID="1960423" linkType="Reference"&gt;1960423&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2019, data were presented from a phase II study (REDUCTOR), which evaluated the safety and efficacy of dabrafenib and trametinib in patients with locally advanced stage III or oligometastatic stage IV melanoma at the 55th ASCO Annual Meeting in Chicago, IL. Patients (n = 25) received dabrafenib (150 mg, bid) and trametinib (2 mg, qd). Median OS was not reached while the one and two year overall survival (OS) rate was 94 and 82%, respectively. The proportion of patients with total, grade 1, 2 and 3 toxicity was 81, 48, 19 and 14%, respectively, the most common toxicity being fever [&lt;ulink linkID="2156036" linkType="Reference"&gt;2156036&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, clinical data from a randomized, open-label, phase II study (&lt;ulink linkID="218087" linkType="Protocol"&gt;NCT02314143&lt;/ulink&gt;; COMBAT) to evaluat the efficacy of dabrafenib + trametinib in patients with BRAF V600-mutant metastatic melanoma were presented at the 109th AACR Annual Meeting in Chicago, IL. Patients (n = 48) were randomized (1:1:1) to arm-1, -2 or -3 to receive dabrafenib (150 mg bid) in treatment period-1 (day 1 to week 8) and then dabrafenib + trametinib (2 mg qd) till week-10, trametinib (2 mg qd) in treatment period-1 and then trametinib + dabrafenib (150 mg bid) till week-10 or dabrafenib (150 mg bid) + trametinib (2 mg qd) from day-1 to week-10, respectively. In arm-1, -2, and -3, the proportion of patients with total decrease in pERK H score (primary endpoint) from baseline to week-2 were 80, 85.7 and 60%, respectively; and from baseline to week-8 were 66.7, 66.7 and 50%, respectively. In arm-1, -2, and -3, discontinuation due to AEs was reported by 0, 6 and 4 patients, respectively [&lt;ulink linkID="2022007" linkType="Reference"&gt;2022007&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, prospective single-institution randomized clinical trials (NCT02231775) were presented from 21 high-risk resectable BRAF-mutant metastatic melanoma patients at the 53rd ASCO meeting in Chicago, IL. Patients were randomized (1:2) to receive SOC (arm A) versus adjuvant dabrafenib + trametinib (arm B; 8 weeks neo + 44 weeks adjuvant). RECIST response rate and the pathologic complete response rate (pCR) was 77 and 58% with neo dabrafenib + trametinib. Significantly improved relapse-free survival (RFS) was observed with dabrafenib + trametinib arm over SOC (p &amp;lt; 0.0001), which lead to early closure to enrollment. Patients with pCR at surgery had significantly improved RFS when compared with patients without pCR (p = 0.04) on neo dabrafenib + trametinib [&lt;ulink linkID="1940295" linkType="Reference"&gt;1940295&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2016, a randomized, open-label, phase II study (NCT02858921; MIA2015/179) was planned to begin in November 2016 in Australia, to assess the safety and efficacy of neoadjuvant dabrafenib, trametinib and/ or &lt;ulink linkID="70667" linkType="Drug"&gt;pembrolizumab&lt;/ulink&gt; in BRAF V600 mutant resectable stage IIIB/C melanoma patients (expected n = 60). At that time, the study was expected to complete in June 2019 [&lt;ulink linkID="1789125" linkType="Reference"&gt;1789125&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, clinical data from phase II study (NCT01972347) in 19 patients with resectable stage IIIB/C BRAF-V600 mutation positive melanoma were presented at the 52nd ASCO meeting in Chicago, IL. Patients received dabrafenib/trametinib (150 mg bid/2 mg qd) for 12 weeks prior to therapeutic dissection and further 40 weeks after therapeutic dissection of pre-therapy tumor bed. Pathological, metabolic and RECIST complete response (CR) was achieved by 5, 11 and 5% of patients, respectively; majority of patients with pathological CR had both RECIST and metabolic CR. Surgical complication rates were found consistent with historical controls and stage. The frequent adverse event was pyrexia, requiring dose interruption [&lt;ulink linkID="1765753" linkType="Reference"&gt;1765753&lt;/ulink&gt;]. In September 2017, further clinical data were presented at the ESMO 2017 Congress in Madrid, Spain. The median time to recurrence was 11.7 months. Recurrence after pathological complete response was observed in 35% patients [&lt;ulink linkID="1960767" linkType="Reference"&gt;1960767&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2015, data were presented from two phase II trials (&lt;ulink linkID="159419" linkType="Protocol"&gt;NCT01972347&lt;/ulink&gt; and Combi-Neo; &lt;ulink linkID="209623" linkType="Protocol"&gt;NCT02231775&lt;/ulink&gt;) in patients with high-risk resectable stage III and IV melanoma at the 51st ASCO meeting in Chicago, IL. In the Combi-Neo study, patients (expected n = 84) with locally advanced stage III or oligometastatic BRAF V600 mutated melanoma would be randomized (2:1) to received 8 weeks of neoadjuvant dabrafenib (150 mg po, bid) and trametinib (2 mg po, qd), followed by definitive surgery and then an additional 44 weeks of adjuvant combination therapy in arm 1 or definitive upfront surgical resection of melanoma, followed by standard of care adjuvant therapy in arm 2. Overall, four patients were assigned to arm 2 and seven patients in arm1. In an open-label, single-center, phase II study (NCT01972347), patients (expected n = 35) with stage IIIB/C melanoma received dabrafenib  and trametinib for 12 weeks, followed by definitive surgery and then an additional 40 weeks of adjuvant combination therapy. At that time, 11 patients were enrolled on eacDabrafenib (GSK2118436) and Trametinib (h of these trials [&lt;ulink linkID="1666324" linkType="Reference"&gt;1666324&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, a multi-cohort, open label, non randomized, parallel group, phase II study (&lt;ulink linkID="168903" linkType="Protocol"&gt;NCT02039947&lt;/ulink&gt;; 117277; COMBI-MB) was initiated in the US, Australia, Italy and Europe, in patients (n = 120) with BRAF mutation-positive melanoma that has metastasized to the brain, to assess the safety and efficacy of combination therapy of dabrafenib and trametinib. At that time,  the trial was to complete  in August 2019 [&lt;ulink linkID="1886070" linkType="Reference"&gt;1886070&lt;/ulink&gt;]. In June 2017, clinical data were presented at the 53rd ASCO meeting in Chicago, IL. The investigator-assessed intracranial response rate (IRR, primary objective), extracranial response rate (ERR) and overall response rate (ORR) was observed in 58, 55 and 58%, respectively, whereas the median time to IR, ER and OR was 6.5, 10.2 and 6.5 months, respectively. The median progression free survival was 5.6 months. . A total of 10% of patients discontinued due to adverse events [&lt;ulink linkID="1932267" linkType="Reference"&gt;1932267&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2014, an open-label, single arm, multicenter, phase II study (&lt;ulink linkID="177285" linkType="Protocol"&gt;NCT02083354&lt;/ulink&gt;; 200104) began in patients (n = 65) to evaluate dabrafenib and trametinib combination therapy  with BRAF V600 mutation-positive unresectable or Stage IV metastatic acral lentiginous or cutaneous melanoma in China, Hong Kong, South Korea, Taiwan and Thailand. The study was expected to complete in December 2018. In October 2018, the trial was ongoing, but was no longer recruiting participants; at that time, the trial was expected to complete in December 2019 [&lt;ulink linkID="1912899" linkType="Reference"&gt;1912899&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;In June 2014, a randomized,  double-blind, parallel assignment, phase I/II trial (&lt;ulink linkID="185164" linkType="Protocol"&gt;NCT02130466&lt;/ulink&gt;; 3475-022: KEYNOTE-022) was initiated in the US, to assess the safety and efficacy of &lt;ulink linkID="18077" linkType="Company"&gt;Merck&lt;/ulink&gt;'s &lt;ulink linkID="70667" linkType="Drug"&gt;&lt;/ulink&gt;&lt;ulink linkID="70667" linkType="Drug"&gt;pembrolizumab&lt;/ulink&gt; (Keytruda) in combination with trametinib and dabrafenib in subjects with advanced melanoma (expected n = 177). At that time, the trial was expected to complete in September 2017 [&lt;ulink linkID="1671692" linkType="Reference"&gt;1671692&lt;/ulink&gt;], [&lt;ulink linkID="1671598" linkType="Reference"&gt;1671598&lt;/ulink&gt;], [&lt;ulink linkID="1671366" linkType="Reference"&gt;1671366&lt;/ulink&gt;]. Initial data were presented at ASCO in Chicago, IL in June 2016. Based on early data from the 15 patients treated in phase I, treatment with pembrolizumab  with dabrafenib plus trametinib  resulted in nine partial responses, five of which were confirmed. Additionally, of the patients with lesion data available, 92.3% experienced a reduction in tumor size [&lt;ulink linkID="1769333" linkType="Reference"&gt;1769333&lt;/ulink&gt;]. In September 2017, further data were presented at the ESMO 2017 Congress in Madrid, Spain. ORR (RECIST v.1.1, investigator; confirmed + unconfirmed) was 67%; one patient had complete response, nine had PR; an additional two pts had SD and three had PD. ORR (RECIST v.1.1, investigator; confirmed only) was 53%; eight patients had PR; an additional three patients had SD and four had PD [&lt;ulink linkID="1960398" linkType="Reference"&gt;1960398&lt;/ulink&gt;], [&lt;ulink linkID="1957627" linkType="Reference"&gt;1957627&lt;/ulink&gt;]. In October 2018, additional results were presented at 2018 ESMO Congress in Munich, Germany. In group 1 (pembrolizumab + dabrafenib + trametinib) and group 2 (placebo + dabrafenib + trametinib), median PFS was 16 versus 10.3 months (HR = 0.66; p = 0.04287) and PFS rate was 59 versus 45%, respectively; and PFS did not attain statistical significance threshold per study design (required HR for significance &amp;lt;/= 0.62; p &amp;lt;/= 0.025). ORR rate was 63.3 versus 71.7% (p = 0.3549), which included CR rate of 19.3 versus 13.3% (p = 0.4229) and PR of 45 versus 58.3% (p = 0.1477); DCR was 85 versus 93.3% (p = 0.1624); SD was noted in 21.7 versus 21.7% of patients and PD in 8.3 versus 5% of patients, respectively, in group 1 versus group 2. Incidence of treatment-related AE was 95 and 93% and grade 3 to 4 AE was 57 and 27%, respectively, in groups 1 and 2 [&lt;ulink linkID="2084650" linkType="Reference"&gt;2084650&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, GSK and Pfizer planned a phase I/II, open-label, dose-escalation trial (200344) of trametinib DMSO plus &lt;ulink linkID="10271" linkType="Drug"&gt;palbociclib&lt;/ulink&gt; in patients with advanced/metastatic melanoma. The study was to determine the recommended combination regimen and to evaluate the effect of the combination on tumor biomarkers, safety and anti-cancer activity in patients with BRAFV600 wild-type melanoma, including those with NRAS mutations [&lt;ulink linkID="1501890" linkType="Reference"&gt;1501890&lt;/ulink&gt;]. In April 2014, the three-part trial (&lt;ulink linkID="173927" linkType="Protocol"&gt;NCT02065063&lt;/ulink&gt;) began in the US in an expected 90 patients; part 1 was a dose-finding phase in solid tumor patients (expected n = 50), part 2 an expansion phase in patients with melanoma (two cohorts of 20 melanoma patients with BRAF wild-type and either NRAS wild-tupe or mutation) and part 3 a randomized phase. The primary endpoints included change from baseline in vital signs, physical examination findings and ECG,  pharmacokinetic parameters and anti-cancer activity in part 1, and change from baseline in tumor biomarkers in part 2. At that time, the trial was expected to complete in June 2015 [&lt;ulink linkID="1593405" linkType="Reference"&gt;1593405&lt;/ulink&gt;]. In November 2015, further clinical data were presented from phase Ib study at the 27th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. Overall, the best response was noted in 2A and 2B dose groups and trametinib (2 mg) + palbociclib (75 mg) and trametinib (1.5 mg) + palbociclib (100 mg) combinations were recommended. Low WBC, neutropenia, dehydration and eye disorders were some of the grade 3 or 4 AEs noted  [&lt;ulink linkID="1711221" linkType="Reference"&gt;1711221&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2010, a phase I/II trial (&lt;ulink linkID="64287" linkType="Protocol"&gt;NCT01072175&lt;/ulink&gt;) began to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of dabrafenib and &lt;ulink linkID="55288" linkType="Drug"&gt;trametinib&lt;/ulink&gt; in combination in patients with melanoma and colorectal cancer. In Part A, the effect of repeat doses of trametinib on the pharmacokinetics of single dose dabrafenib would be investigated prior to evaluating combination regimens. In Part B, the range of tolerated dose combinations would be identified. In Part C, different dose combinations of dabrafenib and trametinib would be evaluated, based on results from the dose escalation cohorts. In Part D, the pharmacokinetics and safety of dabrafenib administered as capsules alone and in combination with trametinib would be evaluated. The primary endpoints were pharmacokinetic parameters, and the trial was expected to complete in May 2013 [&lt;ulink linkID="1429995" linkType="Reference"&gt;1429995&lt;/ulink&gt;]. In June 2011, data from the study were presented at the 47th ASCO meeting in Chicago, IL. The study evaluated the efficacy of the combination of trametinib and dabrafenib.   Patients with melanoma (n = 101) and other primary tumor types (n = 8) were included. In part A of the study, steady-state trametinib (2 mg) had no effect on the pharmacokinetics of the single-dose dabrafenib (75 mg). In melanoma patients without prior BRAF inhibition (n = 71), objective response was observed in 4, 17, 12 and 14 patients in 75 mg bid/1 mg qd, 150 mg bid/1 mg qd, 150 mg bid/1.5 mg qd and 150 mg bid/2 mg qd, groups respectively; complete response was observed in three and two patients in the 150 mg bid/1 mg qd and 150 mg bid/2 mg qd groups, respectively. In melanoma patients with prior BRAF inhibition (n = 24), one patient had clinical progressive disease. At that time, the part C of the phase II study in patients with BRAF V600E mutation + melanoma (n = 150) was ongoing [&lt;ulink linkID="1196607" linkType="Reference"&gt;1196607&lt;/ulink&gt;]. In June 2012, further data from the trial were presented at the 48th ASCO meeting in Chicago, IL. Among BRAF inhibitor-naive patients (n = 77), the median duration of response was 11.3 months and the mean response rate was 57% [&lt;ulink linkID="1299405" linkType="Reference"&gt;1299405&lt;/ulink&gt;]. Data on the relationship between pyrexia and tumor response demonstrated that among 13 melanoma patients treated with dabrafenib plus trametinib, seven had recurrent pyrexia and none had progressive disease at 24 weeks; in contrast, the other six patients without recurrent pyrexia had all progressed by 24 weeks [&lt;ulink linkID="1296167" linkType="Reference"&gt;1296167&lt;/ulink&gt;]. In June 2013, safety data were presented at the 49th ASCO Meeting in Chicago, IL [&lt;ulink linkID="1426105" linkType="Reference"&gt;1426105&lt;/ulink&gt;]. Also at the meeting, data were presented from the melanoma cohort in patients administered 150 mg dabrafenib combined with 2 mg trametinib.  Median PFS was 3.6 months in BRAF-resistant patients (n = 43) receiving 150 mg / 2 mg, and 9.4 months in BRAF-naive patients (n = 54) receiving the same doses, with an overall response rate of 9% and 76%, respectively, indicating that patients with early progression on a BRAF inhibitor derived minimal benefit with subsequent combination therapy [&lt;ulink linkID="1426589" linkType="Reference"&gt;1426589&lt;/ulink&gt;]; in part D,  110 melanoma patients received 75 or 150 mg dabrafenib + 2 mg trametinib in 4 cohorts. The median PFS duration in cohort 1, 2 and 3 was 6.9, 9.3 and 7.5 months, respectively.   Median PFS was not reached in cohort 4. The respective response rate in cohort 1, 2, 3 and 4 was 67, 69, 74 and 67% [&lt;ulink linkID="1425047" linkType="Reference"&gt;1425047&lt;/ulink&gt;]. Further data were also presented from the colorectal cancer cohort of the trial at the same meeting. A total of 42 patients were enrolled. Objective tumor responses were seen in 11% of patients; 22% had minor responses and reductions in tumor size of 10 to 30%. PFS was 3.5 months, and 25% of patients were treated for 6 months or more [&lt;ulink linkID="1427135" linkType="Reference"&gt;1427135&lt;/ulink&gt;]. In January 2014, further data were reported; the investigator-assessed overall response rates were 76 and 54% in melanoma patients treated with the combination or dabrafenib monotherapy, respectively, and the median durations of response were 10.5 and 5.6 months, respectively. The  blinded independent radiologic review committee-assessed overall response rates were 57 and 46%, respectively,  and the median durations of response were 7.6 months in both groups [&lt;ulink linkID="1514072" linkType="Reference"&gt;1514072&lt;/ulink&gt;], [&lt;ulink linkID="1514730" linkType="Reference"&gt;1514730&lt;/ulink&gt;]. In June 2015, updated overall survival data from the trial were presented at the 51st ASCO meeting in Chicago, IL. Median overall survival was 20.2 and 25.0 months, overall survival rates were 70 and 80, 44 and 51, and 31 and 38% at 12, 24, and 36 months, and 41 and 36 deaths were observed in patients treated with dabrafenib monotherapy and dabrafenib + trametinib (150 or 2 mg) treatment, respectively [&lt;ulink linkID="1663953" linkType="Reference"&gt;1663953&lt;/ulink&gt;], [&lt;ulink linkID="1665161" linkType="Reference"&gt;1665161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, an open-label phase II study (&lt;ulink linkID="62851" linkType="Protocol"&gt;NCT01037127&lt;/ulink&gt;; 113583) began in the US and Australia, to evaluate the safety and efficacy of trametinib DMSO in patients (n = 97) with BRAF-mutation-positive melanoma who were previously treated with or without a BRAF inhibitor. The primary endpoint was tumor response at 6 months as defined by RECIST criteria. Patients  were to receive 2 mg qd trametinib DMSO until treatment discontinuation criteria were met. The study was expected to complete in June 2012 [&lt;ulink linkID="1110286" linkType="Reference"&gt;1110286&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In November 2013, phase I clinical data were presented at the NCRI Cancer Conference in Liverpool, UK. Patients (n = 15) received trametinib (1.0, 1.5, 2.0 mg) in escalating doses and a fixed dose of paclitaxel (80 mg/m2; weekly, 3 weeks of 4). DLTs included visual disturbances and elevated liver function test and &amp;gt;/= grade 3 adverse events were observed in 40% of patients. Grade 4 hepatotoxicity was considered related to trametinib. The MTD was found to be 2 mg/day [&lt;ulink linkID="1499054" linkType="Reference"&gt;1499054&lt;/ulink&gt;]. 	In September 2014, further data were presented at the 39th European Society for Medical Oncology congress in Madrid, Spain. In patients with paclitaxel plus trametinib,  									progression free survival and overall survival were 5.5 and 14.1 months, respectively [&lt;ulink linkID="1596166" linkType="Reference"&gt;1596166&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2010, data were presented at the Seventh International Melanoma Research Congress and Fourth Melanoma &amp;amp; Skin Cancer Centers Meeting in Sydney, Australia. In a phase I trial of trametinib DMSO in melanoma patients (n = 162) unselected for their BRAF mutation status, a bias towards a response in BRAF-mutated patients (response rate: 40%) compared with individuals whose melanoma were BRAF wild-type (response rate: 9%) was seen [&lt;ulink linkID="1146023" linkType="Reference"&gt;1146023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, an IND was  filed in China, presumed to be for the treatment of melanoma; in October 2012,  GSK withdrew  application  [&lt;ulink linkID="1337701" linkType="Reference"&gt;1337701&lt;/ulink&gt;]. In January 2014, GSK refiled the clinical trial application [&lt;ulink linkID="1516936" linkType="Reference"&gt;1516936&lt;/ulink&gt;], [&lt;ulink linkID="1513655" linkType="Reference"&gt;1513655&lt;/ulink&gt;]. In February 2015, approval to conduct a clinical trial application was obtained [&lt;ulink linkID="1662920" linkType="Reference"&gt;1662920&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other Studies&lt;/subtitle&gt;In June 2018, data from a study which evaluated the ORR and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma patients receiving first-line targeted therapy (TT; dabrafenib/trametinib  or vemurafenib/&lt;ulink linkID="56544" linkType="Drug"&gt;cobimetinib&lt;/ulink&gt;; n = 283) or immuno-oncology (IO; ipilimumab/nivolumab  or PDL1 monotherapy (nivolumab  or pembrolizumab); n = 157) agents at US-based community oncology practices, were presented at the 54th ASCO meeting in Chicago, IL. In TT group, the ORR was significantly (p &amp;lt; 0.01) higher (60.1%) compared to IO group (45.9%). In TT and IO groups, the median TTF was 11.4 and 7.2 months, respectively (p &amp;lt; 0.001) [&lt;ulink linkID="2039419" linkType="Reference"&gt;2039419&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, data from a study which evaluated the efficacy of dabrafenib + trametinib versus ipilimumab + nivolumab and nivolumab or pembrolizumab monotherapy in patients with BRAF v600 mutated metastatic melanoma, were presented at the 54th ASCO meeting in Chicago, IL. Patients received dabrafenib + trametinib (n = 188), ipilimumab + nivolumab (n = 86), and nivolumab or pembrolizumab monotherapy (n = 71) as first-line treatment. In dabrafenib + trametinib, ipilimumab + nivolumab and nivolumab or pembrolizumab monotherapy groups, the ORR was 60.6 (p = 0.01 versus ipilimumab + nivolumab), 48.8 and 42.3% (p &amp;lt; 0.05 versus dabrafenib + trametinib), respectively; and median time to treatment failure was 11.4 (p &amp;lt; 0.001 versus ipilimumab + nivolumab), 4.6 (p &amp;lt; 0.05 versus dabrafenib + trametinib) and 12.0 months, respectively [&lt;ulink linkID="2039498" linkType="Reference"&gt;2039498&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2018, an interventional, open-label, single-arm, multicenter,  phase II study (&lt;ulink linkID="306853" linkType="Protocol"&gt;NCT03232892&lt;/ulink&gt;; 166521; NCI-2017-02295) was initiated to assess the efficacy and safety of trametinib monotherapy in patients (expected n = 27) with advanced non-squamous NSCLC whose tumors non-synonymous NF1 mutations and are KRAS wildtype. The primary endpoint was objective response rate (ORR) according to response evaluation criteria in solid tumors (RECIST) v 1.1 criteria. At that time, the trial was expected to complete in  September 2021 [&lt;ulink linkID="2073808" linkType="Reference"&gt;2073808&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, a  single group, unmasked, phase I/II study (&lt;ulink linkID="291542" linkType="Protocol"&gt;NCT03087448&lt;/ulink&gt;; CC# 166512 ) of &lt;ulink linkID="69858" linkType="Drug"&gt;ceritinib&lt;/ulink&gt; + trametinib in patients (expected n=69) with advanced ALK-positive non-small cell lung cancer (NSCLC) was planned to be initiated in the US later that month. At that time, the trial was expected to be completed in March 2021 [&lt;ulink linkID="1911257" linkType="Reference"&gt;1911257&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2016, an open-label, multicenter, non-randomized, single-arm, phase II study (&lt;ulink linkID="252475" linkType="Protocol"&gt;NCT02672358&lt;/ulink&gt;; CDRB436E1201) was to start in December 2016 to assess efficacy and safety of  dabrafenib in combination with  trametinib   Japanese patients (estimated n = 10)  with any line, stage IV NSCLC harboring a confirmed BRAF V600E mutation. The primary endpoint was the assessment of overall response rate, defined as the percentage of patients with a confirmed complete response or partial response by RECIST v1.1 criteria. At that time, the trial was expected to complete in May 2019  [&lt;ulink linkID="1735990" linkType="Reference"&gt;1735990&lt;/ulink&gt;]. By August  2018, the trial was withdrawn by the company [&lt;ulink linkID="1735990" linkType="Reference"&gt;1735990&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, data were presented from an open-label, randomized, multicenter, phase II study (&lt;ulink linkID="77773" linkType="Protocol"&gt;NCT01362296&lt;/ulink&gt;) in 134  advanced NSCLC patients at the 49th ASCO meeting in Chicago, IL. The median overall survival duration was 8 months in trametinib arm and was not reached in docetaxel arm. In trametinib arm, 10 patients showed partial response, 38 patients had stable disease and 28 patients had progressive disease; tumor reductions from the baseline were observed [&lt;ulink linkID="1427852" linkType="Reference"&gt;1427852&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, a non-randomized, open-label, single-group-assignment, phase II trial (&lt;ulink linkID="76520" linkType="Protocol"&gt;NCT01336634&lt;/ulink&gt;; 113928; presumably E2201) was initiated in the   US, Europe, Taiwan, Japan and Korea to assess for dabrafenib in combination with &lt;ulink linkID="55288" linkType="Drug"&gt;trametinib&lt;/ulink&gt; in patients  (n = 174) with advanced NSCLC with the V600E BRAF mutation. The trial was expected to complete in August 2016 [&lt;ulink linkID="1199605" linkType="Reference"&gt;1199605&lt;/ulink&gt;]. In June 2013, data were presented at the 49th ASCO Meeting in Chicago, IL. Patients received oral dabrafenib at 150 mg bid. Of 17 patients, 13 were evaluable. The best partial response, stable disease and progressive disease were observed in seven, one and four patient(s), respectively. The overall response rate (primary endpoint) was 54% and the median duration of treatment was 9 weeks [&lt;ulink linkID="1426133" linkType="Reference"&gt;1426133&lt;/ulink&gt;]. In May 2015, further data were presented at the 51st ASCO meeting in Chicago, IL. Of the 24 patients evaluable for response, 15 had a partial response, 6 had stable disease and disease progression was seen in 2 patients. Disease control rate was 88% and the median duration of response was not yet reached [&lt;ulink linkID="1662306" linkType="Reference"&gt;1662306&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 52nd ASCO meeting in Chicago, IL. Of 52 evaluable patients, overall response rate and disease control rates were 63 and 79%, respectively. The secondary endpoints of median progression free survival and median duration of response was 9.7 and 9 months, respectively. Overall, dabrafenib + trametinib was found to be highly efficacious with a manageable adverse event profile [&lt;ulink linkID="1769542" linkType="Reference"&gt;1769542&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 53rd ASCO meeting in Chicago, IL. The overall response rate was observed in 66.7 and 63.2% based on months based on investigator assessed response (primary endpoint) and independent review committee (IRC), respectively,  whereas disease control rate was observed in 80.7 and 75.4% based on investigator assessed response and IRC, respectively [&lt;ulink linkID="1932382" linkType="Reference"&gt;1932382&lt;/ulink&gt;]. In September 2017, data were presented at ESMO 2017 Congress in Madrid, Spain. In patients treated with dabrafenib + trametinib, investigator (INV)-assessed confirmed overall survival rate was 64%; complete response achieved by 6% of patients. In patients treated with dabrafenib + trametinib, all patients experienced &amp;gt;/= 1 adverse event (AE), while 69% had &amp;gt;/= 1 grade 3/4 AE; serious AEs like alanine aminotransferase increase, aspartate aminotransferase increase and ejection fraction decrease were reported by &amp;gt; 2 patients [&lt;ulink linkID="1960714" linkType="Reference"&gt;1960714&lt;/ulink&gt;] [&lt;ulink linkID="1960108" linkType="Reference"&gt;1960108&lt;/ulink&gt;]. In May 2018, the trial was expected to complete in December 2020  [&lt;ulink linkID="1199605" linkType="Reference"&gt;1199605&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In January 2019, an IND application for  trametinib  presumably in combination with &lt;ulink linkID="53133" linkType="Drug"&gt;dabrafenib&lt;/ulink&gt; for the treatment of BRAF V600E mutation-positive  NSCLC was filed in China [&lt;ulink linkID="2107483" linkType="Reference"&gt;2107483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2017,  an interventional, non-randomized, parallel assignment phase Ib trial (&lt;ulink linkID="314545" linkType="Protocol"&gt;NCT03299088&lt;/ulink&gt;; UCDCC#259; NCI-2017-01633; UCDCC#259; P30CA093373) was planned to  initiate in patients(expected n = 42) with NSCLC and KRAS gene mutations to assess the side effects of pembrolizumab and trametinib. At that time, the trial was expected to start in December 2017 and complete in March 2021 [&lt;ulink linkID="1968612" linkType="Reference"&gt;1968612&lt;/ulink&gt;]; in June 2018, the trial was initiated in the US  [&lt;ulink linkID="1968612" linkType="Reference"&gt;1968612&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In June 2017, a phase I/II trial of trametinib was planned in combination with  &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; and &lt;ulink linkID="36630" linkType="Drug"&gt;ipilimumab&lt;/ulink&gt;  in patients with metastatic colorectal cancer with MSS tumors where the tumors were proficient in mismatch repair (MSS mCRC pMMR)  [&lt;ulink linkID="1934696" linkType="Reference"&gt;1934696&lt;/ulink&gt;], [&lt;ulink linkID="1934528" linkType="Reference"&gt;1934528&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, a randomized, parallel-assignment, open-label, three-part, phase I/II trial (&lt;ulink linkID="101873" linkType="Protocol"&gt;NCT01750918&lt;/ulink&gt;; 116833) was planned in patients with BRAF-mutation V600E- or V600K-positive colorectal cancer (expected n = 200) to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of trametinib and dabrafenib in combination with &lt;ulink linkID="12646" linkType="Drug"&gt;panitumumab&lt;/ulink&gt;. The primary endpoint would be the dose-limiting toxicity measured over 1 year. At that time, the trial was expected to complete in March 2015. In March 2013, the study was initiated [&lt;ulink linkID="1387848" linkType="Reference"&gt;1387848&lt;/ulink&gt;]. In June 2014, data were presented from 43 patients at the 50th ASCO meeting in Chicago, IL.  Overall, 5 patients achieved partial response or better, including 1 patient with complete response and  22  patients had stable disease at first restaging, of which 11 patients had a minor response (10 to 30% tumor reduction) [&lt;ulink linkID="1562986" linkType="Reference"&gt;1562986&lt;/ulink&gt;].  Of the six evaluable patients on triplet dose, four patients showed partial response and two patients had stable disease. Out of eight evaluable patients on doublet dose, seven achieved stable disease [&lt;ulink linkID="1562983" linkType="Reference"&gt;1562983&lt;/ulink&gt;]. In May 2015, further data were presented at the 51st ASCO meeting in Chicago, IL. In the dabrafenib plus panitumumab arm, complete response/partial response and stable disease were seen in 1 and 16 patients. In the dabrafenib plus panitumumab and trametinib arm, complete response/partial response and stable disease were seen in 9 and 21 patients [&lt;ulink linkID="1662159" linkType="Reference"&gt;1662159&lt;/ulink&gt;]. In July 2015, data from the trial were presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain. For dabrafenib + panitumumab and dabrafenib + trametinib + panitumumab treatment groups, the confirmed response rates were 10 and 26%, respectively. Data demonstrated that significant dermatologic toxicity was observed with full dose trametinib + panitumumab treatment and acceptable tolerability was seen with dabrafenib + trametinib + panitumumab treatment [&lt;ulink linkID="1678098" linkType="Reference"&gt;1678098&lt;/ulink&gt;]. In October 2016, further data were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Confirmed complete/partial response and stable disease rates for dabrafenib + panitumumab were 10 and 80%, respectively; for trametinib + panitumumab were 0 and 53%, respectively; and for dabrafenib + trametinib + panitumumab were 18 and 67%, respectively. For dabrafenib + panitumumab and trametinib + panitumumab, the median progression-free survival was 3.4 and 2.8 months, respectively [&lt;ulink linkID="1806082" linkType="Reference"&gt;1806082&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pancreatic cancer&lt;/subtitle&gt;In April 2015, an open-label, single group assignment, phase II trial (&lt;ulink linkID="227937" linkType="Protocol"&gt;NCT02428270&lt;/ulink&gt;; MOBILITY-002) of GSK-2256098 and &lt;ulink linkID="55288" linkType="Drug"&gt;trametinib&lt;/ulink&gt; was planned to be initiated in June 2015, in advanced pancreatic cancer patients (expected n = 24). At that time, the trial was expected to complete in December 2018. In April 2016, the trial was initiated in Canada. In February  2018, the trial was ongoing but was no longer recruiting participants [&lt;ulink linkID="1655393" linkType="Reference"&gt;1655393&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, a multinational, phase II randomized, double-blind, placebo-controlled trial (&lt;ulink linkID="71807" linkType="Protocol"&gt;NCT01231581&lt;/ulink&gt;; 113487) was initiated, to evaluate the safety and efficacy of trametinib DMSO plus gemcitabine in patients (estimated n = 150)  with metastatic pancreatic cancer. The primary endpoint was overall survival at 18 months. The trial completed in February 2013 [&lt;ulink linkID="1141173" linkType="Reference"&gt;1141173&lt;/ulink&gt;]. In January 2013, first clinical data were presented at ASCO's Gastrointestinal Cancer Symposium in San Francisco, CA. Patients (n = 160) received gemcitabine plus trametinib or placebo daily. Results showed that combination with trametinib failed to improve overall survival, progression-free survival, overall response rate, and duration of response when compared to placebo treated patients. The incidence of skin, gastrointestinal and hematologic  toxicities were also increased. More patients in the gemcitabine arm required dose reduction or interruption in treatment [&lt;ulink linkID="1363527" linkType="Reference"&gt;1363527&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Thyroid cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2012, a National Comprehensive Cancer Network (NCCN)-led randomized, crossover assignment, open-label, phase II trial (&lt;ulink linkID="97344" linkType="Protocol"&gt;NCT01723202&lt;/ulink&gt;; OSU-12064, NCI-2012-01700, NCCNGSK20008) was initiated in the US to evaluate trametinib in combination with dabrafenib in treating patients with recurrent thyroid cancer. The primary endpoint was overall objective response rate over 24 weeks. At that time, the trial was expected to complete in December 2019 [&lt;ulink linkID="2102032" linkType="Reference"&gt;2102032&lt;/ulink&gt;]. In June 2017, clinical data were presented at the 53rd ASCO meeting in Chicago, IL. Patients with recurrent thyroid cancer (n = 53) received dabrafenib 150 mg (po, bid) or  dabrafenib 150 mg (po bid) + trametinib 2 mg (po, qd). Median follow-up period was 13 months. Partial response, minor response, stable disease and progressive disease was observed in 10, 1, 9 and 2 patients in the dabrafenib group (n = 22) and in  9, 4, 10 and 1 patients in the dabrafenib + trametinib group (n = 24), respectively. Median progression-free survival and median duration of response was 11.4 and 15.6 months with dabrafenib and 15.1 and 13.3 months with dabrafenib + trametinib, respectively. Both treatments were well tolerated [&lt;ulink linkID="1932530" linkType="Reference"&gt;1932530&lt;/ulink&gt;]. In April 2018, the trial was ongoing, but was no longer recruiting participants  [&lt;ulink linkID="2102032" linkType="Reference"&gt;2102032&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;/&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In March 2017, an interventional, single-group assigned, phase I trial (&lt;ulink linkID="291387" linkType="Protocol"&gt;NCT03085056&lt;/ulink&gt;; 15-055) to evaluate the safety and tolerability of trametinib in combination with paclitaxel in patients (expected n = 12) with ATC was initiated in the US. In April 2018, the trial was expected to complete in March 2019  [&lt;ulink linkID="1910990" linkType="Reference"&gt;1910990&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, a multicenter, open-label, single-group, phase I study (&lt;ulink linkID="81015" linkType="Protocol"&gt;NCT01438554&lt;/ulink&gt;; J1162; NA_00048646) began in the US to assess the safety of pazopanib in combination with trametinib in patients with  advanced solid tumors, particularly advanced differentiated thyroid cancer (expected n = 61). The primary endpoints were maximum tolerated dose and  adverse events. The study was expected to complete in October 2013 [&lt;ulink linkID="1255249" linkType="Reference"&gt;1255249&lt;/ulink&gt;]. In June 2012,  phase I data were presented at the 48th ASCO meeting in Chicago, IL.   In the study, patients with advanced differentiated thyroid cancer  (n  =25), received trametinib (1, 1.5 and 2.0  mg, qd, po) plus     pazopanib (400, 600 or 800 mg, qd, po). No dose limiting toxicities  were  observed   at dose level one. At that time, the trial was ongoing [&lt;ulink linkID="1299639" linkType="Reference"&gt;1299639&lt;/ulink&gt;]. The trial completed in August 2018 [&lt;ulink linkID="1255249" linkType="Reference"&gt;1255249&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Biliary cancer&lt;/subtitle&gt;In May 2015, data from an investigator-led, open-label, randomized, phase II study (SWOG S1310; &lt;ulink linkID="169253" linkType="Protocol"&gt;NCT02042443&lt;/ulink&gt;) of trametinib compared with 5-fluorouracil or capecitabine in patients (expected n = 80) with refractory advanced biliary cancer were presented  at the 51st ASCO meeting in Chicago, IL. Patients would be randomized to receive trametinib (2 mg daily) compared with 5-fluorouracil (400 mg/m2 bolus and 2400 mg/m2 infusion over 48 h) with leucovorin (400 mg/m2, q2w) or capecitabine (1000 mg/m2 bid) 14 days on 7 days off. At that time, the protocol was closed to further accrual and final analysis was to follow [&lt;ulink linkID="1666201" linkType="Reference"&gt;1666201&lt;/ulink&gt;]. In June 2017, clinical data were presented at the 53rd ASCO meeting in Chicago, IL. Partial response and progressive disease was observed in 8 (p &amp;gt; 0.99) and 79% (trametinib), 10 and 40% (chemotherapy), respectively. In chemotherapy group, 40% achieved disease control rate. The median progression free survival and overall survival was 2.8 and 7.9 months (5-fluorouracil + leucovorin/capecitabine), 1.3 and 4.3 months (trametinib). The adverse events reported were rash acneiform, fatigue, nausea, vomiting, anemia, thrombocytopenia, diarrhea, edema limbs, hand foot skin reaction, increase in ALT and AST, hypertension, thromboembolic events and decrease in WBC [&lt;ulink linkID="1931779" linkType="Reference"&gt;1931779&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, a non-randomized, single group assignment, open-label phase II study (&lt;ulink linkID="154887" linkType="Protocol"&gt;NCT01943864&lt;/ulink&gt;; 117134) was planned to be initiated in patients (expected n = 20) with advanced or metastatic biliary tract cancers, in Japan, later that month. The primary endpoint was the percentage of patients with non-progressive disease (PD) rate at week 12. At that time, the study was expected to be completed in February 2015. Later that month, the trial was initiated. In February 2016, the trial was ongoing, but was no longer recruiting participants. By October 2016, data reported from 20 patients analyzed a 12 weeks showed that 2 patients had stable disease, 3 had progressive disease, while 12 patients had progressive disease before week 12. Censored before week 12 were 3 patients, and 2 patients were categorized as complete response plus partial response plus stable disease plus non-complete response/partial response [&lt;ulink linkID="1483778" linkType="Reference"&gt;1483778&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gastrointestinal stromal tumor&lt;/subtitle&gt;In January 2015, an open label, non-randomized, single group assignment, phase II study (&lt;ulink linkID="220381" linkType="Protocol"&gt;NCT02342600&lt;/ulink&gt;; SARC029), was planned to be initiated in March 2015,  to evaluate the combination of trametinib and &lt;ulink linkID="43738" linkType="Drug"&gt;pazopanib&lt;/ulink&gt; in patients (expected n = 45), with advanced gastrointestinal stromal tumors (GIST). At that time the trial was expected to be completed in March 2018;  in March 2016, the trial was to start in January 2017 [&lt;ulink linkID="1635892" linkType="Reference"&gt;1635892&lt;/ulink&gt;]. However, in March 2017, the trial was withdrawn prior to enrollment [&lt;ulink linkID="1635892" linkType="Reference"&gt;1635892&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical cancer&lt;/subtitle&gt;In October 2013, an open-label, single-arm, single-stage, interventional, single group assignment, safety/efficacy, phase II trial (&lt;ulink linkID="157304" linkType="Protocol"&gt;NCT01958112&lt;/ulink&gt;; 13-334) of GSK-1120212 in combination with &lt;ulink linkID="63799" linkType="Drug"&gt;GSK-2141795&lt;/ulink&gt;, was expected to be initiated in the US, in patients with persistent or recurrent cervical cancer  (expected n = 35). At that time the trial was estimated to complete in March 2020. In February 2014, recruitment was initiated  [&lt;ulink linkID="1503966" linkType="Reference"&gt;1503966&lt;/ulink&gt;]. In May 2015, it was rteported at the 51st ASCO meeting in Chicago, IL, that patients in the trial received GSK-1120212 (1.5 mg, po, qd) + GSK-2141795 (50 mg, po, qd) continuously in 28 day cycles. Primary objective was to evaluate the best objective response (complete + partial remission) as per response evaluation criteria in solid tumors. The secondary objectives were to evaluate the progression free survival and overall survival [&lt;ulink linkID="1666045" linkType="Reference"&gt;1666045&lt;/ulink&gt;]. In June 2015, recruitment to the trial was suspended  due to drug supply [&lt;ulink linkID="1503966" linkType="Reference"&gt;1503966&lt;/ulink&gt;], and by by August 2016, recruitment to the trial had been terminated  [&lt;ulink linkID="1666045" linkType="Reference"&gt;1666045&lt;/ulink&gt;];  in November 2017,  the trial  completed [&lt;ulink linkID="1503966" linkType="Reference"&gt;1503966&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumor&lt;/subtitle&gt;In  October 2018, it was reported at the 2018 ESMO Congress in Munich, Germany that a global, open-label, phase II study (&lt;ulink linkID="253525" linkType="Protocol"&gt;NCT02684058&lt;/ulink&gt;) was planned to evaluate the anti-tumor activity of the combination of dabrafenib + trametinib in pediatric patients with BRAF V600amutant high-grade glioma (HGG; estimated n = 40) or low-grade glioma (LGG; estimated n = 102). For both glioma cohorts, primary endpoint was overall response rate; and secondary endpoints included duration of response, progression-free survival, time to response, clinical benefit rate, overall survival, and safety/tolerability. At that time, recruitment was ongoing from up to 70 sites across 17 countries [&lt;ulink linkID="2084668" linkType="Reference"&gt;2084668&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, phase I data from a phase I/IIa study (MEK116540; &lt;ulink linkID="184235" linkType="Protocol"&gt;NCT02124772&lt;/ulink&gt;) which evaluated the safety and tolerability of trametinib with or without dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 progressive plexiform neurofibromas were presented at the 54th ASCO Annual Meeting in Chicago, IL. Patients in dose-finding cohort (part-A; n = 40) received trametinib (0.0125, 0.025, 0.032, and 0.04 mg/kg, qd) and combination cohort (part C; n = 12) received trametinib (0.025 mg/kg) + dabrafenib (50 or 100% of recommend phase II dose). Mucosal inflammation, hyponatremia, pelvic abscess, ALT increase, dermatitis acneiform and hypotension were the DLTs reported in part A study. The recommended trametinib dose based on DLTs and initial pharmacokinetic data was 0.032 and 0.025 mg/kg for patients with &amp;lt; 6 and &amp;gt;/= 6 years of age, respectively. In Part C study, DLTs were not reported. In Part A and C, paronychia and rash were the most commonly reported treatment-related adverse events. Partial responses, stable disease, progressive disease were observed in 7, 19 and 4 patients, respectively, in part A and 2, 8 and 2 patients, respectively, in part C [&lt;ulink linkID="2039451" linkType="Reference"&gt;2039451&lt;/ulink&gt;]. Further safety and efficacy interim analyses results were presented at the same conference. Best overall response using Dombi criteria by independent radiologic review was complete response (CR), partial response (PR), stable disease (SD), progressive disease, not evaluable, objective response (CR + PR) and disease control (CR + PR + SD) in 0, 46, 35, 4, 15, 46 and 81% of patients, respectively. Median progression-free survival was not yet reached. A total of six disease progression events were reported. Incidence of any grade treatment-related serious adverse events (AEs) and any treatment-related AE was 12 and 96%, respectively [&lt;ulink linkID="2039257" linkType="Reference"&gt;2039257&lt;/ulink&gt;], [&lt;ulink linkID="2055965" linkType="Reference"&gt;2055965&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, an open-label, non-randomized, parallel-assigned, phase I/II trial (&lt;ulink linkID="255305" linkType="Protocol"&gt;NCT02703571&lt;/ulink&gt;; CTMT212X2106  2015-005019-34) of &lt;ulink linkID="65360" linkType="Drug"&gt;ribociclib&lt;/ulink&gt; in combination with trametinib began in the US, Australia, Europe and Canada to assess safety and efficacy in patients (expected n = 124) with metastatic or advanced solid tumors, including advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer. Coprimary endpoints were incidence of dose limiting toxicities and ORR until progression of disease up to 1 year. At that time,  the trial was expected to complete in  March 2021 [&lt;ulink linkID="1742727" linkType="Reference"&gt;1742727&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, a non-randomized, open-label, single-group-assignment, phase II trial (&lt;ulink linkID="167700" linkType="Protocol"&gt;NCT02034110&lt;/ulink&gt;; 117019; ROAR) was initiated in the US, Europe, Canada, Japan and Korea to assess trametinib plus dabrafenib in subjects (expected n = 225) with BRAF V600E-mutated cancer, including anaplastic thyroid cancer, biliary tract cancer, gastrointestinal stromal tumor, non-seminomatous germ cell tumor/non-geminomatous germ cell tumor, hairy cell leukemia, WHO Grade 1 or 2 glioma, WHO Grade 3 or 4 (high-grade) glioma, multiple myeloma and adenocarcinoma of the small intestine. The primary endpoint was overall response rate. The trial was expected to complete in August 2020 [&lt;ulink linkID="1955309" linkType="Reference"&gt;1955309&lt;/ulink&gt;]. In June 2017, clinical data regarding the efficacy of dabrafenib and trametinib in patients with BRAF V600E–mutated anaplastic thyroid cancer (ATC) were presented at the 53rd ASCO meeting in Chicago, IL. Investigator-assessed confirmed overall response rate  was 69% (primary endpoint) with seven ongoing responses. Dabrafenib + trametinib combination therapy significantly improved outcomes in patients with BRAF V600E–mutated anaplastic thyroid cancer with a favorable safety profile [&lt;ulink linkID="1932260" linkType="Reference"&gt;1932260&lt;/ulink&gt;].  In October 2018, updated  safety and efficacy results  were presented at 2018 ESMO Congress in Munich, Germany.   In intent-to-treat-evaluation population, complete response, partial response, stable disease, progressive disease and objective response rates were 7, 59, 22, 11 and 67% by investigator assessment; 7, 48, 19, 22 and 56% by independent review; and in BRAFV600E-evaluation population, respective values were 8, 67, 13, 13 and 75% by investigator assessment and 8, 54, 13, 21, 4 and 63% by independent review, respectively [&lt;ulink linkID="2084711" linkType="Reference"&gt;2084711&lt;/ulink&gt;]. In November 2018, results were presented at the 30th EORTC-NCI-AACR Symposium for Molecular Targets and Cancer Therapeutics in Dublin, Ireland. Overall 78% of patients with advanced HCL with the BRAF V600E mutation whose cancer did not respond to first-line treatment or who had relapsed after two or more lines of treatment responded many with complete responses. In patients with advanced biliary tract cancer and adenocarcinoma of the small intestine, dabrafenib+trametinib had shranken the tumor.  As of November 16, out of 32, 13 evaluable patients with biliary tract cancer and two of the three patients with adenocarcinoma of the small intestine had experienced enough reduction in the size of their tumors to be classified as a tumor response. Patients with advanced or metastatic biliary tract cancer survived a median of 12 months [&lt;ulink linkID="2103266" linkType="Reference"&gt;2103266&lt;/ulink&gt;]. In December 2018, further data of 43 patients with BRAF V600E–mutated hairy cell leukemia were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. CR without minimal residual disease (MRD) was achieved by 6 patients, CR with MRD was achieved by 14 patients, PR was achieved by 12 patients, minor response was achieved by 8 patients, SD was not observed, PD was observed in 1 patient, and ORR was 78%. The estimated PFS and OS rates at 12 months were both 97.6%. Any grade AE was reported by 41 patients, grade 3/4 AE was reported by 21 patients, and any grade serious AE was reported by 18 patients [&lt;ulink linkID="2098565" linkType="Reference"&gt;2098565&lt;/ulink&gt;]. By December 2018, the trial was active but not recruiting patients. At that time, the trial was expected to complete in June 2020 [&lt;ulink linkID="1955309" linkType="Reference"&gt;1955309&lt;/ulink&gt;]. In January 2019, further data of 33 patients with BRAF V600E-mutated biliary tract cancer were presented at 2019 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA. In 32 evaluable patients, investigator-assessed ORR was 41% with 6 of 13 responses were ongoing at data cutoff, 7 of 13 patients had duration of response for &amp;gt;/= 6 months. Median PFS and OS were 7.2 and 11.3 months, respectively. Increased gamma-glutamyltransferase (9%) and decreased white blood cell count (9%) were grade 3/4 adverse events [&lt;ulink linkID="2113109" linkType="Reference"&gt;2113109&lt;/ulink&gt;]. In November 2018, clinical study results were presented at 23 Annual Scientific Meeting of the Society for Neuro-Oncology in New Orleans, LA. The ORR was 26% ,  median progression-free survival  was 1.9-month and median overall survival  was 11.7-month. Grade 3/4 adverse events noted in patients with HGG included neutropenia (8%) and fatigue (5%). It was concluded that dabrafenib + trametinib demonstrated promising efficacy in patients with BRAF V600E-mutated recurrent/refractory HGG [&lt;ulink linkID="2118158" linkType="Reference"&gt;2118158&lt;/ulink&gt;].  At the same conference, results from patients with BRAF V600E mutations in nine rare tumor types, including low-grade glioma (LGG; n = 9) were presented.  Out of nine patients with LGG enrolled at the time of data cutoff (January 2018), eight were evaluable for response. Investigator assessed confirmed ORR was 50%, and three of four responses were ongoing at data cutoff. Duration of response was &amp;gt;/= 18 months in two out of these four patients. Kaplan-Meier estimates for PFS and OS were 50 and 86%, respectively. Fatigue (22%), arthralgia (11%), headache (11%) and diarrhea (11%) were the grade 3/4 AEs observed  &lt;ulink linkID="2118208" linkType="Reference"&gt;[2118208&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Leukemia&lt;/subtitle&gt;In October 2013, an NCI-sponsoered, open-label, single-group, phase II efficacy study (&lt;ulink linkID="147791" linkType="Protocol"&gt;NCT01907815&lt;/ulink&gt;; NCI-2013-01354, 2013-0001, P30CA016672, N01CM00039) of po GSK-2141795 in combination with trametinib was initiated in patients (n = 45) with acute myeloid leukemia (AML) with RAS mutations in the US. In April 2016, the trial was ongoing but not recruiting participants. However, in January 2016, the trial was terminated due to lack of efficacy [&lt;ulink linkID="1468513" linkType="Reference"&gt;1468513&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, clinical data were presented from a phase I/II trial at the 54th ASH meeting in Atlanta, GA. Of 57  patients with NRAS or KRAS mutation, 7, 4, 1 and 4 patients showed best complete remission (CR)/CR with incomplete platelet recovery, marrow CR/morphological leukemia-free state, partial remission (PR) and hematological improvement (HI)-neutrophil/HI-platelet, respectively. PR and hematological improvement (HI)-neutrophil/HI-platelet were observed in 1/37 and 5/37 patients with RAS wild-type or unknown mutation, respectively. The overall response rate was 28 and 20% in patients with  NRAS or KRAS mutation and RAS wild-type or unknown mutation, respectively. At that time, the study and the expansion of a cohort with RAS positive chronic myelomonocytic leukemia patients were ongoing [&lt;ulink linkID="1346642" linkType="Reference"&gt;1346642&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2011, an open-label, single-group-assignment, non-randomized, phase II rollover trial (&lt;ulink linkID="78365" linkType="Protocol"&gt;NCT01376310&lt;/ulink&gt;; 114375) was initiated in the US, Canada, Europe, Korea and Taiwan to allow subjects (expected n = 250) with solid tumors or leukemias who were participating in a clinical trial and benefiting from the drug, either in monotherapy or as part of a combination, continued access. The primary endpoint was number of participants with adverse events. The trial completed in January 2018 [&lt;ulink linkID="2097299" linkType="Reference"&gt;2097299&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, an open-label, non-randomized, US phase II study (&lt;ulink linkID="57847" linkType="Protocol"&gt;NCT00920140&lt;/ulink&gt;; 111759) was initiated in patients (expected n = 75) with relapsed or refractory leukemia. Patients were to receive the maximum tolerated dose (MTD) of trametinib DMSO based on phase I results. The primary outcomes were safety and clinical response. Secondary endpoints included pharmacokinetics and pharmacodynamics [&lt;ulink linkID="1045072" linkType="Reference"&gt;1045072&lt;/ulink&gt;]. In June 2011, preliminary data from 47 patients were presented at the 47th ASCO meeting in Chicago, IL. A 25% overall response rate in patients with RAS mutation was demonstrated. The safety profile of the monotherapy suggested the treatment would work well with other anti-leukemic therapies [&lt;ulink linkID="1196464" linkType="Reference"&gt;1196464&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, data were presented from a phase I study of  trametinib DMSO  in patients (n = 14) with relapsed/refractory acute myelogenous leukemia and other hematological malignancies at the 52nd ASH meeting in Orlando, FL. A dose of  2 mg qd was determined as the recommended phase II dose. A complete response was seen in one KRAS mutant patient   at the 2 mg dose level. Duration of complete response was 4 weeks [&lt;ulink linkID="1152314" linkType="Reference"&gt;1152314&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic colon and colorectal cancerPhase II&lt;/subtitle&gt;In March 2018, an investigator (&lt;ulink linkID="23382" linkType="Company"&gt;MD Anderson Cancer Center&lt;/ulink&gt;)-initiated, company-sponsored open-label, single-group-assignment, phase II trial (&lt;ulink linkID="328791" linkType="Protocol"&gt;NCT03428126&lt;/ulink&gt;; 2017-0514; NCI-2018-00911) was initiated in the US to assess the safety of &lt;ulink linkID="81193" linkType="Drug"&gt;durvalumab&lt;/ulink&gt; in combination with trametinib in patients (expected n = 56) with MSS metastatic colon and colorectal cancer . The primary endpoint was to determine the MTD at 28 days and best overall response at 2 months. At that time, the trial was expected to complete in November 2019 [&lt;ulink linkID="2049230" linkType="Reference"&gt;2049230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies in solid tumors&lt;/subtitle&gt;In June 2017, clinical data from a dose escalation, phase I study (&lt;ulink linkID="146945" linkType="Protocol"&gt;NCT01902173&lt;/ulink&gt;; SWOG S1221) in BRAF mutant cancer were presented at the 53rd ASCO meeting in Chicago, IL. Patients (n = 21) were randomized to receive 3 + 3 escalated doses of dabrafenib (150 mg, po, bid) + GSK-214179 (50 or 75 mg, po, qd) or dabrafenib (150 mg, po, bid) + trametinib (25, 50 or 75 mg, po, bid) + GSK-214179 (1.5 or 2 mg, po, qd). . The grade-3 or higher adverse events reported were fever, lymphopenia, hyperglycemia, hyponatremia, maculopapular rash, skin nitric oxide synthetase, capillary leak syndrome and vascular nitric oxide synthetase [&lt;ulink linkID="1931906" linkType="Reference"&gt;1931906&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2016, an open-label, non-randomized, single-arm, phase I trial (&lt;ulink linkID="255708" linkType="Protocol"&gt;CTR20160115&lt;/ulink&gt;; CTMT212A2103) was planned to be initiated in China to evaluate the PK characteristics and safety of single and repeat oral administrations in Chinese subjects (expected n = 10) with solid tumors [&lt;ulink linkID="1742448" linkType="Reference"&gt;1742448&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, clinical data were presented from a phase Ib dose finding study in 30 patients with selected advanced solid tumors at the 51st ASCO meeting in Chicago, IL. Patients in dose-finding and expansion cohort received trametinib (1.0, 0.5, 0.5, 0.25 and 0.375 mg qd; five dose levels) in combination with GSK-2256098 (500 mg bid) and the dose-escalation was continued until the MTD was established. At dose levels at or below MTD, the combination had an acceptable safety profile.  In combination with GSK-2256098, the AUC of trametinib was 2- to 4-fold increased in plasma, while pharmacokinetics was not altered [&lt;ulink linkID="1664377" linkType="Reference"&gt;1664377&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In ​April 2015, clinical data were presented  from a multicenter, non-randomized, single-sequence, patient-blind, placebo-controlled, phase I study (MEK114655; &lt;ulink linkID="193134" linkType="Protocol"&gt;NCT01658553&lt;/ulink&gt;) in 35 patients with solid tumors at the 106th AACR meeting in Philadelphia, PA. Patients received placebo on day 1 and 2-mg trametinib  qd on days 2 to 14 and finally all patients received a single 3-mg dose of trametinib on day 15. Trametinib had no effect on change in baseline QTc using Fridericia's formula (QTcF), Bazett's formula or individual formula when compared with time-matched placebo. ECG abnormalities were not reported and QTcF had no association with plasma levels of trametinib [&lt;ulink linkID="1648941" linkType="Reference"&gt;1648941&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, a phase I, open-label, multicenter, dose-escalation study (study number P3K113794)  and safety data were presented at the 105th AACR meeting in San Diego, CA. Patients (n = 69) received oral continuous &lt;ulink linkID="64359" linkType="Drug"&gt;GSK-2126458&lt;/ulink&gt;  or intermittent GSK-2126458 bid  + trametinib. For GSK-2126458 and trametinib, the MTD in QD cohort was 2 and 1 mg, respectively, and also 1 and 1.5 mg, respectively [&lt;ulink linkID="1539847" linkType="Reference"&gt;1539847&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, data were presented from an open-label, multi-arm, two-part, phase I/Ib study  (&lt;ulink linkID="69713" linkType="Protocol"&gt;NCT01192165&lt;/ulink&gt;) in patients with advanced solid tumors or Kras mutant advanced NSCLC at the 49th ASCO meeting in Chicago, IL.  Patients  received  trametinib  plus &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt;. Trametinib plus docetaxel was tolerable in the presence of growth factor support. Of the 25 patients with Kras-positive, 7 patients showed partial response and 8 patients had stable disease, of whom 5 patients showed minor response [&lt;ulink linkID="1427850" linkType="Reference"&gt;1427850&lt;/ulink&gt;]. Further data were presented at the same conference. Patients  received  trametinib  plus  &lt;ulink linkID="3536" linkType="Drug"&gt;pemetrexed&lt;/ulink&gt;. Of the 23 patients with Kras-positive cells, 4 patients showed partial response and 11 patients had stable disease, of whom 2 patients showed minor response [&lt;ulink linkID="1427848" linkType="Reference"&gt;1427848&lt;/ulink&gt;]; In October 2013,  similar data were presented at the 15th World Conference on Lung Cancer in Sydney, Australia [&lt;ulink linkID="1491634" linkType="Reference"&gt;1491634&lt;/ulink&gt;] [&lt;ulink linkID="1491635" linkType="Reference"&gt;1491635&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, a single-group assignment, open-label, phase I study (&lt;ulink linkID="100526" linkType="Protocol"&gt;NCT01740648&lt;/ulink&gt;, OSU-12054, NCI-2012-02158) was initiated in the US to evaluate trametinib + 5-FU + radiation in patients with stage II-III rectal cancer. The primary endpoint was the MTD of the combination. At that time, the trial was expected to complete in December 2022 [&lt;ulink linkID="2102050" linkType="Reference"&gt;2102050&lt;/ulink&gt;]. In June 2016, clinical data from a standard 3+3 design phase I study (&lt;ulink linkID="100526" linkType="Protocol"&gt;NCT01740648&lt;/ulink&gt;) for the potential treatment of locally advanced rectal cancer were presented at the 52nd ASCO meeting in Chicago, IL. Patients (n = 10) were received trametinib (0.5, 1 and 2 mg, daily) in combination with 5-fluorouracil (225 mg/m2/day, 5 days week) and a total of 50.4 Gy radiation (1.8 Gy daily fractions). There were no grade 4 adverse events reported. No interruptions were reported in radiation therapy and 5-fluorouracil was held in one patient for 3 days due to mucositis [&lt;ulink linkID="1770119" linkType="Reference"&gt;1770119&lt;/ulink&gt;]. In January 2017, further clinical data from 15 patients were presented at the 2017 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA.  After two weeks of therapy, one patient had discontinued the treatment due to generalized skin rash. Of 9 (33%) patients, 3 and 2 patients had a pathologic complete response (pCR) and near pCR, at the 2 mg dose cohort. However, the neoadjuvant rectal score   was 11.3 and 9.7 in the 2 mg cohort alone, after the exclusion of one DLTexperienced patient and 5-fluorouracil chemoradiation. Dose-dependent decrease in phosphorylated-ERK1/2 with increases in doses of trametinib was observed in the analysis of tumor tissue [&lt;ulink linkID="1896916" linkType="Reference"&gt;1896916&lt;/ulink&gt;]. In April 2017, further clinical data were presented at the 108th AACR Annual Meeting in Washington DC. A DLT of diarrhea was reported in 2 mg trametinib treated group. Total mesorectal excision was completed in all patients and two patients each had wound infection and perineal wound infection at 2 and 4 weeks after total mesorectal excision, respectively [&lt;ulink linkID="1914512" linkType="Reference"&gt;1914512&lt;/ulink&gt;]. In April 2018, the trial was ongoing, but was no longer recruiting participants  [&lt;ulink linkID="2102050" linkType="Reference"&gt;2102050&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, a randomized, open-label, crossover, bio-availability, phase I trial (&lt;ulink linkID="89786" linkType="Protocol"&gt;NCT01647659&lt;/ulink&gt;; 115892) evaluating the relative bio-availability of the tablet versus a pediatric oral solution formulation of trametinib over 168 h began in adult patients (expected n = 15) in the US with solid tumors. At that time, the trial was estimated to complete in November 2012 [&lt;ulink linkID="1396021" linkType="Reference"&gt;1396021&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2012, a phase I trial   (&lt;ulink linkID="67911" linkType="Protocol"&gt;NCT01155453&lt;/ulink&gt;) of trametinib DMSO in combination with &lt;ulink linkID="61901" linkType="Drug"&gt;buparlisib&lt;/ulink&gt;   had been initiated in patients with solid tumors [&lt;ulink linkID="1271722" linkType="Reference"&gt;1271722&lt;/ulink&gt;].  In June 2012, data from the trial were presented at the 48th ASCO meeting in Chicago, IL. The recommended phase 2 dose was 70 mg of buparlisib with 1.5 mg of &lt;ulink linkID="55288" linkType="Drug"&gt;&lt;/ulink&gt;trametinib DMSO. At the time data were reported, dose expansion was ongoing in patients with RAS- or BRAF-mutant pancreatic, ovarian  or NSCLC [&lt;ulink linkID="1296533" linkType="Reference"&gt;1296533&lt;/ulink&gt;]. In September 2013,  data  from the  dose-escalation study were presented at the 2013 European Cancer Congress in Amsterdam, The Netherlands.  The  recommended phase II dose was 60 mg BKM-120 + 1.5 mg GSK-1120212  . A total of 19 of 21 KRAS-/BRAF-mutant ovarian cancer patients were evaluable for response. Best overall response (BOR) of partial response was observed in seven patients and stable disease (SD) was observed in nine patients. Of 24 pancreatic patients, 19 were evaluable for efficacy. A total 12 of 19 patients achieved BOR of SD. Overall, 7 of 11 evaluable NSCLC patients (n = 17) had BOR of SD [&lt;ulink linkID="1480284" linkType="Reference"&gt;1480284&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I/II trial (&lt;ulink linkID="82595" linkType="Protocol"&gt;NCT01476137&lt;/ulink&gt;) was initiated in November 2011; the phase I portion of the trial was to the establish MTD in patients with advanced cancer, and the phase II portion of the trial would evaluate overall response rate at 1 year in patients with multiple myeloma or solid tumors, putatively endometrial and triple-negative breast cancer. The trial completed in March 2013 [&lt;ulink linkID="1352404" linkType="Reference"&gt;1352404&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, clinical data were presented at the 23rd AACR-NCI-EORTC International Conference in San Francisco, CA. A phase Ib, open-label, dose-escalation, non-randomized, multicenter study evaluated the safety and tolerability, and investigated the recommended phase II dose (RRP2D) of trametinib DMSO (0.5, 1, 1.5 or 2 mg/kg qd) in combination with &lt;ulink linkID="13340" linkType="Drug"&gt;everolimus&lt;/ulink&gt; (5 or 7.5 mg qd or qod). DLTs of grade 3 stomatitis, mucositis, dermatitis acneiform, dehydration and grade 4 thrombocytopenia were observed: the RRP2D  was not determined. There were no adverse pharmacokinetic interactions between the two drugs [&lt;ulink linkID="1240066" linkType="Reference"&gt;1240066&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2011, GSK began a non-randomized, open label, phase I trial (&lt;ulink linkID="75836" linkType="Protocol"&gt;NCT01324258&lt;/ulink&gt;, 114784), of GSK-1120212 in combination with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; in   subjects (n = 19) with solid tumors in Japan [&lt;ulink linkID="1248163" linkType="Reference"&gt;1248163&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2010, a phase I, dose-escalation, open-label, US study (&lt;ulink linkID="67101" linkType="Protocol"&gt;NCT01138085&lt;/ulink&gt;; 113886) was initiated to determine the recommended phase II dose and regimen for a combination of the MEK inhibitor trametinib DMSO  and &lt;ulink linkID="63799" linkType="Drug"&gt;GSK-2141795&lt;/ulink&gt; in subjects (expected n = 125) with solid tumors (part 1) and pancreatic, endometrial or colorectal cancer (part 2). At that time, the trial was expected to be completed in October 2011  [&lt;ulink linkID="1167817" linkType="Reference"&gt;1167817&lt;/ulink&gt;]. In June 2011, clinical data were presented at the 47th ASCO meeting in Chicago, IL.  Patients were administered trametinib DMSO  at 0.5, 1, 1.5  and  2 mg, plus GSK-2141795 at 25, 50 and 75 mg po qd in cohorts of 1 to 10.  By week 8, nine patients showed clinical progression. Partial response was seen in three patients. Two patients had no measurable disease    [&lt;ulink linkID="1195598" linkType="Reference"&gt;1195598&lt;/ulink&gt;]. In November 2011, further data from this trial were presented at the 23rd AACR-NCI-EORTC International Conference in San Francisco, CA. By this time, 34 patients had been treated, several of whom reported stable disease, with 2 patients remaining on the study for &amp;gt; 6 months [&lt;ulink linkID="1240101" linkType="Reference"&gt;1240101&lt;/ulink&gt;].In August 2009, a non-randomized, open-label, single group assignment, pharmacokinetics phase Ib trial (&lt;ulink linkID="80521" linkType="Protocol"&gt;NCT01428427&lt;/ulink&gt;;  	112111) was initiated in the US in patients (expected n = 32) with solid tumors to assess trametinib DMSO in combination with gemcitabine.In November 2011, the trial was completed [&lt;ulink linkID="1466449" linkType="Reference"&gt;1466449&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2009, an open-label, single-group assignment, phase I trial (&lt;ulink linkID="59469" linkType="Protocol"&gt;NCT00955773&lt;/ulink&gt;; 112110) evaluating trametinib in combination with &lt;ulink linkID="13340" linkType="Drug"&gt;everolimus&lt;/ulink&gt; began in patients (expected n = 90) in the US with solid tumors, including metastatic pancreatic cancer and KRAS mutant NSCLC. The primary endpoint was adverse events and changes in laboratory values and vital signs. At that time, the trial was estimated to complete in November 2011 [&lt;ulink linkID="1395999" linkType="Reference"&gt;1395999&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2008, an open-label, comparative, multiple dose, dose-ranging, US phase I trial (&lt;ulink linkID="34707" linkType="Protocol"&gt;NCT00687622&lt;/ulink&gt;; MEK111054) was initiated in patients (expected n = 94) with solid tumors or lymphoma in the US. Patients were to receive escalating oral doses of the drug for 21 days. The study was to be in three parts: part I to identify the MTD; part II to explore the safety, tolerability and effectiveness of trametinib DMSO; and part III to determine a range of effective doses.The study completed in November 2011 [&lt;ulink linkID="945050" linkType="Reference"&gt;945050&lt;/ulink&gt;]. In June 2010, data were presented at the 46th ASCO meeting in Chicago, IL. Trametinib DMSO was well tolerated in patients (n = 84); DLTs included rash, diarrhea and central serious retinopathy. The recommended phase II dose was 2 mg qd and MTD was 3 mg qd. Partial responses (PR) and stable disease were observed in BRAF+, BRAF mutant, and BRAF wild-type melanoma patients. Pancreatic cancer patients reported tumor reduction [&lt;ulink linkID="1103876" linkType="Reference"&gt;1103876&lt;/ulink&gt;]. In November 2010, data were presented at the 22nd EORTC-NCI-AACR Symposium in Berlin, Germany. Trametinib DMSO generally showed a linear and dose-proportional pharmacokinetic profile. Of 16 patients with B-RAFV600E mutant melanoma, one showed complete response and 5 showed PRs; and of the 6 patients with B-RAFV600K mutant melanoma, four showed PRs [&lt;ulink linkID="1145227" linkType="Reference"&gt;1145227&lt;/ulink&gt;]. In April 2011, population pharmacodynamic data were presented at the 102nd AACR meeting in Orlando, FL. The results suggested an optimal once daily dosing schedule [&lt;ulink linkID="1175462" linkType="Reference"&gt;1175462&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In December 2017, an expanded access, compassionate use trial (&lt;ulink linkID="324153" linkType="Protocol"&gt;NCT03386071&lt;/ulink&gt;; 17-001886) was initiated in Switzerland in males with progressive mCRPC [&lt;ulink linkID="1995660" linkType="Reference"&gt;1995660&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In June 2016, clinical data from a study to evaluate combination of dabrafenib and trametinib were presented at the 52nd ASCO meeting in Chicago, IL.  Obesity was associated with improved PFS and overall-survival in patients treated with dabrafenib + trametinib. In normal, overweight and obese patients, the median PFS was 9.6, 11, 15.7 months; median overall-survival was 19.8, 25.6 and 33 months; response rate was 64, 65 and 77%, respectively [&lt;ulink linkID="1767235" linkType="Reference"&gt;1767235&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. In various cell line xenograft models, &lt;ulink linkID="70877" linkType="Drug"&gt;GSK-525762&lt;/ulink&gt; in combination with trametinib (daily dosed) improved efficacy when compared with monotherapy. In small-cell lung cancer cell lines with elevated p-ERK 1/2, GSK-525762 + trametinib combination showed synergistic effect [&lt;ulink linkID="1749145" linkType="Reference"&gt;1749145&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2014, preclinical data were presented at the 105th AACR meeting in San Diego, CA.  Dabrafenib and trametinib up-regulated the HLA molecules and melanoma antigen MART1 expression on tumor cells. In BRAF (V600E) melanoma cell lines, dabrafenib and trametinib down-regulated immune-suppressive factors such as PD-L1, VEGF and IL8. At that time, combination studies of of trametinib + immunomodulators in murine syngeneic tumor models was ongoing [&lt;ulink linkID="1540034" linkType="Reference"&gt;1540034&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the AACR annual meeting in Chicago, IL. Data showed that nine of 11 BRAF-V600E, four of 5 BRAF-V600K and the BRAF-V600D cell lines were sensitive to cell growth inhibition by trametinib. The combination of trametinib and dabrafenib also showed synergistic activity, with enhanced decrease of ppERK phosphorylation and S6 ribosomal protein phosphorylation (pS6P) in the lines sensitive to either single agents. Overall, the combination of trametinib or dabrafenib with &lt;ulink linkID="64359" linkType="Drug"&gt;&lt;/ulink&gt;GSK-2126458 synergistically inhibited cell growth, enhanced apoptosis  and decreased pS6P in 17/17, 9/9, and 3/3 BRAF-V600E mutant cell lines, respectively [&lt;ulink linkID="1275198" linkType="Reference"&gt;1275198&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, preclinical data were presented at the 70th Annual Meeting of the JCA in Nagoya, Japan. In most colo&lt;/para&gt;&lt;para&gt; cancer cell line trametinib DMSO led to growth inhibition with upregulation of p15INK4b and/or p27KIP1. Tumor growth was seen with po trametinib DMSO in HT-29 and COLO205 xenografts; COLO205 was more sensitive to trametinib DMSO-induced apoptosis [&lt;ulink linkID="1266251" linkType="Reference"&gt;1266251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, preclinical data were presented at the 2011 ARVO Annual Meeting in Fort Lauderdale, FL. Preclinical studies evaluated the activity of combination treatment with the MEK inhibitor trametinib DMSO  and the PI3K inhibitor GSK-2126458 for metastatic uveal melanoma. The combination of MEK and PI3K inhibition potentiated the induction of apoptosis in uveal melanoma cells in vitro [&lt;ulink linkID="1181004" linkType="Reference"&gt;1181004&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, data were presented at the 102nd AACR meeting in Orlando, FL. When tested against RAS/RAF mutant NSCLC cell lines, trametinib DMSO inhibited cell growth in 12 of 28 of the cell lines and induced apoptosis in 7 of 28 of the cell lines; in contrast, &lt;ulink linkID="13340" linkType="Drug"&gt;everolimus&lt;/ulink&gt; and &lt;ulink linkID="11961" linkType="Drug"&gt;erlotinib&lt;/ulink&gt; displayed minimal to no activity as single agents. The combination of trametinib DMSO and everolimus augmented suppression of cell growth in 23 of 28  RAS/RAF mutant cell lines and enhanced apoptosis induction in a subset of the RAS/RAF mutant cell lines [&lt;ulink linkID="1177118" linkType="Reference"&gt;1177118&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, preclinical data  were presented at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland. Trametinib DMSO demonstrated preferential binding and  more potent inhibition of unactivated MEK over  the activated enzyme [&lt;ulink linkID="951984" linkType="Reference"&gt;951984&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007,  data were presented. Trametinib DMSO exhibited potency and specificity for MEK-1 and MEK-2, but did not compete with the ATP binding site. The compound was active against 100% of B-raf mutant lines and 71% of Ras mutant cell lines tested. Efficacy had also been observed in multiple tumor xenograft models. The molecule exhibited potential for broad antitumor activity when combined with Akt/PI3K inhibitors [&lt;ulink linkID="805587" linkType="Reference"&gt;805587&lt;/ulink&gt;]. In April 2011, further mechanism of action data were presented at the 102nd AACR meeting in Orlando, FL [&lt;ulink linkID="1177039" linkType="Reference"&gt;1177039&lt;/ulink&gt;], [&lt;ulink linkID="1181220" linkType="Reference"&gt;1181220&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In 2010, GSK and &lt;ulink linkID="14783" linkType="Company"&gt;bioMerieux&lt;/ulink&gt; formed a collaboration to develop a molecular theranostic test to detect BRAF-V600 (V600E and V600K) gene mutations. By August 2012, bioMerieux had filed the test for FDA pre-approval [&lt;ulink linkID="1313077" linkType="Reference"&gt;1313077&lt;/ulink&gt;]. In May 2013, bioMerieux  received FDA premarket approval for the test (THxID-BRAF) [&lt;ulink linkID="1430300" linkType="Reference"&gt;1430300&lt;/ulink&gt;],  [&lt;ulink linkID="1431652" linkType="Reference"&gt;1431652&lt;/ulink&gt;]. In June 2014, bioMerieux launched the THxID-BRAF test kit through an agreement with &lt;ulink linkID="DOL1000590" linkType="Company"&gt;Quest Diagnostics&lt;/ulink&gt;, in which it would manufacture the test and Quest Diagnostics would distribute it [&lt;ulink linkID="1567702" linkType="Reference"&gt;1567702&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, the EMA's pediatric committee (PDCO) adopted an opinion agreeing a pediatric investigation plan for the drug in the area of oncology [&lt;ulink linkID="1257233" linkType="Reference"&gt;1257233&lt;/ulink&gt;]. In February 2014, the PDCO adopted a positive opinion on modification to the agreed pediatric investigation plan for the treatment of malignant neoplasms (except melanoma, nervous system, hematopoietic and lymphoid tissue) [&lt;ulink linkID="1528112" linkType="Reference"&gt;1528112&lt;/ulink&gt;]. In December 2015, the PDCO adopted a positive opinion on further modification to the agreed pediatric investigation plan for malignant neoplasms [&lt;ulink linkID="1722938" linkType="Reference"&gt;1722938&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2011, the &lt;ulink linkID="1041750" linkType="Company"&gt;National Comprehensive Cancer Network&lt;/ulink&gt; (NCCN) announced that its Oncology Research Program (ORP) had received two research grants from GSK totaling $4 million to fund research projects on trametinib DMSO. The grants would support investigator-led studies and clinical trials [&lt;ulink linkID="1229754" linkType="Reference"&gt;1229754&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Michael Postow &amp;amp; Richard Carvajal, Memorial Sloan-Kettering Cancer Center, New York, USA&lt;/para&gt;&lt;para&gt;Submission date: 06 August 2011&lt;br/&gt;Publication date: 31 January 2012&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;Trametinib DMSO, being developed by &lt;ulink linkType="Company" linkID="21948"&gt;GlaxoSmithKline&lt;/ulink&gt; under license from &lt;ulink linkType="Company" linkID="17327"&gt;Japan Tobacco&lt;/ulink&gt;, targets MEK-1/-2, a protein that plays an important role in the MAPK growth-promoting signaling pathway. It is expected that trametinib DMSO will be used to treat malignancies driven by mutations that render the MAPK pathway abnormally active, including, but not limited to, melanoma, colorectal cancer, pancreatic cancer, thyroid cancer, NSCLC and leukemia. Preclinical studies demonstrated that trametinib DMSO results in growth inhibition of tumor cell lines and tumor xenografts, especially in cases when a BRAF or RAS mutation is present. The pharmacokinetic profile of trametinib DMSO, in particular its long t1/2, may be an advantage over other MEK inhibitors. Phase I clinical data demonstrated that trametinib DMSO was well tolerated with rash and diarrhea being the most common side effects. A small number of patients experienced central serous retinopathy and this will need to be closely monitored during ongoing clinical evaluation. At the time of publication, a phase III clinical trial was comparing the safety and efficacy of trametinib DMSO with that of chemotherapy in patients with BRAF-mutant advanced melanoma, but results had not been reported. The available data for trametinib DMSO support its continued development as single-agent therapy and in combination with other targeted inhibitors, particularly for patients with activating mutations involving the MAPK pathway.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Melanoma is diagnosed in ~ 85,000 individuals worldwide annually [&lt;ulink linkType="Reference" linkID="1197481"&gt;1197481&lt;/ulink&gt;]. Although typically diagnosed when limited to the skin, melanoma that is metastatic or unresectable is a difficult disease to treat and affected patients face poor prognoses. The only US FDA approved chemotherapy for metastatic melanoma, dacarbazine (DTIC; an alkylating agent), has never been demonstrated to confer an overall survival benefit in a phase III clinical trial and is associated with low response rates of ~ 5 to 20% [&lt;ulink linkType="Reference" linkID="1197725"&gt;1197725&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1222483"&gt;1222483&lt;/ulink&gt;]. Standard chemotherapy has provided only limited benefits for patients with metastatic melanoma, but significant progress has been made with immunotherapeutic and molecularly targeted therapeutic approaches [&lt;ulink linkType="Reference" linkID="1230858"&gt;1230858&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The first FDA approved immunotherapeutic agent for metastatic melanoma was &lt;ulink linkType="Drug" linkID="6306"&gt;aldesleukin&lt;/ulink&gt; (high-dose IL-2) [&lt;ulink linkType="Reference" linkID="242484"&gt;242484&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="272968"&gt;272968&lt;/ulink&gt;]. Approval was granted based on the results of a clinical trial demonstrating a 16% response rate, with a 6% complete response rate. Of particular importance, a small proportion of patients who responded achieved a durable response without further disease progression for several years [&lt;ulink linkType="Reference" linkID="541898"&gt;541898&lt;/ulink&gt;]. Despite the promise of IL-2 therapy, toxicities and significant challenges in its administration have limited its more widespread use.&lt;/para&gt;&lt;para&gt;In 2011, a second immunotherapeutic approach for the treatment of melanoma was approved by the US FDA [&lt;ulink linkType="Reference" linkID="1187080"&gt;1187080&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="36630"&gt;Ipilimumab&lt;/ulink&gt; is a mAb that enhances T-cell activation and proliferation by blocking cytotoxic T-lymphocyte-associated antigen 4, a negative regulator of T-cells. In a randomized, phase III clinical trial (ClinicalTrials.gov identifier: &lt;ulink linkType="Protocol" linkID="25525"&gt;NCT00094653&lt;/ulink&gt;), patients whose disease had progressed on prior therapy had improved overall survival if they received &lt;ulink linkType="Drug" linkID="36630"&gt;ipilimumab&lt;/ulink&gt;, either alone or in combination with a gp100 peptide vaccine &lt;ulink linkType="Drug" linkID="51010"&gt;MDX-1379&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt;; phase III [&lt;ulink linkType="Reference" linkID="1187257"&gt;1187257&lt;/ulink&gt;]), compared with patients who received only &lt;ulink linkType="Drug" linkID="51010"&gt;MDX-1379&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1126655"&gt;1126655&lt;/ulink&gt;]. The overall survival benefit of &lt;ulink linkType="Drug" linkID="36630"&gt;ipilimumab&lt;/ulink&gt; was again validated in a phase III trial in which randomized patients who had not received prior systemic therapy for metastatic disease were treated with DTIC in combination with &lt;ulink linkType="Drug" linkID="36630"&gt;ipilimumab&lt;/ulink&gt; or placebo. In this trial, patients who received &lt;ulink linkType="Drug" linkID="36630"&gt;ipilimumab&lt;/ulink&gt; in combination with DTIC had improved survival compared with patients receiving DTIC and placebo [&lt;ulink linkType="Reference" linkID="1197719"&gt;1197719&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In parallel with advances in immunotherapy, a deeper understanding of the oncogenic signal transduction pathways that are central to melanoma pathophysiology has led to the development of targeted therapeutics. Similar to novel immunotherapeutic strategies for metastatic melanoma, molecularly targeted agents have demonstrated remarkable clinical benefits. Mutations in the tyrosine kinase receptor KIT have been described in melanomas arising from different tissue types, including 39% of mucosal melanomas, 36% of acral melanomas and 28% of melanomas arising from chronically sun-damaged skin [&lt;ulink linkType="Reference" linkID="1222633"&gt;1222633&lt;/ulink&gt;]. Activating KIT mutations initiate a series of signaling events that result in cellular proliferation and propagation of cancer. &lt;ulink linkType="Drug" linkID="11460"&gt;Imatinib&lt;/ulink&gt;, an inhibitor of KIT signaling, has displayed promising clinical efficacy in patients with KIT-mutant melanoma [&lt;ulink linkType="Reference" linkID="901596"&gt;901596&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1212893"&gt;1212893&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1222639"&gt;1222639&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1222640"&gt;1222640&lt;/ulink&gt;]. At the time of publication, several trials with KIT inhibitors, such as &lt;ulink linkType="Drug" linkID="51388"&gt;nilotinib&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="48946"&gt;dasatinib&lt;/ulink&gt;, were ongoing (eg, &lt;ulink linkType="Protocol" linkID="65339"&gt;NCT01099514&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="65529"&gt;NCT01092728&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;Uveal (ocular) melanomas display a pattern of genomic alteration that is distinct from other types of melanoma. A high prevalence of activating mutations involving GNAQ and GNA11, genes which encode for the heterotrimeric G-protein alpha subunits Q and 11, respectively, have been identified [&lt;ulink linkType="Reference" linkID="1222647"&gt;1222647&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1222649"&gt;1222649&lt;/ulink&gt;]. In melanoma, activation of GNAQ or GNA11 results in activation of the MAPK pathway. Melanoma associated with such mutations, therefore, may be especially sensitive to inhibitors of the MAPK pathway, such as MEK inhibitors [&lt;ulink linkType="Reference" linkID="1090207"&gt;1090207&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The best-characterized oncogene in melanoma is BRAF, a serine-threonine kinase. Among a large series of tumors screened for the presence of BRAF mutations, melanoma was found to have the highest prevalence of BRAF mutations (66%) [&lt;ulink linkType="Reference" linkID="1086873"&gt;1086873&lt;/ulink&gt;]. Melanomas harboring BRAF mutations typically arise in skin that has had intermittent sun exposure [&lt;ulink linkType="Reference" linkID="1222681"&gt;1222681&lt;/ulink&gt;]. Several years after the discovery of BRAF mutations in melanoma, clinical trials of targeted inhibitors of mutant BRAF were conducted. The pan-kinase inhibitor &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt; was not effective, possibly because of its incomplete inhibition of the MAPK pathway [&lt;ulink linkType="Reference" linkID="734759"&gt;734759&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1044011"&gt;1044011&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="54469"&gt;Vemurafenib&lt;/ulink&gt;, the first selective BRAF inhibitor to enter clinical development, was associated with a remarkably high response rate in phase I trials [&lt;ulink linkType="Reference" linkID="1126454"&gt;1126454&lt;/ulink&gt;]. A recent, randomized phase III trial (&lt;ulink linkType="Protocol" linkID="61618"&gt;NCT01006980&lt;/ulink&gt;) demonstrated an overall survival benefit of &lt;ulink linkType="Drug" linkID="54469"&gt;vemurafenib&lt;/ulink&gt; compared with the previous reference standard, DTIC [&lt;ulink linkType="Reference" linkID="1197725"&gt;1197725&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Despite high response rates to BRAF inhibition in patients with melanoma, responses are limited in duration and disease progression ultimately ensues [&lt;ulink linkType="Reference" linkID="1222685"&gt;1222685&lt;/ulink&gt;]. Next-generation genetic sequencing modalities have determined that resistance to &lt;ulink linkType="Drug" linkID="54469"&gt;vemurafenib&lt;/ulink&gt; is not caused by the development of secondary BRAF mutations [&lt;ulink linkType="Reference" linkID="1158559"&gt;1158559&lt;/ulink&gt;]. Instead, resistance mechanisms may be heterogeneous, possibly involving alternative cell survival signaling pathways, such as PDGFRbeta. Another possibility is the concept of oncogene bypass, in which RAS activation of downstream components of the MAPK pathway occurs independently of RAF, possibly via a protein called COT [&lt;ulink linkType="Reference" linkID="1158563"&gt;1158563&lt;/ulink&gt;]. Recent research has also implicated a particular splice variant in the BRAF gene that is believed to contribute to resistance to BRAF inhibitors. The encoded variant BRAFVal600Glu protein lacks a region that encompasses the RAS-binding domain and was identified in 6 of 19 patients with acquired resistance to &lt;ulink linkType="Drug" linkID="54469"&gt;vemurafenib&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1248730"&gt;1248730&lt;/ulink&gt;]. Regardless of the proposed mechanism, in many cases, resistance to BRAF inhibition appears to be at least partially dependent upon activation of MEK, a downstream signaling element in the MAPK pathway. Restored MEK activation is sufficient to confer BRAF inhibitor resistance in models of BRAF-mutant melanoma. This raises the intriguing possibility that combination therapy involving a selective BRAF inhibitor, such as &lt;ulink linkType="Drug" linkID="54469"&gt;vemurafenib&lt;/ulink&gt;, with a MEK inhibitor may overcome this mechanism of resistance.&lt;/para&gt;&lt;para&gt;To understand the role of MEK inhibition, it is essential to understand the elements that lead to MEK activation within the MAPK pathway [&lt;ulink linkType="Reference" linkID="1258021"&gt;1258021&lt;/ulink&gt;]. Signaling via the MAPK pathway is initiated by binding of a growth-promoting stimulus (a mitogen) to cell surface receptors. Receptor activation leads to recruitment of additional proteins to the cell plasma membrane, including a protein called RAS. RAS is then activated by conversion of its guanosine diphosphate moiety to guanosine triphosphate (GTP). Activated RAS, in its GTP-bound form, activates RAF, a serine-threonine kinase that phosphorylates its downstream target protein MEK. Once MEK is phosphorylated and therefore activated, MEK phosphorylates ERK. Phosphorylated ERK ultimately enhances the function of a number of transcription factors that are important for gene expression of proteins involved in cell cycle progression and cell growth [&lt;ulink linkType="Reference" linkID="1258021"&gt;1258021&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Several MEK inhibitors have been developed and evaluated in phase I and II clinical trials. The first MEK inhibitor to enter trials was &lt;ulink linkType="Drug" linkID="22774"&gt;PD-184352&lt;/ulink&gt;; however, &lt;ulink linkType="Drug" linkID="22774"&gt;PD-184352&lt;/ulink&gt; did not display promising activity in a phase II trial and further development was halted [&lt;ulink linkType="Reference" linkID="1222690"&gt;1222690&lt;/ulink&gt;]. A second-generation MEK inhibitor, &lt;ulink linkType="Drug" linkID="48980"&gt;PD-0325901&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="18767"&gt;Pfizer&lt;/ulink&gt;), was evaluated in a phase I clinical trial in which 50 of the 66 patients enrolled had melanoma. Among 58 patients who were evaluable for tumor response, confirmed partial responses were observed in 3 patients with melanoma. In addition, stable disease after two treatment cycles was achieved in 23 patients (21 with melanoma), while 10 patients with melanoma still had stable disease after four treatment cycles. Diarrhea and rash were the observed DLTs, possibly preventing dose-escalation to the point of adequate suppression of the MAPK pathway [&lt;ulink linkType="Reference" linkID="1110646"&gt;1110646&lt;/ulink&gt;]. A phase II trial of &lt;ulink linkType="Drug" linkID="48980"&gt;PD-0325901&lt;/ulink&gt; was suspended and further development of the agent halted after several patients suffered retinal vein thromboses and neurological toxicity [&lt;ulink linkType="Reference" linkID="947491"&gt;947491&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1110685"&gt;1110685&lt;/ulink&gt;]. At the time of publication, an additional phase I trial (&lt;ulink linkType="Protocol" linkID="77585"&gt;NCT01347866&lt;/ulink&gt;) of &lt;ulink linkType="Drug" linkID="48980"&gt;PD-0325901&lt;/ulink&gt; in combination with the dual PI3K/mTOR inhibitor &lt;ulink linkType="Drug" linkID="64036"&gt;PF-4691502&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="18767"&gt;Pfizer&lt;/ulink&gt;; phase I [&lt;ulink linkType="Reference" linkID="1145245"&gt;1145245&lt;/ulink&gt;]) had recently been initiated. Another MEK inhibitor, &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca&lt;/ulink&gt;; phase II [&lt;ulink linkType="Reference" linkID="1164873"&gt;1164873&lt;/ulink&gt;]), was evaluated in a phase I trial in patients with advanced solid tumors [&lt;ulink linkType="Reference" linkID="906292"&gt;906292&lt;/ulink&gt;]. None of the melanoma patients in this trial achieved an objective response, but four had disease stabilization. Additional trials with &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; have been completed or are underway [&lt;ulink linkType="Reference" linkID="1137234"&gt;1137234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1222692"&gt;1222692&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Trametinib DMSO (dimethyl sulfoxide), being developed by &lt;ulink linkType="Company" linkID="21948"&gt;GlaxoSmithKline&lt;/ulink&gt; (GSK) under license from &lt;ulink linkType="Company" linkID="17327"&gt;Japan Tobacco&lt;/ulink&gt;, is a reversible, allosteric, ATP non-competitive oral inhibitor of MEK-1/-2, for the potential treatment of solid and hematological cancers, in particular metastatic melanoma [&lt;ulink linkType="Reference" linkID="662918"&gt;662918&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1231025"&gt;1231025&lt;/ulink&gt;]. In October 2011, GSK awarded US $4 million to the Oncology Research Program of the &lt;ulink linkType="Company" linkID="1041750"&gt;National Comprehensive Cancer Network&lt;/ulink&gt;. The funding was provided in the form of two research grants that were to be used to support investigator-initiated clinical and correlative studies of trametinib DMSO as well as GSK's BRAF inhibitor &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; (phase III [&lt;ulink linkType="Reference" linkID="1162994"&gt;1162994&lt;/ulink&gt;]) [&lt;ulink linkType="Reference" linkID="1229754"&gt;1229754&lt;/ulink&gt;]. At the time of publication, single-agent trametinib DMSO was being evaluated in multiple phase I and II clinical trials as well as a phase III trial (&lt;ulink linkType="Protocol" linkID="72448"&gt;NCT01245062&lt;/ulink&gt;) in patients with BRAF-mutant cutaneous melanoma. Trametinib DMSO was also being evaluated in combination with approved and investigational anticancer agents, including &lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt;'s PI3K inhibitor &lt;ulink linkType="Drug" linkID="61901"&gt;BKM-120&lt;/ulink&gt; (phase II; [&lt;ulink linkType="Reference" linkID="1230254"&gt;1230254&lt;/ulink&gt;]) and &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Trametinib was synthesized from 3-cyclopropyl-5-hydroxy-6,8-methyl-1-(2-fluoro-4-iodophenyl-1H,8H-pyrido[2,3-d]pyrimidine-2,4,7-trione, by first converting the 5-hydroxy group to its 5-(3-nitroanilino) derivative. The resultant compound was rearranged via ring opening-ring closure under basic conditions to yield 1-(3-nitrophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1H,6H-pyrido[4,3-d]pyrimidine-2,4,7-trione, which was reduced to the corresponding 1-(3-aminophenyl)amine derivative and transformed to an N-acetyl compound. Malonic acid was added to a suspension of 1-cyclopropyl-3-(2-fluoro-4-iodophenyl)urea in acetic anhydride, and heated at 100degC to produce a pyrimidine-2,4,6-trione intermediate that was converted to the corresponding 4-methylamino derivative. The 4-methylamino-pyrimidine-2,4,6-trione was cyclized with diethyl malonate in diphenyl ether at 220degC to afford the starting 5-hydroxy-pyrido[2,3-d]pyrimidine-2,4,7-trione. The 5-hydroxy group of the starting pyrido[2,3-d]pyrimidine-2,4,7-trione was triflated and then heated with 3-nitroaniline at 130degC to yield 3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-5-(3-nitro-anilino)-1H,8H-pyrido[2,3-d]pyrimidine-2,4,7-trione. Potassium carbonate was added to a suspension of the 5-(3-nitro-anilino)-1H,8H-pyrido[2,3-d]pyrimidine-2,4,7-trione intermediate in methanol and THF, and heated at 80degC for 3 h. The 3-nitro group was then reduced by sodium bisulfite and acetylated with acetic anhydride/pyridine to generate trametinib in good yield. A suspension of trametinib in DMSO was heated at 80degC for 1 to 2 h, and the white precipitate formed was separated to afford trametinib DMSO solvate [&lt;ulink linkType="Reference" linkID="1180150"&gt;1180150&lt;/ulink&gt;]. Alternative syntheses were described in &lt;ulink linkType="Patent" linkID="PA3068897"&gt;WO-2005121142&lt;/ulink&gt;, while other salts and solvates of trametinib were given in &lt;ulink linkType="Patent" linkID="PA6395991"&gt;WO-2011038380&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;Trametinib DMSO was identified by HTS for compounds that induce expression of the cyclin-dependent kinase (CDK) inhibitor p15INK4b. Research by several groups, including the group that discovered trametinib DMSO, demonstrated that several molecularly targeted anticancer agents, including the EGFR inhibitor &lt;ulink linkType="Drug" linkID="11603"&gt;gefitinib&lt;/ulink&gt; and the antiHER2 mAb &lt;ulink linkType="Drug" linkID="6386"&gt;trastuzumab&lt;/ulink&gt;, enhanced expression levels of CDK inhibitors, including p15INK4b, p21WAF1 and p27KIP1. HTS for compounds that induce expression of p15INK4b, an endogenous inhibitor of CDK-4/-6, led to the discovery of the 5-anilino-1-phenyl-pyrido[2,3-d]pyrimidine derivative &lt;ulink linkType="Drug" linkID="67740"&gt;JTP-70902&lt;/ulink&gt;. Further studies resulted in the production of trametinib and its DMSO-solvate form trametinib DMSO, which displayed the highest MEK-1/-2 inhibitory activity within the series [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1180150"&gt;1180150&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Trametinib DMSO was developed from 5-(4-chloro-anilino)-8-methyl-1,3-diphenyl-1H,8H-pyrido[2,3-d]pyrimidine-2,4,7-trione, an analog of &lt;ulink linkType="Drug" linkID="67740"&gt;JTP-70902&lt;/ulink&gt;. Initial SAR studies aimed to reduce the hydrophobicity of the initial lead by replacing one or more of the three aromatic rings on its pyridopyrimidine core with small alkyl groups. Substitution of the benzene ring at the 1- or 5-position of the initial lead compound led to a reduction in potency; however, substitution of the benzene ring at position 3 with a cyclopropyl ring, as well as replacement of the chlorine atom of the aniline ring with a bromine atom, resulted in a compound that was less hydrophobic than the initial lead and displayed antitumor activity in an HT29 colorectal tumor xenograft model. The inclusion of a fluorine atom at position 2 on the aniline ring led to a small increase in hydrophobicity and an increase in potency of ~ 4-fold. The resultant compound exhibited IC50 values of 325 and 15 nM against ACHN renal adenocarcinoma cells and HT29 colorectal adenocarcinoma cells, respectively. To further optimize potency, the size limit of the 4-position substituent of the aniline ring was investigated. Results demonstrated that steric constraint between the target protein and the 4-substitution affected the anticancer activity of the compound. An iodo analog had IC50 values of 13 and 15 nM against ACHN renal adenocarcinoma cells and HT29 colorectal adenocarcinoma cells, respectively, and a 500-fold increase in potency compared with the initial lead [&lt;ulink linkType="Reference" linkID="1180150"&gt;1180150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Further studies demonstrated that the pyrido[2,3-d]pyrimidine core was unstable under weak basic conditions and not suitable for drug candidate development. In the presence of potassium carbonate in methanol/chloroform, the pyrido[2,3-d]pyrimidine core was rearranged to pyrido[4,3-d]pyrimidine, but the rearranged compound was inactive. Because the spatial arrangement of the two phenyl and cyclopropyl rings and the three carbonyl rings were identical on both scaffolds, further research was conducted to improve activity by adding different groups to the rings. Introduction of 2-fluoro and 4-iodo groups to the aniline moiety produced a compound with IC50 values of 25 and 1.7 nM against ACHN and HT29 tumor cells, respectively. To improve the aqueous solubility, substitution with polar groups in the phenyl ring at the 1-position of the pyrido[4,3-d]pyrimidine core was explored. Both 3-acetamide and 3-methanesulfonamide analogs displayed enhanced potency and reduced hydrophobicity. Trametinib (JTP-74057), the 3-acetamide analog possessed good solubility and permeability, superior bioavailability, and IC50 values of 9.8 and 0.57 nM against ACHN and HT29 tumor cells, respectively [&lt;ulink linkType="Reference" linkID="1180150"&gt;1180150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Although preliminary assessment of trametinib indicated that it possessed adequate oral bioavailability, later studies demonstrated that the most stable form of trametinib displayed poor oral exposure. Because trametinib was weakly basic and not suitable for salt formation, a variety of solvate forms of the compound were prepared. The DMSO solvate of trametinib (trametinib DMSO), had favorable solid state characteristics and was chosen for preclinical development [&lt;ulink linkType="Reference" linkID="1180150"&gt;1180150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;&lt;subtitle&gt;In vitro&lt;/subtitle&gt;Trametinib DMSO inhibited a cascade kinase reaction consisting of CRAF/BRAF, MEK-1/-2 and ERK-2 with an IC50 value of ~ 2 nM, but the individual kinase activities of CRAF, BRAF and ERK-1/-2 were not affected by trametinib DMSO, suggesting that it inhibited the RAF-MEK-ERK pathway by targeting MEK-1/-2 [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;]. Trametinib DMSO (10 microM) did not display significant inhibitory activity against ~ 180 other kinases tested, including MEK-5, the kinase with greatest homology to MEK-1/-2 [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Incubation of human colorectal cancer cell lines with trametinib DMSO resulted in growth inhibition of 9 out of the 10 cell lines tested, an effect that was accompanied by upregulation of the cell cycle inhibitors p15INK4b and/or p27KIP1 [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;]. Notably, the cell line that was resistant to trametinib DMSO (10 microM), COLO320DM, expresses wild-type BRAF and KRAS, and treatment with trametinib DMSO did not cause upregulation of either p15INK4b or p27KIP1. In contrast, the two colorectal cancer cell lines that were most sensitive to trametinib DMSO, HT29 and COLO205 cells (IC50 = 0.48 and 0.52 nM, respectively), are known to have constitutively active BRAF mutations, and upregulation of both p15INK4b and p27KIP1 was observed following exposure to trametinib DMSO. With the exception of the trametinib DMSO-insensitive cell line, constitutive ERK phosphorylation was present in all the cell lines tested and it was inhibited by trametinib DMSO. In addition, treatment with trametinib DMSO for 24 h resulted in G1-phase cell cycle arrest in all the sensitive cell lines [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Although in vitro IC50 values for trametinib DMSO against the HT29 and COLO205 colorectal cancer cell lines were similar, in vivo studies suggested that COLO205 tumors were more susceptible to the MEK inhibitor than HT29 tumors [&lt;ulink linkType="Reference" linkID="1175237"&gt;1175237&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;]. Further in vitro experiments demonstrated that concentrations of 10 and 100 nM of trametinib DMSO were sufficient to induce apoptosis in COLO205 and HT29 cells, respectively. In particular, Western blotting revealed that cleavage of PARP and caspases-3, -7 and -9 occurred at a concentration of 10 nM of trametinib DMSO in COLO205 cells, whereas a concentration of 100 nM was required for induction of caspase activity in HT29 cells [&lt;ulink linkType="Reference" linkID="1175237"&gt;1175237&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Next, the effect of suppressing the PI3K/AKT pathway on MEK inhibitor-mediated apoptosis was tested. Treatment of HT29 colorectal cancer cells with the combination of trametinib DMSO (10 nM) and an inhibitor of AKT phosphorylation, triciribine (10 microM; &lt;ulink linkType="Company" linkID="1048215"&gt;Cahaba Pharmaceuticals&lt;/ulink&gt;, phase II [&lt;ulink linkType="Reference" linkID="1232480"&gt;1232480&lt;/ulink&gt;]) demonstrated that apoptosis induction was enhanced (p &amp;lt; 0.001) relative to trametinib DMSO alone. Furthermore, cotreatment of HT29 cells with trametinib DMSO and standard-of-care agents for colorectal cancer, such as the antimetabolite 5-FU, the alkylating agent &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;, or the topoisomerase inhibitor SN-38 (the active component of the anticancer drug &lt;ulink linkType="Drug" linkID="2871"&gt;irinotecan&lt;/ulink&gt;), caused additive growth inhibition with the former two agents and synergistic effects with the latter agent [&lt;ulink linkType="Reference" linkID="1175237"&gt;1175237&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Trametinib DMSO is an ATP non-competitive inhibitor of MEK-1/-2 [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;]. Analysis of the interaction between trametinib DMSO and MEK demonstrated that trametinib DMSO shares the same binding domain as the allosteric MEK inhibitor &lt;ulink linkType="Drug" linkID="48980"&gt;PD-0325901&lt;/ulink&gt;, binding at a position adjacent to the MEK active site and restricted on one side by the activation loop. Trametinib DMSO exhibited greater potency against unphosphorylated inactive MEK-1 or MEK-2 (mean IC50 = 0.7 nM) compared with diphosphorylated active MEK-1 (mean IC50 = 14.9 nM). In all cancer cell lines tested, trametinib DMSO inhibited MEK-1/-2-dependent dual phosphorylation (at residues Thr202 and Tyr204) of ERK-1/-2. Incubation of BRAF-mutant SKMEL28 and A375PF11 melanoma cells, and KRAS-mutant A549 NSCLC and HCT116 colon cancer cells with 250 nM of trametinib DMSO resulted in inhibition of ERK phosphorylation for up to 72 h. Trametinib DMSO was also associated with an increase in p27KIP1/CDKN1B for 6 to 48 h after treatment. Inhibition of ERK-1/-2 phosphorylation by trametinib DMSO did not necessarily correlate with reduced cell proliferation. These data indicated that the effect of trametinib DMSO on cell proliferation was related to cellular dependence on MEK-1/-2 signaling, as opposed to differences in the degree of MEK-1/-2 inhibition by trametinib DMSO. Further studies demonstrated that the impact of trametinib DMSO on MEK-1/-2 phosphorylation varied between cell types [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1177039"&gt;1177039&lt;/ulink&gt;]; for example, in BRAFVal600Glu-mutant A375PF11 and KRASGly13Asp-mutant HCT116 cells, the reduction in phosphorylated MEK was transient with levels reverting to normal by 48 h, whereas in BRAFVal599Glu-mutant SKMEL28 cells, the decrease in phosphorylated MEK was sustained for &gt;/= 72 h. In contrast, in KRASGly12Ser-mutant A549 cells, trametinib DMSO produced a time-dependent increase in phosphorylated MEK levels along with a concomitant increase in phosphorylation and activation of CRAF upstream of MEK. The investigators concluded that, as well as affecting MEK-dependent ERK-1/-2 phosphorylation, in some cell types, trametinib DMSO partially inhibits RAF-dependent phosphorylation of MEK [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;]. Pharmacodynamic studies indicated that in BRAF-mutant SKMEL28 cells and KRAS-mutant HCT116 cells, trametinib DMSO displayed 50% inhibition of ERK-1/-2 phosphorylation at a concentration of 0.8 and 1.8 nM, respectively, while 90% inhibition of ERK-1/-2 phosphorylation was achieved with a concentration of 3.4 and 33.3 nM, respectively. For both cell lines, growth inhibition of 50% (GI50) was only achieved at concentrations of trametinib DMSO that resulted in almost complete ERK-1/-2 inhibition (85 to 90%) [&lt;ulink linkType="Reference" linkID="1180150"&gt;1180150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The in vitro MEK inhibitory activity of trametinib DMSO was evaluated in more detail using mass spectrometry and high resolution liquid chromatography [&lt;ulink linkType="Reference" linkID="951984"&gt;951984&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1177039"&gt;1177039&lt;/ulink&gt;]. While CRAF- or BRAF-mediated phosphorylation of MEK-1 at position Ser217 was completely prevented by trametinib DMSO, phosphorylation of MEK-1 at position Ser221 was not affected. The IC50 for trametinib DMSO against purified MEK-1 phosphorylated at Ser221 was 6-fold lower than that for dual Ser217- and Ser221-phosphorylated MEK-1. Immunoblotting demonstrated that treatment of A549 NSCLC and A375PF11 melanoma cells with 250 nM of trametinib DMSO resulted in an increase in levels of Ser221 phosphorylation and a decrease in levels of Ser217 phosphorylation. These data, together with the fact that trametinib DMSO did not display direct inhibition of either CRAF or BRAF, suggested that trametinib DMSO binds to MEK in a manner that precludes RAF kinase-mediated phosphorylation of Ser217 [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The in vitro antitumor activity of trametinib DMSO was assessed using 72-h proliferation assays and 94 different cancer cell lines [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;]. Trametinib DMSO was most potent against cells expressing the BRAFVal600Glu mutation. Among the 10 BRAFVal600Glu-mutant cell lines tested, trametinib DMSO displayed a GI50 of &amp;lt; 50 nM for all 10 cell lines and a cytotoxic response occurred in 7 of the 10 cell types. Activating mutations in KRAS (specifically Gly12, Gly13 or Gln61) or NRAS (Gln61Leu/Arg) were also associated with sensitivity to trametinib DMSO. Among 25 KRAS-mutant cell lines tested, 16 had a GI50 of &amp;lt; 50 nM. Four NRAS-mutant cell types were tested and two displayed a GI50 of &amp;lt; 10 nM [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;]. Additional analysis demonstrated that in RAF- or RAS-mutant cell lines without concomitant PI3K/PTEN mutations, trametinib DMSO was cytotoxic, whereas a concomitant PI3K/PTEN mutation conferred resistance to trametinib DMSO with only cytostatic effects observed. Breast cancer cell lines with high expression levels of progesterone and estrogen receptors also displayed resistance to trametinib DMSO, suggesting that triple-negative breast cancers may be susceptible to the drug [&lt;ulink linkType="Reference" linkID="951964"&gt;951964&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1256253"&gt;1256253&lt;/ulink&gt;]. Preliminary data from a study using melanoma cell lines demonstrated inhibition of cell proliferation may be enhanced by combining trametinib DMSO with &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1256250"&gt;1256250&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Screening of an siRNA library indicated that inhibition of the MAPK pathway may enhance the antitumor activity of an inhibitor of centromere protein-E, such as &lt;ulink linkType="Drug" linkID="54621"&gt;GSK-923295&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="26068"&gt;Cytokinetics&lt;/ulink&gt;; phase I [&lt;ulink linkType="Reference" linkID="1233441"&gt;1233441&lt;/ulink&gt;]). As measured using caspase assays, the combination of trametinib DMSO with &lt;ulink linkType="Drug" linkID="54621"&gt;GSK-923295&lt;/ulink&gt; produced a synergistic response in 5 of 6 colon cancer, 5 of 15 lung cancer and 6 of 8 pancreatic cancer cell lines. The two-drug combination also yielded a very substantial increase in the apoptotic response in two colon cancer cell lines (SW48 and RKO) relative to either agent alone [&lt;ulink linkType="Reference" linkID="1163625"&gt;1163625&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The potential antitumor efficacy of trametinib DMSO in combination with the PI3K inhibitor &lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt; (GSK; phase I [&lt;ulink linkType="Reference" linkID="1195401"&gt;1195401&lt;/ulink&gt;]) was assessed in wild-type and GNAQ or GNA11-mutant uveal melanoma cell lines [&lt;ulink linkType="Reference" linkID="1181004"&gt;1181004&lt;/ulink&gt;]. In both wild-type and GNAQ/11-mutant uveal melanoma cells, single-agent treatment with trametinib DMSO (&gt;/= 10 nM) and &lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt; (&gt;/= 1 nM) resulted in loss of MAPK phosphorylation and AKT phosphorylation, respectively. While both single-agent treatments induced G1-phase cell cycle arrest in wild-type and GNAQ/11-mutant uveal melanoma cells, apoptotic cell death did not occur in either cell type following single-agent treatment. The combination of trametinib DMSO and &lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt; did not induce apoptotic cell death in wild-type uveal melanoma cells. In contrast, dual treatment of GNAQ/11-mutant uveal melanoma cells with trametinib DMSO and &lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt; resulted in a substantial increase in apoptotic cell death, as assessed by Annexin V staining and the proportion of cells in the sub-G0 phase of the cell cycle [&lt;ulink linkType="Reference" linkID="1181004"&gt;1181004&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Potential mechanisms of resistance to allosteric MEK inhibitors were assessed by generating a population of KRAS-mutant HCT116 colon cancer cells that were able to proliferate at a concentration of 1 mM of trametinib DMSO (GI50 &amp;gt; 7 mM) [&lt;ulink linkType="Reference" linkID="1163644"&gt;1163644&lt;/ulink&gt;]. Isolation of trametinib DMSO-resistant HCT116 clones, followed by sequencing of MAPK pathway-related genes, revealed the presence of a Leu119Pro mutation in MEK-2. SiRNA knockdown of MEK-2 led to a decrease in expression of Leu119Pro-mutant MEK-2, but not MEK-1, and sensitivity of cells to trametinib DMSO was restored. Expression of the homologous mutation in MEK-1, Leu115Pro, also conferred resistance to trametinib DMSO. Nevertheless, to date, neither mutation has been detected in clinical tumor samples [&lt;ulink linkType="Reference" linkID="1163644"&gt;1163644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The in vitro antitumor activity as well as molecular markers of response to trametinib DMSO, alone and in combination with the EGFR inhibitor &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;, the mTOR inhibitor &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; or the microtubule inhibitor &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;, were assessed using a panel of 28 different RAF/RAS-mutant NSCLC cell lines [&lt;ulink linkType="Reference" linkID="1177118"&gt;1177118&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1237856"&gt;1237856&lt;/ulink&gt;]. After 24 h of trametinib DMSO treatment, apoptosis induction was observed in 7 of the 28 cell lines, and, after 72 h of treatment, cell growth was potently inhibited (IC50 &amp;lt;/= 50 nM) in 12 of the 28 cell lines. Gene expression profiling demonstrated that expression of some genes, such as TGFA, EREG, LGALS3, CTNND1, ARHGEF3, KLF4, RPH3AL, STN2, TWIST2 and FOXC1, was highly correlated with a response to trametinib DMSO. Evaluation of cell signaling pathways revealed that wild-type PTEN, high levels of phosphorylated MEK and low levels of phosphorylated AKT/phosphorylated FOXO3a were predictive of a response to trametinib DMSO, whereas resistance to trametinib DMSO was associated with mutations in PTEN, PIK3CA and CTNNB1, and high levels of phosphorylated AKT/phosphorylated FOXO3a. The combination of trametinib DMSO and &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; was synergistic and/or promoted cell growth inhibition in 6 of 10 RAF/RAS-mutant NSCLC cell lines tested. Among the 6 sensitive cell lines, 3 displayed HER1 amplification or overexpression of TGFA and EREG. Testing of the 28 RAF/RAS-mutant NSCLC cell lines demonstrated that the trametinib DMSO/&lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; combination promoted cell growth inhibition and increased apoptosis induction in 23 and 12 of the cell lines, respectively. The combination of trametinib DMSO and &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; was either synergistic or increased apoptosis induction in 20 of the 28 RAF/RAS-mutant NSCLC cell lines [&lt;ulink linkType="Reference" linkID="1177118"&gt;1177118&lt;/ulink&gt;]. Results from another study demonstrated that combining trametinib DMSO with the mTOR inhibitor &lt;ulink linkType="Drug" linkID="4200"&gt;sirolimus&lt;/ulink&gt; resulted in cell death in 47 of 98 (48%) cell lines tested, including 7 of 10 pancreatic cancer cell lines (compared with 28 and 15% for the respective agents alone) [&lt;ulink linkType="Reference" linkID="1240066"&gt;1240066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;In vivo&lt;/subtitle&gt;Trametinib DMSO (0.3 and 1 mg/kg po, qd for 14 days) was administered to nude mice bearing either HT29 or COLO205 colorectal tumor xenografts [&lt;ulink linkType="Reference" linkID="1175237"&gt;1175237&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;]. Growth of HT29 tumor xenografts was inhibited by both dose levels of trametinib DMSO and the 1-mg/kg dose almost completely prevented increases in tumor volume. Pharmacodynamic analyses demonstrated that treatment of HT29 xenograft tumors with 1 mg/kg of trametinib DMSO correlated with complete inhibition of ERK-1/-2 phosphorylation in the established tumor tissues. In addition, upregulation of protein levels of p15INK4b and p27KIP1 was observed after 14 days of treatment with either dose level. In COLO205 tumor xenografts, both dose levels of trametinib DMSO caused tumor regression. Complete tumor regression (tumor volume not measurable) was observed in four of six mice treated with the 1-mg/kg dose of trametinib DMSO [&lt;ulink linkType="Reference" linkID="1175237"&gt;1175237&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;]. Further experiments in a COLO205 tumor xenograft model revealed that trametinib DMSO (1 mg/kg po, qd or bid for 14 days) displayed superior efficacy when dosed twice-daily rather than once-daily; however, in the same model, administration of trametinib DMSO at a dose of 1 mg/kg, once-daily on a 7 days on/7 days off schedule, was associated with both long-term efficacy and improved tolerability [&lt;ulink linkType="Reference" linkID="1163643"&gt;1163643&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vivo studies confirmed the ability of trametinib DMSO to inhibit downstream MAPK signaling pathways. Following administration of trametinib DMSO (3 mg/kg po, qd for 7 days) to nude mice bearing A375PF11 BRAFVal600Glu-mutant melanoma xenografts, ELISAs and immunohistochemistry demonstrated that inhibition of ERK phosphorylation in tumor tissue was observed for &amp;gt; 8 and &amp;gt; 24 h after the first and the last dose, respectively [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;]. Inhibition of ERK phosphorylation was not detected in brain tissue. Immunohistochemical analysis of tumor tissue also indicated that after 4 days of trametinib DMSO treatment, cellular proliferation was reduced (decreased Ki67) and G1 cell cycle arrest was enhanced (increased p27KIP1/CDKN1B) [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Studies using nude mice bearing A375PF11 BRAFVal600Glu-mutant melanoma xenografts demonstrated that treatment with trametinib DMSO (0.1 to 3 mg/kg po, qd for 14 days) caused dose-dependent tumor growth inhibition (TGI) [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;]. Trametinib DMSO was associated with significant suppression of tumor growth and some cases of tumor regression; however, if treatment with trametinib DMSO was interrupted, most A375PF11 tumors resumed growth. Subsequently, the antitumor activity of the 14-day MTD of trametinib DMSO (3 mg/kg po, qd for 14 days) was assessed in comparison with vehicle control in a range of different mouse tumor xenograft models. In the A375PF11 melanoma, and the COLO205 and HT29 colorectal xenograft models, mean TGI with trametinib DMSO was 80, 85 and 87%, respectively, and complete and partial tumor regressions were observed. In xenograft models of BT474 breast, BxPC3 pancreatic and PC3 prostate tumors, which all express wild-type RAF/RAS, trametinib DMSO produced moderate TGI of 44, 45 and 46%, respectively. In A549 NSCLC and HCT116 colon xenograft models, trametinib DMSO elicited TGI of 75 and 83%, respectively; however, significant tumor regressions did not occur [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;]. A separate study of trametinib DMSO (0.1, 0.5, 2.5 and 5 mg/kg po, qd for 21 days) in an A549 NSCLC xenograft model demonstrated that antitumor activity was dose-dependent; TGI of 58, 62, 87 and 92% was observed with doses of 0.1, 0.5, 2.5 and 5 mg of trametinib DMSO, respectively [&lt;ulink linkType="Reference" linkID="1180150"&gt;1180150&lt;/ulink&gt;]. Additionally, HCT116 colon tumor xenografts that harbor a MEK-2Lys115Pro mutation displayed resistance to trametinib DMSO compared with wild-type HCT116 tumors [&lt;ulink linkType="Reference" linkID="1163644"&gt;1163644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;At the time of publication, detailed data from preclinical toxicity studies of trametinib DMSO were not available. Trametinib DMSO displayed minimal cytotoxicity against normal, non-proliferating human cells [&lt;ulink linkType="Reference" linkID="1163643"&gt;1163643&lt;/ulink&gt;]. Using recombinant proteins and the RAF-MEK-ERK cascade kinase assay, trametinib DMSO inhibited the phosphorylation of myelin basic protein, independently of RAF and MEK isotypes, with IC50 values ranging from 0.92 to 3.4 nM; this finding raises the concern of potential neurotoxicity with trametinib DMSO [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;]. In vivo preclinical studies demonstrated that in nude mice bearing either HT29 or COLO205 xenograft tumors, treatment with 1 mg/kg of trametinib DMSO for 14 days did not result in significant changes in body mass or gross lesions on autopsy [&lt;ulink linkType="Reference" linkID="1201150"&gt;1201150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;The in vivo pharmacokinetic profile of trametinib DMSO was assessed in A375PF11 melanoma-bearing nude mice and non-tumor-bearing Sprague-Dawley rats [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;]. In nude mice bearing melanoma xenografts, plasma levels of trametinib DMSO (3 mg/kg po, qd for 7 days) reached steady-state at day 4. Trametinib DMSO displayed a mean Cmax of 1410 nmol/l (observed at 4 h post-dose on day 7) and an estimated effective t1/2 of 33 h. In accordance with the lack of ERK phosphorylation in brain tissue, only low levels of trametinib DMSO were detected in the brain on day 7. In Sprague-Dawley rats, each dose of trametinib DMSO (1 mg/kg po, qd for 3 weeks) resulted in a gradual increase in plasma drug concentrations (mean Cmax = 42.4 nmol/l; Tmax = 4 h post-dose), followed by a gradual decline in plasma drug concentrations. Repeat-dose trametinib DMSO was associated with a 2.5- to 3-fold increase in the AUC. Steady-state drug levels were attained on day 4 and the effective t1/2 for trametinib DMSO was estimated to be ~ 36 h. Following both single- and repeat-dose trametinib DMSO, a narrow peak/trough plasma drug concentration ratio (~ 1.6 to 2.8) was observed [&lt;ulink linkType="Reference" linkID="1163620"&gt;1163620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I, first-in-human clinical trial (&lt;ulink linkType="Protocol" linkID="34707"&gt;NCT00687622&lt;/ulink&gt;) in patients (n = 202) with solid tumors or lymphoma, trametinib DMSO (0.125 to 10 mg po, single dose, followed by 0.125 to 4 mg po, qd for 21 days of each 28-day cycle) displayed a low peak-to-trough ratio of ~ 2 and an effective t1/2 of 4.5 days. Steady-state drug concentrations were attained by day 15 [&lt;ulink linkType="Reference" linkID="1163630"&gt;1163630&lt;/ulink&gt;]. Mean AUC and Cmax values indicated that after repeat dosing for 15 days at doses of 0.125 to 0.5 mg, plasma trametinib DMSO exposure increased in a dose-proportional manner, with a median Tmax of ~ 1.5 h [&lt;ulink linkType="Reference" linkID="1163622"&gt;1163622&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from the dose-escalation part of this trial were used to develop and validate a population pharmacokinetic model for trametinib DMSO [&lt;ulink linkType="Reference" linkID="1175462"&gt;1175462&lt;/ulink&gt;]. Plasma concentrations of trametinib DMSO were best described using a two-compartment model with first-order absorption and elimination. The final model included two sequential absorption rates, with a change point estimated at 0.41 h post-dose. Using the final model, population mean estimates for the clearance, volume of the central compartment, volume of the peripheral compartment and intercompartmental clearance of trametinib DMSO were 6.76 l/h, 125 l, 746 l and 114 l, respectively. Trametinib DMSO displayed 43 to 88% interindividual variability, 8 to 74% interoccasion variability and a residual variability of 13 ng/ml. Covariates, such as gender, body mass or race, did not affect the pharmacokinetics of trametinib DMSO. A visual predictive check of the simulated (n = 1000) and observed (n = 1373 patient plasma samples) data confirmed the model's validity. The final model was to be used to support future pharmacokinetic-pharmacodynamic analyses using both tumor response and adverse event data [&lt;ulink linkType="Reference" linkID="1175462"&gt;1175462&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The steady-state pharmacokinetics of trametinib DMSO, in combination with GSK's AKT inhibitor &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; (phase I [&lt;ulink linkType="Reference" linkID="1196065"&gt;1196065&lt;/ulink&gt;]), were evaluated in the first part of a phase I clinical trial (&lt;ulink linkType="Protocol" linkID="67101"&gt;NCT01138085&lt;/ulink&gt;) in patients with solid tumors. Data from four patients demonstrated that coadministration of 0.5 mg of trametinib DMSO and 25 mg of &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; (both po, qd for 15 days) resulted in a &amp;lt; 25% increase in pharmacokinetic parameters for trametinib DMSO and a 40% decrease to a 40% increase in pharmacokinetic parameters for &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1195598"&gt;1195598&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Pharmacokinetic data from 45 patients with hematological malignancies who were treated with trametinib DMSO (3 mg loading dose followed by 1 mg po, qd, 1 mg po, qd or 2 mg po, qd) in a phase I/II clinical trial (&lt;ulink linkType="Protocol" linkID="57847"&gt;NCT00920140&lt;/ulink&gt;) demonstrated that plasma drug exposure was maintained above the preclinical target threshold for 24 h after each dose. Trametinib DMSO displayed a narrow peak/trough plasma concentration ratio. Repeat administration of the 2-mg dose level of trametinib DMSO yielded an AUC0-t of 298 ng.h/ml, a Cmax of 18.7 ng/ml, a median Tmax of 3 h, an accumulation ratio of 10.1 and an effective t1/2 of 6.5 days [&lt;ulink linkType="Reference" linkID="1152314"&gt;1152314&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1196464"&gt;1196464&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase Ib clinical trial (&lt;ulink linkType="Protocol" linkID="80521"&gt;NCT01428427&lt;/ulink&gt;) in patients (n = 28) with advanced solid tumors demonstrated that coadministration of trametinib DMSO (1 to 2.5 mg po, qd) and the DNA synthesis inhibitor &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (1000 mg/m2 iv, on days 1, 8 and 15 every 28 days) did not affect the pharmacokinetic profile of either drug [&lt;ulink linkType="Reference" linkID="1237851"&gt;1237851&lt;/ulink&gt;]. In another phase Ib clinical trial (&lt;ulink linkType="Protocol" linkID="59469"&gt;NCT00955773&lt;/ulink&gt;) in patients (n = 67) with advanced solid tumors, no pharmacokinetic interaction was observed between trametinib DMSO (0.5 to 2 mg po, qd) and &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; (5 to 7.5 mg po, qd; 5 mg po, 5 days on/2 days off; 5 mg po, 7 days on/7 days off; 5 mg po, q2d [3 days/week]; or 7.5 mg po, q2d [3 days/week]) [&lt;ulink linkType="Reference" linkID="1240066"&gt;1240066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from seven patients treated with trametinib DMSO (2 mg po, qd from day 2 to 15) in combination with &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; (po, qd on day 1 and 15) in part 1 of a phase I/II (&lt;ulink linkType="Protocol" linkID="64287"&gt;NCT01072175&lt;/ulink&gt;) clinical trial demonstrated that trametinib DMSO did not affect the pharmacokinetic profile of single-dose &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt;. In part 2 of the trial, repeat dosing of patients (n = 45) with BRAFVal600-mutant solid tumors with trametinib DMSO (1, 1.5 and 2 mg po, qd) in combination with &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; (75 to 150 mg po, bid) did not reveal any clinically relevant drug-drug interactions [&lt;ulink linkType="Reference" linkID="1196607"&gt;1196607&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the time of publication, the bioavailability and metabolism of trametinib DMSO was being evaluated in three ongoing, open-label phase I clinical trials (&lt;ulink linkType="Protocol" linkID="79977"&gt;NCT01416337&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="78973"&gt;NCT01387204&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="78067"&gt;NCT01371487&lt;/ulink&gt;). Data were not available for these trials, but a brief summary of the protocol details is provided below.&lt;/para&gt;&lt;para&gt;A single-group-assignment, single-period, single-center clinical trial (&lt;ulink linkType="Protocol" linkID="79977"&gt;NCT01416337&lt;/ulink&gt;) was designed to determine the absolute bioavailability of trametinib DMSO in patients (expected n = 6) with solid tumors. A single oral dose of 2 mg of trametinib DMSO would be coadministered with a single intravenous dose of 5 microg of radiolabeled (&amp;lt;/= 7.4 kBq or 200 nCi) trametinib DMSO. A non-randomized, single-group-assignment, single-dose trial (&lt;ulink linkType="Protocol" linkID="78973"&gt;NCT01387204&lt;/ulink&gt;) was to evaluate the ADME profile of radiolabeled (~ 79 microCi) trametinib DMSO (2 mg po, single dose) in male patients (expected n = 6) with solid tumors. A randomized, crossover-assignment, two-period trial (&lt;ulink linkType="Protocol" linkID="78067"&gt;NCT01371487&lt;/ulink&gt;) was to investigate the effect of a high-fat, high calorie meal on the pharmacokinetics of trametinib DMSO (po, single dose) in patients (expected n = 40) with solid tumors.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;A phase I, non-randomized, open-label, single-group-assignment, multiple-dose-escalation, three-part, multicenter, first-in-human clinical trial (&lt;ulink linkType="Protocol" linkID="34707"&gt;NCT00687622&lt;/ulink&gt;) assessed the MTD (part 1), the safety, tolerability and efficacy (part 2), and the efficacious dose range (part 3), of trametinib DMSO (0.125 to 10 mg po, single dose, followed by 0.125 to 4 mg po, qd for 21 days of each 28-day cycle) in patients (n = 202) with solid tumors or lymphoma. The trial involved dose-escalation to determine the MTD (part 1), evaluation of 2 or 2.5 mg of trametinib DMSO in patients with melanoma, pancreatic cancer, colorectal cancer or NSCLC (part 2) and pharmacodynamic-pharmacokinetic evaluation using tumor biopsies or fluorodeoxyglucose-PET data (part 3). The recommended phase II dose of trametinib DMSO was 2 mg once-daily, and the MTD was 3 mg once-daily [&lt;ulink linkType="Reference" linkID="1103876"&gt;1103876&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1145227"&gt;1145227&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1163622"&gt;1163622&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1163630"&gt;1163630&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1163638"&gt;1163638&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1175462"&gt;1175462&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1237856"&gt;1237856&lt;/ulink&gt;]. At the time of publication, the trial was ongoing.&lt;/para&gt;&lt;para&gt;Tumor response data were available for 42 patients with melanoma [&lt;ulink linkType="Reference" linkID="1163638"&gt;1163638&lt;/ulink&gt;], 26 patients with advanced chemoresistant pancreatic cancer, 27 patients with advanced chemoresistant colorectal cancer [&lt;ulink linkType="Reference" linkID="1163630"&gt;1163630&lt;/ulink&gt;] and 18 patients with KRAS-mutant NSCLC [&lt;ulink linkType="Reference" linkID="1237856"&gt;1237856&lt;/ulink&gt;], all of whom had received &gt;/= 1 dose of trametinib DMSO [&lt;ulink linkType="Reference" linkID="1163630"&gt;1163630&lt;/ulink&gt;]. Tumor biopsies revealed that the 2-mg dose of trametinib DMSO was associated with a decrease of &amp;gt; 90% in levels of phosphorylated ERK and the cell proliferation marker Ki67. Among 20 patients with BRAF-mutant melanoma, two complete and six partial responses were observed, four of which were confirmed (preliminary response rate = 40%). Two patients who had previously received &lt;ulink linkType="Drug" linkID="54469"&gt;vemurafenib&lt;/ulink&gt; experienced stable disease and one of the two patients was still on treatment at 27 weeks [&lt;ulink linkType="Reference" linkID="1163638"&gt;1163638&lt;/ulink&gt;]. Among 22 patients with wild-type BRAF melanoma, two partial responses, one of which occurred in a patient with a GNAQ mutation [&lt;ulink linkType="Reference" linkID="1103876"&gt;1103876&lt;/ulink&gt;], and eight cases of stable disease were noted [&lt;ulink linkType="Reference" linkID="1163638"&gt;1163638&lt;/ulink&gt;]. Fluorodeoxyglucose-PET data from four patients with melanoma demonstrated that the maximum standardized uptake value of tumors was reduced by 23 to 48% after 2 weeks of treatment with 0.5 to 1 mg of trametinib DMSO [&lt;ulink linkType="Reference" linkID="1163638"&gt;1163638&lt;/ulink&gt;]. Among the 26 patients with advanced chemoresistant pancreatic cancer, two partial responses and 11 cases of stable disease were observed. One of the two partial responses occurred in a patient with KRAS-mutant disease who was still on treatment at 28 weeks. Among the patients with stable disease, a &gt;/= 20% reduction in tumor volume was experienced by 2 patients and &gt;/= 3 patients received treatment for &gt;/= 16 weeks. Levels of serum carbohydrate-associated antigen (CA19-9), a marker of biliopancreatic malignancies, were reduced by &gt;/= 55% in both patients with a partial response and three patients with stable disease, one of whom remained on treatment for 40 weeks. Among 12 patients with KRAS-mutant colorectal cancer, four patients had stable disease and these patients remained on treatment for 31, 28, 16 and 16 weeks, respectively. For 12 patients with colorectal cancer that was KRAS-mutant negative or of unknown mutational status, stable disease occurred in two patients but neither patient received treatment for &amp;gt; 19 weeks. Two of three patients with BRAF-mutant colorectal cancer had stable disease and both patients were still on treatment after &amp;gt; 16 weeks [&lt;ulink linkType="Reference" linkID="1163630"&gt;1163630&lt;/ulink&gt;]. For the 18 patients with KRAS-mutant NSCLC, two partial responses were observed (preliminary response rate of 11%) and the preliminary progression-free survival was 3.8 months. An inverse correlation existed between the duration of trametinib treatment and prior &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; treatment for the patients with NSCLC [&lt;ulink linkType="Reference" linkID="1237856"&gt;1237856&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the time of publication, an ongoing, phase I, randomized, open-label, parallel-group-assignment, dose-escalation, three-part, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="67101"&gt;NCT01138085&lt;/ulink&gt;) was evaluating the safety, tolerability and the recommended phase II dose of trametinib DMSO (0.5, 1, 1.5 and 2 mg po, qd on a continuous dose schedule), in combination with GSK's AKT inhibitor &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; (25, 50 and 75 mg po, qd), in patients (expected n = 125) with solid tumors [&lt;ulink linkType="Reference" linkID="1195598"&gt;1195598&lt;/ulink&gt;]. In part 1 of the trial, a zone-based dose-escalation procedure allowed evaluation of multiple combination doses of the two drugs in parallel cohorts. Part 2 of the trial was to evaluate the recommended phase II doses of trametinib DMSO and &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; in patients with selected cancer types, including pancreatic, endometrial or KRAS-mutant colorectal cancer. Part 3 of the trial would comprise pharmacodynamic-pharmacokinetic evaluation using tumor biopsies or fluorodeoxyglucose-PET data. Data had been reported from part 1 of the trial, in which 62 patients were enrolled into 10 different dose cohorts of trametinib DMSO/&lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; (0.5 mg/25 mg, 0.5 mg/50 mg, 0.5 mg/75 mg, 1 mg/25 mg, 1 mg/50 mg, 1 mg/75 mg, 1.5 mg/25 mg, 1.5 mg/50 mg, 2 mg/25 mg and 2 mg/50 mg). Tumor types included in the trial were colon or rectal cancer (n = 11), melanoma (n = 11), ovarian (n = 7), pancreatic (n = 6), breast (n = 3), endometrial (n = 3) and thyroid (n = 3) cancer. MTDs for the trametinib DMSO/&lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; combination were 1.5 mg/50 mg, 2 mg/25 mg and 0.5 mg/75 mg. Tumor response data were not available for 13 patients, disease progression was experienced by 9 patients before the first assessment at week 8, and 2 patients did not have measurable disease. Evaluation of best unconfirmed tumor responses at the cut-off point (April 2011) demonstrated that among the 38 evaluable patients, progressive and stable disease was experienced by 17 and 18 patients, respectively. Partial responses were achieved by two patients: one patient with KRAS-mutant/PTEN-deficient endometrial cancer who was treated with 1 mg of trametinib DMSO and 75 mg of &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt;, and one patient with uveal melanoma who received 2 mg of trametinib DMSO and 25 mg of &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt;. In addition, one patient with triple-negative breast cancer who received 2 mg of trametinib DMSO and 25 mg of &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; had a partial response at week 8; however, further data for this patient were not available at the cut-off point. At the time data were reported, evaluation of trametinib DMSO in combination with another AKT inhibitor from GSK, &lt;ulink linkType="Drug" linkID="65865"&gt;GSK-2110183&lt;/ulink&gt; (phase I; [&lt;ulink linkType="Reference" linkID="1230625"&gt;1230625&lt;/ulink&gt;]), was in progress [&lt;ulink linkType="Reference" linkID="1195598"&gt;1195598&lt;/ulink&gt;]. Trial completion had been scheduled for October 2011.&lt;/para&gt;&lt;para&gt;A phase I, non-randomized, open-label, single-group-assignment, zone-based dose-escalation, two-part, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="72595"&gt;NCT01248858&lt;/ulink&gt;) was to characterize the safety, tolerability, pharmacokinetic-pharmacodynamic profile and clinical activity of trametinib DMSO, in combination with the PI3K inhibitor &lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt; (GSK; phase I [&lt;ulink linkType="Reference" linkID="1195401"&gt;1195401&lt;/ulink&gt;]), in patients (expected n = 110) with advanced solid tumors. The trial would be conducted in two parts: a dose-escalation phase and a tumor-specific cohort expansion phase [&lt;ulink linkType="Reference" linkID="1240101"&gt;1240101&lt;/ulink&gt;]. At the time of publication, the trial was ongoing. Data were reported after 34 patients had been enrolled into seven dose cohorts of trametinib DMSO/&lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt; (0.5 mg/0.5 mg, 0.5 mg/1 mg, 1 mg/0.5 mg, 1 mg/1 mg, 1 mg/1.5 mg, 1.5 mg/0.5 mg and 2 mg/0.5 mg, all po, qd). Stable disease was achieved by two patients, one with KRAS-mutant colorectal cancer and one with renal cell carcinoma; both patients had remained on treatment for &amp;gt; 6 months. The preliminary safety profile and antitumor activity of the trametinib DMSO/&lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt; combination was to be further explored during continued dose-escalation and the tumor-specific expansion phase [&lt;ulink linkType="Reference" linkID="1240101"&gt;1240101&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase Ib, non-randomized, open-label, single-group-assignment, dose-escalation, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="80521"&gt;NCT01428427&lt;/ulink&gt;) assessed the recommended dose level and regimen of trametinib DMSO (1 to 2.5 mg po, qd on a continuous dose schedule) in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (1000 mg/m2 iv, on days 1, 8 and 15 every 28 days) in patients (n = 28) with advanced solid tumors, including pancreatic (n = 8), breast (n = 6) and NSCLC (n = 4) [&lt;ulink linkType="Reference" linkID="1237851"&gt;1237851&lt;/ulink&gt;]. The MTD and recommended phase II regimen was 2 mg of trametinib in combination with 1000 mg/m2 of &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;. One patient with pancreatic cancer, who had been treated previously with radiotherapy and two cycles of &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;, experienced a partial response and remained on the trial for 6 months. Stable disease was achieved by three patients with pancreatic cancer, two of whom remained on the trial for 3.5 to 5 months and one of whom remained on the trial at the time data were presented. Complete target lesion responses were experienced by one patient with chemotherapy-refractory triple-negative breast cancer and one patient with parotid cancer [&lt;ulink linkType="Reference" linkID="1237851"&gt;1237851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase Ib, non-randomized, open-label, single-group-assignment, dose-escalation, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="59469"&gt;NCT00955773&lt;/ulink&gt;) assessed the recommended dose level and regimen for trametinib DMSO (po, qd) in combination with &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; (po) in patients (expected n = 90) with advanced solid tumors. The dose-escalation part of the trial would determine the MTDs of the two agents in combination. The two-drug combination would then be further explored in patients with metastatic pancreatic cancer. In addition, a sub-study was to be conducted in patients with KRAS-mutant NSCLC. At the time of publication, the trial was ongoing. Data were reported after 67 patients had been enrolled into 10 different dose cohorts of trametinib DMSO/&lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; (0.5 mg/0.5 mg qd, 1 mg/5 mg qd, 1 mg/7.5 mg qd, 1.5 mg/5 mg qd, 1.5 mg/7.5 mg qd, 2 mg/5 mg qd, 2 mg/5 mg 5 days on/2 days off, 2 mg/5 mg 7 days on/7 days off, 2 mg/5 mg q2d [3 days/week] and 2 mg/7.5 mg q2d [3 days/week]). The recommended phase II regimen for the trametinib DMSO/&lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; combination was not identified because coadministration of the two drugs was limited by their toxicity profiles. Tumor response data for 62 patients who had measurable disease at baseline revealed that five partial responses and 18 cases of stable disease were observed [&lt;ulink linkType="Reference" linkID="1240066"&gt;1240066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the time of publication, the safety and efficacy of trametinib DMSO was being evaluated in four open-label, single-group-assignment, multicenter, phase I and Ib clinical trials: two phase I trials (&lt;ulink linkType="Protocol" linkID="75836"&gt;NCT01324258&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="81015"&gt;NCT01438554&lt;/ulink&gt;), a phase I/Ib trial (&lt;ulink linkType="Protocol" linkID="69713"&gt;NCT01192165&lt;/ulink&gt;) and a phase Ib trial (&lt;ulink linkType="Protocol" linkID="67911"&gt;NCT01155453&lt;/ulink&gt;). Data were not available for any of these ongoing trials, but a summary of the protocol for each trial is provided below.&lt;/para&gt;&lt;para&gt;The &lt;ulink linkType="Protocol" linkID="75836"&gt;NCT01324258&lt;/ulink&gt; clinical trial was designed to be a non-randomized, two-part evaluation of the recommended dose level and regimen of trametinib DMSO (po, continuous daily dosing schedule) in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (iv) in Japanese patients (expected n = 19) with solid tumors. Part 1 of the trial would involve dose-escalation with trametinib DMSO alone. Part 2 of the trial would assess trametinib DMSO (at the recommended dose from part 1 of the trial) in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;, in patients with NSCLC, pancreatic, biliary or urothelial cancer, or other tumor types for which a 4-week schedule of &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; is approved. The &lt;ulink linkType="Protocol" linkID="81015"&gt;NCT01438554&lt;/ulink&gt; clinical trial was to assess the safety, tolerability and the MTD of the combination of trametinib DMSO (po) and the VEGF inhibitor &lt;ulink linkType="Drug" linkID="43738"&gt;pazopanib&lt;/ulink&gt; (po) in patients (expected n = 61) with thyroid cancer. The &lt;ulink linkType="Protocol" linkID="69713"&gt;NCT01192165&lt;/ulink&gt; clinical trial was designed to be a non-randomized assessment of the safety and tolerability of escalating doses of trametinib DMSO (po) in combination with &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (iv), &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; (po), the dihydrofolate reductase inhibitor pemetrexed (iv), pemetrexed (iv) plus the alkylating agent &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; (iv), or the microtubule stabilizer &lt;ulink linkType="Drug" linkID="29016"&gt;nab-paclitaxel&lt;/ulink&gt; (Abraxane; iv), in patients (expected n = 146) with advanced solid tumors. The &lt;ulink linkType="Protocol" linkID="67911"&gt;NCT01155453&lt;/ulink&gt; clinical trial was designed as a non-randomized, dose-finding, dose-escalation trial to determine the MTD and/or the recommended phase II dose and schedule for trametinib DMSO (po, qd on a continuous dose schedule), in combination with the PI3K inhibitor &lt;ulink linkType="Drug" linkID="61901"&gt;BKM-120&lt;/ulink&gt; (po, qd on a continuous dose schedule), in patients (expected n = 60) with selected advanced solid tumors, in particular RAS/RAF-mutant tumors and triple-negative breast cancer.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;At the time of publication, a phase I/II, non-randomized, open-label, parallel-group-assignment, dose-escalation, three-part, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="64287"&gt;NCT01072175&lt;/ulink&gt;) was evaluating the safety, pharmacokinetics, pharmacodynamics and clinical activity of trametinib DMSO (1, 1.5 and 2 mg po, qd) in combination with &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; (75 to 150 mg po, bid) in patients (expected n = 280) with BRAFVal600-mutant solid tumors [&lt;ulink linkType="Reference" linkID="1196607"&gt;1196607&lt;/ulink&gt;]. Part 1 assessed the effect of repeat doses of trametinib DMSO (2 mg po, qd from day 2 to 15) on the pharmacokinetics of single-dose &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; (po, qd on day 1 and 15). Part 2 used dose-escalation to determine the MTDs of the two drugs in combination. Part 3 of the trial was to be a phase II, randomized evaluation of different dose combinations of trametinib DMSO and &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; in patients with untreated stage IV melanoma. The recommended dose was 2 mg of trametinib once-daily in combination with 150 mg of &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; twice-daily. At the time interim data were reported, 45 patients (43 with BRAF inhibitor-naive melanoma, one with NSCLC and one with salivary duct carcinoma) had received &gt;/= 1 dose of trametinib DMSO in combination with &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt;. In part 2 of the trial, 14 of the 16 evaluable patients remained on treatment. Partial responses and stable disease were experienced by 13 and 3 patients, respectively, corresponding to an objective response rate of 81%. Among 10 evaluable patients treated with &gt;/= 1 mg of trametinib DMSO and 150 mg of &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt;, 9 partial responses and 1 case of stable disease was observed [&lt;ulink linkType="Reference" linkID="1196607"&gt;1196607&lt;/ulink&gt;]. At the time data were reported, patient recruitment to phase II of the trial was ongoing. Trial completion was scheduled for June 2012.&lt;/para&gt;&lt;para&gt;At the time of publication, a phase I/II, non-randomized, open-label, single-group-assignment, dose-escalation, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="57847"&gt;NCT00920140&lt;/ulink&gt;) was evaluating the safety and clinical activity of trametinib DMSO (3 mg loading dose followed by 1 mg po, qd, 1 mg po, qd or 2 mg po, qd) in patients (expected n = 120) with relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia or chronic myelomonocytic leukemia (CMML). Patients were screened for mutations in KRAS (residues 12 and 13) and NRAS (residues 12, 13 and 61) [&lt;ulink linkType="Reference" linkID="1152314"&gt;1152314&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1196464"&gt;1196464&lt;/ulink&gt;]. At the time the most recent data were reported, a total of 45 patients had been treated, including 30 patients with AML and 12 patients with MDS transformed to AML. Tumor response evaluations were available for 39 patients, 13 with NRAS- or KRAS-mutant tumors and 26 with either unknown mutational status or wild-type RAS tumors. Among the 13 patients with NRAS- or KRAS-mutant tumors, 3 experienced a complete response, 1 had a morphological leukemia-free state, 1 had hematological improvements, 7 had stable disease and 1 had progressive disease. Among the 26 patients with wild-type RAS or unknown mutational status, 2 partial responses, 4 cases of hematological improvement, 9 cases of stable disease and 11 cases of progressive disease were observed. Objective response rates for the NRAS-/KRAS-mutant and the wild-type RAS/unknown tumor status group were 31 and 8%, respectively [&lt;ulink linkType="Reference" linkID="1196464"&gt;1196464&lt;/ulink&gt;]. At the time data were reported, phase II recruitment of patients with NRAS- or KRAS-mutant AML/MDS and CMML was ongoing. Trial completion was scheduled for December 2012.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;At the time of publication, five multicenter phase II clinical trials (&lt;ulink linkType="Protocol" linkID="78365"&gt;NCT01376310&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="71815"&gt;NCT01231594&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="62851"&gt;NCT01037127&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="71807"&gt;NCT01231581&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="77773"&gt;NCT01362296&lt;/ulink&gt;) of trametinib DMSO were ongoing. Another phase II trial (&lt;ulink linkType="Protocol" linkID="76077"&gt;NCT01328106&lt;/ulink&gt;) had been withdrawn. Data were not available for these trials, but a brief summary of the protocol is provided below.&lt;/para&gt;&lt;para&gt;A non-randomized, open-label, single-group-assignment, rollover clinical trial (&lt;ulink linkType="Protocol" linkID="78365"&gt;NCT01376310&lt;/ulink&gt;) was being conducted to allow patients (expected n = 200) with solid tumors or leukemia who benefited from trametinib DMSO (alone or in combination with other approved anticancer agents) in another trial to continue to receive the drug/drug combination. A non-randomized, open-label, parallel-group-assignment, rollover trial (&lt;ulink linkType="Protocol" linkID="71815"&gt;NCT01231594&lt;/ulink&gt;) was designed to allow patients (expected = 200) with BRAF-mutant tumors who benefited from the combination of trametinib DMSO and &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; in another trial to continue to receive the two-drug combination. An open-label, single-group-assignment trial (&lt;ulink linkType="Protocol" linkID="62851"&gt;NCT01037127&lt;/ulink&gt;) was to evaluate the objective response rate, safety and pharmacokinetics of trametinib DMSO (po) in patients (n = 97) with BRAF-mutant melanoma who had received previous treatment, either with or without a BRAF inhibitor. A randomized, double-blind, placebo-controlled, parallel-group-assignment trial (&lt;ulink linkType="Protocol" linkID="71807"&gt;NCT01231581&lt;/ulink&gt;) was to assess the efficacy (overall survival rate) and safety of trametinib DMSO (po) plus &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (iv), compared with that of &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (iv) alone, in patients (estimated n = 150) with metastatic pancreatic cancer. Once the defined number of survival events had occurred, eligible patients could enroll in the &lt;ulink linkType="Protocol" linkID="78365"&gt;NCT01376310&lt;/ulink&gt; rollover trial. A randomized, open-label, parallel-group-assignment trial (&lt;ulink linkType="Protocol" linkID="77773"&gt;NCT01362296&lt;/ulink&gt;) was to compare the efficacy (progression-free survival) and safety of trametinib DMSO (po, qd) with that of &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (iv, q3w), for the second-line treatment of patients (expected n = 141) with locally advanced or metastatic KRAS-mutant NSCLC who had failed one platinum-containing chemotherapy regimen. A group of patients with BRAF-, NRAS- or MEK-1-mutant NSCLC would also be included for exploratory purposes. An open-label, single-group-assignment trial (&lt;ulink linkType="Protocol" linkID="76077"&gt;NCT01328106&lt;/ulink&gt;) was designed to assess the efficacy and safety of trametinib DMSO (po) in patients (expected = 100) with metastatic uveal or GNAQ/GNA11-mutant metastatic melanoma; however, the trial was terminated prior to enrollment.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;At the time of publication, a phase III, randomized, open-label, two-arm crossover-assignment, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="72448"&gt;NCT01245062&lt;/ulink&gt;; METRIC) was comparing the safety and efficacy of trametinib DMSO with that of chemotherapy (either DTIC or &lt;ulink linkType="Drug" linkID="75471"&gt;paclitaxel&lt;/ulink&gt;), in patients (expected n = 297) with BRAF-mutant, stage IIIc or IV cutaneous melanoma. Trial completion was expected in September 2012.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;Results from the phase I, first-in-human &lt;ulink linkType="Protocol" linkID="34707"&gt;NCT00687622&lt;/ulink&gt; clinical trial were reported after 202 patients with solid tumors or lymphoma had been treated with &gt;/= 1 dose of trametinib DMSO. DLTs were rash (n = 2), diarrhea (n = 1) and central serous retinopathy (n = 2), which were all reversible. Among 68 patients treated with 2 mg of trametinib DMSO, the most frequent adverse events were rash (total n = 60; 88%) and diarrhea (total n = 37; 54%), which were of grade 1 severity in 32 and 28 patients, respectively, grade 2 severity in 25 and 8 patients, respectively, and grade 3 severity in 3 and 1 patient, respectively. One case of retinal vein occlusion was reported [&lt;ulink linkType="Reference" linkID="1163630"&gt;1163630&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from part 1 of the phase I &lt;ulink linkType="Protocol" linkID="67101"&gt;NCT01138085&lt;/ulink&gt; clinical trial of trametinib DMSO in combination with &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; in patients with solid tumors demonstrated that seven DLTs occurred, all of which were reversible with drug interruption [&lt;ulink linkType="Reference" linkID="1195598"&gt;1195598&lt;/ulink&gt;]. DLTs observed with the combination of trametinib DMSO/&lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; were grade 2 rash and mucositis (0.5 mg/50 mg; n = 1), grade 2 AST elevation requiring drug interruption for &gt;/= 14 days (1 mg/50 mg), grade 3 chest pain in association with sustained ventricular tachycardia (1.5 mg/25 mg), grade 2 fatigue requiring drug interruption for &gt;/= 14 days, grade 3 mucositis and diarrhea (1 mg/75 mg), grade 2 nausea, dehydration, vomiting and mucositis (1 mg/75 mg), grade 3 diarrhea and esophagitis (2 mg/50 mg), and grade 2 diarrhea requiring drug interruption for &gt;/= 14 days (2 mg/50 mg). Treatment-related grade 1 and 2 adverse events were reported by 54 of 62 (87%) patients and treatment-related serious adverse events were reported by 3 of 62 (5%) patients. The most frequently reported adverse events were gastrointestinal issues (diarrhea [n = 23], nausea [n = 11], vomiting [n = 8] and dyspepsia [n = 6]), skin irritation (dermatitis acneiform [n = 8], rash and maculopapular rash [n = 8 and 6, respectively] and dry skin [n = 6]), stomatitis (n = 7), dry mouth (n = 6), AST elevation (n = 6) and fatigue (n = 6) [&lt;ulink linkType="Reference" linkID="1195598"&gt;1195598&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I &lt;ulink linkType="Protocol" linkID="72595"&gt;NCT01248858&lt;/ulink&gt; clinical trial in patients with advanced solid tumors, DLTs were experienced by three of five patients in the 2-mg trametinib DMSO/0.5-mg &lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt; group (grade 3 stomatitis [n = 1], grade 3 hypertension [n = 1], and grade 3 hypophosphatemia and grade 2 diarrhea (n = 1). Of 21 serious adverse events reported by 14 patients, 3 were considered related to treatment and were also reported as DLTs. The trial was discontinued by one patient treated with the 1.5-mg trametinib DMSO/0.5-mg &lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt; dose following a grade 2 acneiform rash and a grade 3 macular rash; however, neither of these events was considered serious or treatment-related. Adverse events data from 31 patients indicated that the most frequent adverse events (&gt;/= 20% of patients) were rash (30 patients, 97%), diarrhea (21 patients; 68%), fatigue, nausea, vomiting (all 9 patients each; 29% each) and decreased appetite (8 patients; 26%) [&lt;ulink linkType="Reference" linkID="1240101"&gt;1240101&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The phase Ib &lt;ulink linkType="Protocol" linkID="80521"&gt;NCT01428427&lt;/ulink&gt; clinical trial of the combination of trametinib DMSO and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; in patients with advanced solid tumors revealed that the DLTs were grade 3/4 febrile neutropenia (n = 2), grade 3 AST elevation (n = 2) and grade 2 uveitis (n = 1) [&lt;ulink linkType="Reference" linkID="1237851"&gt;1237851&lt;/ulink&gt;]. A total of 16 serious adverse events were reported and 5 of these, pneumonitis (n = 1), febrile neutropenia (n = 3) and dyspnea (n = 1), were considered to be possibly related to treatment. All DLTs and serious adverse events resolved. Among patients (n = 18) who received the recommended phase II regimen of trametinib DMSO (2 mg) and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (1000 mg/m2), the most frequent adverse events were rash (78%), fatigue (67%), thrombocytopenia (61%), neutropenia (50%), reduced appetite (50%), nausea (44%), and diarrhea and constipation (39%). All these adverse events were &amp;lt;/= grade 2 in severity, with the exception of some cases of &gt;/= grade 3 thrombocytopenia (17%) and neutropenia (33%) [&lt;ulink linkType="Reference" linkID="1237851"&gt;1237851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The phase Ib &lt;ulink linkType="Protocol" linkID="59469"&gt;NCT00955773&lt;/ulink&gt; clinical trial of trametinib DMSO in combination with &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; in patients with solid tumors demonstrated that the toxicity profile of the two drugs in combination was not acceptable [&lt;ulink linkType="Reference" linkID="1240066"&gt;1240066&lt;/ulink&gt;]. Seven patients experienced DLTs as follows: grade 3 stomatitis (n = 1; 1 mg trametinib DMSO/5 mg qd &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;), grade 3 mucositis and hyperkalemia (n = 1), grade 3 dermatitis acneiform, fatigue and dehydration (n = 1), grade 4 thrombocytopenia (n = 1; all at 1.5 mg trametinib DMSO/7.5 mg qd &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;), and grade 3 mucositis (n = 3; 2 mg trametinib DMSO/5 mg &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; 7 days on/7 days off). Of 40 serious adverse events reported, 15 were deemed to be treatment-related (3 mucositis, 3 diarrhea, 2 thrombocytopenia, and 1 case each of nausea, vomiting, dehydration, fever, pancreatitis, ALT elevation and bilirubin elevation). Two patients had fatal, non-treatment-related serious adverse events (pneumonia and gastrointestinal hemorrhage). All patients reported &gt;/= 1 adverse event and the most frequent adverse events were rash, mucositis/stomatitis and fatigue, which occurred in 54 (81%), 45 (67%) and 40 (60%) patients, respectively, with 3 (4%), 8 (12%) and 3 (4%) of the respective events being of grade 3 severity. The majority of adverse events were &amp;lt;/= grade 2 in severity, although grade 3 AST elevations and grade 3 hyperglycemia were observed in 7 (10%) and 5 (7%) patients, respectively [&lt;ulink linkType="Reference" linkID="1240066"&gt;1240066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I/II &lt;ulink linkType="Protocol" linkID="64287"&gt;NCT01072175&lt;/ulink&gt; clinical trial of trametinib DMSO in combination with &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; in patients with BRAFVal600-mutant solid tumors, one DLT, recurrent grade 2 neutrophilic panniculitis, was identified at the 1.5-mg dose of trametinib DMSO [&lt;ulink linkType="Reference" linkID="1196607"&gt;1196607&lt;/ulink&gt;]. One grade 4 adverse event of sepsis-like syndrome with fever/hypotension and four grade 3 adverse events, generalized rash (n = 2; 4%) and neutropenia (n = 2; 4%), were observed. Skin toxicity of &gt;/= grade 2 severity was reported by 9 (20%) patients, including 4 (8%) patients with grade 2 rash and 1 (2%) patient with grade 2 macular rash. There was no evidence of cutaneous squamous cell carcinoma or hyperproliferative skin lesions at any dose level. Additional grade 2 toxicities were pyrexia (n = 5; 11%), vomiting (n = 2; 4%) and fatigue (n = 2; 4%) [&lt;ulink linkType="Reference" linkID="1196607"&gt;1196607&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I/II &lt;ulink linkType="Protocol" linkID="57847"&gt;NCT00920140&lt;/ulink&gt; clinical trial, treatment-related adverse events reported by &amp;gt; 10% of patients were diarrhea (29% [n = 13], all grades; 24% [n = 11], grade 1/2; 4% [n = 2], grade 3) and rash (22% [n = 10], all grades; 20% [n = 9], grade 1/2; 2% [n = 1], grade 3). No cases of myelosuppression were observed. Adverse events considered possibly related to treatment were blurred vision (n = 2, grade 1; n = 1, grade 3) and decreased cardiac ejection fraction (n = 1, grade 3) [&lt;ulink linkType="Reference" linkID="1196464"&gt;1196464&lt;/ulink&gt;]. One patient discontinued treatment because of grade 2 central serous retinopathy. Disease-related thrombocytopenia and pneumonia, which was considered to be a DLT, was experienced by one patient who also had a grade 5 hemorrhage [&lt;ulink linkType="Reference" linkID="1152314"&gt;1152314&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;&lt;ulink linkType="Company" linkID="17327"&gt;Japan Tobacco&lt;/ulink&gt; first claimed trametinib (JTP-74057) and its salts in &lt;ulink linkType="Patent" linkID="PA3068897"&gt;WO-2005121142&lt;/ulink&gt;, which describes trioxypyrimidopyrimidine derivatives, useful for the treatment of tumors. Trametinib DMSO is generically claimed in claim 2 and exemplified specifically as example 4-1 on page 144. The &lt;ulink linkType="Patent" linkID="PA3068897"&gt;WO-2005121142&lt;/ulink&gt; product case has been granted in the US (&lt;ulink linkType="Patent" linkID="PA3076630"&gt;US-07378423&lt;/ulink&gt;), Europe (&lt;ulink linkType="Patent" linkID="PA3478019"&gt;EP-01761528&lt;/ulink&gt;), Japan (&lt;ulink linkType="Patent" linkID="PA5118684"&gt;JP-04163738&lt;/ulink&gt;), China (&lt;ulink linkType="Patent" linkID="PA5985087"&gt;CN-101006086&lt;/ulink&gt;), Canada (&lt;ulink linkType="Patent" linkID="PA4743185"&gt;CA-02569850&lt;/ulink&gt;) and Australia (&lt;ulink linkType="Patent" linkID="PA4742671"&gt;AU-2005252110&lt;/ulink&gt;). With the exception of the US equivalent, &lt;ulink linkType="Patent" linkID="PA3076630"&gt;US-07378423&lt;/ulink&gt;, which has an expiry date in September 2025 following US154 extension, all these regional equivalents are due to expire in June 2025. &lt;ulink linkType="Patent" linkID="PA3076630"&gt;US-07378423&lt;/ulink&gt; specifically claims trametinib in claim 13 and its DMSO salt is covered in claim 17. The &lt;ulink linkType="Patent" linkID="PA3068897"&gt;WO-2005121142&lt;/ulink&gt; application has also been granted in Korea and Germany as &lt;ulink linkType="Patent" linkID="PA5995464"&gt;KR-00883289&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA5130757"&gt;DE-602005004286&lt;/ulink&gt;, respectively, with expiry due in January 2027 and June 2025, respectively. At the time of publication, additional US applications (&lt;ulink linkType="Patent" linkID="PA5778241"&gt;US-20100240613&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3724672"&gt;US-20080312228&lt;/ulink&gt;), European applications (&lt;ulink linkType="Patent" linkID="PA6389350"&gt;EP-02298768&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3613265"&gt;EP-01894932&lt;/ulink&gt;), and a Chinese application (&lt;ulink linkType="Patent" linkID="PA6299484"&gt;CN-101912400&lt;/ulink&gt;), were pending grant.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="26068"&gt;Cytokinetics&lt;/ulink&gt; had a licensing agreement with GSK that was terminated in February 2010 [&lt;ulink linkType="Reference" linkID="1063253"&gt;1063253&lt;/ulink&gt;]. This licensing agreement resulted in &lt;ulink linkType="Company" linkID="26068"&gt;Cytokinetics&lt;/ulink&gt; filing &lt;ulink linkType="Patent" linkID="PA6381553"&gt;WO-2011031308&lt;/ulink&gt;, which claims a combination of &lt;ulink linkType="Drug" linkID="54621"&gt;GSK-923295&lt;/ulink&gt; and a sensitizer of centromere protein-E inhibition, preferably trametinib DMSO, for the treatment of cancer. Trametinib DMSO is specifically disclosed in claim 9 of &lt;ulink linkType="Patent" linkID="PA6381553"&gt;WO-2011031308&lt;/ulink&gt;. At the time of publication, this application had not been granted; however, &lt;ulink linkType="Company" linkID="26068"&gt;Cytokinetics&lt;/ulink&gt; may not be pursuing this application because the company discontinued its oncology research following the termination of its licensing agreement with GSK [&lt;ulink linkType="Reference" linkID="1063253"&gt;1063253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;GSK later filed six combination cases for the treatment of cancer, claiming the combination of trametinib DMSO with other anticancer drugs. AKT inhibitors (&lt;ulink linkType="Patent" linkID="PA6395879"&gt;WO-2011038085&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA6395878"&gt;WO-2011038082&lt;/ulink&gt;), PI3K inhibitors (&lt;ulink linkType="Patent" linkID="PA6395991"&gt;WO-2011038380&lt;/ulink&gt;), mTOR inhibitors (&lt;ulink linkType="Patent" linkID="PA6453232"&gt;WO-2011062930&lt;/ulink&gt;), &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; (&lt;ulink linkType="Patent" linkID="PA6416760"&gt;WO-2011047238&lt;/ulink&gt;) and &lt;ulink linkType="Drug" linkID="33591"&gt;lapatinib&lt;/ulink&gt; (&lt;ulink linkType="Patent" linkID="PA6659864"&gt;WO-2011146712&lt;/ulink&gt;) are specified in these applications. At the time of publication, corresponding regional equivalents for these applications had not been published.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;Persistent activation of the MAPK pathway is believed to drive the pathogenesis of several malignancies, including, but not limited to, colorectal, pancreatic, lung and thyroid cancers, and melanoma [&lt;ulink linkType="Reference" linkID="1248730"&gt;1248730&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1248731"&gt;1248731&lt;/ulink&gt;]. For patients with melanoma, inhibition of aberrant MAPK pathway activity using &lt;ulink linkType="Drug" linkID="54469"&gt;vemurafenib&lt;/ulink&gt;, an inhibitor selective for Val600Glu-mutant BRAF, has already been demonstrated to be a successful therapeutic strategy. MEK inhibition blocks MAPK pathway signaling downstream from BRAF, and there is great optimism for the therapeutic efficacy of MEK inhibitors, such as trametinib DMSO.&lt;/para&gt;&lt;para&gt;Although other MEK inhibitors have been tested clinically, trametinib DMSO holds particular promise relative to others in its drug class. &lt;ulink linkType="Drug" linkID="22774"&gt;PD-184352&lt;/ulink&gt; was the first MEK inhibitor to enter clinical trials. Side effects of &lt;ulink linkType="Drug" linkID="22774"&gt;PD-184352&lt;/ulink&gt;, including rash and diarrhea, were similar to those observed with trametinib DMSO, but phase II evaluation of &lt;ulink linkType="Drug" linkID="22774"&gt;PD-184352&lt;/ulink&gt; disappointingly revealed limited activity, likely because of low oral bioavailability and the short t1/2 of &lt;ulink linkType="Drug" linkID="22774"&gt;PD-184352&lt;/ulink&gt; compared with trametinib DMSO [&lt;ulink linkType="Reference" linkID="1222690"&gt;1222690&lt;/ulink&gt;]. To address these problems, &lt;ulink linkType="Company" linkID="18767"&gt;Pfizer&lt;/ulink&gt; reformulated &lt;ulink linkType="Drug" linkID="22774"&gt;PD-184352&lt;/ulink&gt; into a second-generation compound, &lt;ulink linkType="Drug" linkID="48980"&gt;PD-0325901&lt;/ulink&gt;, which has improved bioavailability and increased MEK inhibitory potency compared with &lt;ulink linkType="Drug" linkID="22774"&gt;PD-184352&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1110646"&gt;1110646&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1110685"&gt;1110685&lt;/ulink&gt;]. Clinical testing of &lt;ulink linkType="Drug" linkID="48980"&gt;PD-0325901&lt;/ulink&gt;, however, was suspended after patients experienced retinal vein occlusions and neuropathies that may have resulted from the drug crossing the blood-brain-barrier, a finding reproduced in animal models treated with this drug [&lt;ulink linkType="Reference" linkID="1066384"&gt;1066384&lt;/ulink&gt;]. Based upon data from preclinical tumor xenograft models, trametinib DMSO is not believed to accumulate in the CNS to appreciable levels, suggesting the neurotoxicity of &lt;ulink linkType="Drug" linkID="48980"&gt;PD-0325901&lt;/ulink&gt; may be avoided.&lt;/para&gt;&lt;para&gt;A third MEK inhibitor, &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; has been demonstrated to be tolerable in a phase I clinical trial in 57 patients [&lt;ulink linkType="Reference" linkID="906292"&gt;906292&lt;/ulink&gt;]. Side effects of &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; reported in this trial included most commonly rash and diarrhea, similar to the side effects reported with trametinib DMSO. Unfortunately, the results of phase II trials comparing &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; with chemotherapy have not been promising [&lt;ulink linkType="Reference" linkID="1137234"&gt;1137234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1222692"&gt;1222692&lt;/ulink&gt;]. One potential advantage of trametinib DMSO is its long t1/2 of ~ 6.5 days compared with the shorter t1/2 of 12 h of &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt;. Once-daily dosing of trametinib DMSO, therefore, would have the benefit of increased convenience compared with &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt;, which needs to be dosed twice-daily. The longer t1/2 of trametinib DMSO may additionally lead to more prolonged suppression of MEK activity compared with &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt;, and the potential for improved efficacy, but this requires further confirmation.&lt;/para&gt;&lt;para&gt;Similar to other targeted therapies directed against abnormal cellular signaling pathways, the future success of trametinib DMSO will depend upon selecting patients who are most likely to respond. Preclinical evidence has supported the notion that BRAF-mutant tumors are particularly sensitive to MEK inhibition compared with either wild-type tumors or tumors with enhanced MAPK pathway activation caused by alternative mechanisms, such as mutant RAS [&lt;ulink linkType="Reference" linkID="1087410"&gt;1087410&lt;/ulink&gt;]. It is expected, therefore, that patients with BRAF mutations will be selected for clinical trials evaluating trametinib DMSO, which is the case for the ongoing phase III trial of trametinib DMSO in melanoma. It is possible that prior phase II trials of other MEK inhibitors demonstrated disappointing efficacy because of the lack of selectivity for patients with BRAF-mutant malignancies. Interestingly, in a phase II trial comparing &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; with the alkylating agent &lt;ulink linkType="Drug" linkID="4529"&gt;temozolomide&lt;/ulink&gt; for patients with melanoma, five out of the six patients who responded had BRAF-mutant tumors [&lt;ulink linkType="Reference" linkID="1248734"&gt;1248734&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Uveal melanoma represents a melanoma subtype that may be particularly responsive to MEK inhibition with trametinib DMSO. In uveal melanoma, the MAPK pathway is often overly active, an effect that is thought to be caused by oncogenic driver mutations in the G-proteins, GNAQ and GNA11, and not mutant BRAF activity [&lt;ulink linkType="Reference" linkID="1222696"&gt;1222696&lt;/ulink&gt;]. In vitro evidence has demonstrated the ability of &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; to inhibit the growth of GNAQ-mutant ocular melanoma cells [&lt;ulink linkType="Reference" linkID="1090207"&gt;1090207&lt;/ulink&gt;]. Additionally, clinical efficacy of the MEK inhibitor &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; has been suggested by subset analyses of patients with uveal melanoma treated in trials of &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1222697"&gt;1222697&lt;/ulink&gt;]. To determine if GNAQ or GNA11 mutational status is predictive of response, further data are awaited from &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt;-treated patients with uveal melanoma. Addressing this issue is a goal of a randomized phase II trial (&lt;ulink linkType="Protocol" linkID="67263"&gt;NCT01143402&lt;/ulink&gt;) of &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; versus &lt;ulink linkType="Drug" linkID="4529"&gt;temozolomide&lt;/ulink&gt; in patients with advanced uveal melanoma, stratified by GNAQ and GNA11 mutational status.&lt;/para&gt;&lt;para&gt;Although trametinib DMSO may have a future role as a single agent, it is likely that it will be most effective when used as part of combination strategies. In addition to BRAF mutations that activate the MAPK pathway, patients with melanoma also display amplification of the PI3K/AKT/mTOR signaling pathway, often via activating mutations in AKT or deletion of the PTEN tumor suppressor gene [&lt;ulink linkType="Reference" linkID="1248735"&gt;1248735&lt;/ulink&gt;]. To effectively suppress tumor growth, inhibition of both the MAPK and PI3K pathways will probably be necessary. Preclinical models have demonstrated that treatment of inducible KRAS-mutant lung cancers with &lt;ulink linkType="Drug" linkID="28972"&gt;selumetinib&lt;/ulink&gt; and the PI3K/mTOR inhibitor &lt;ulink linkType="Drug" linkID="57048"&gt;BEZ-235&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt;; phase II [&lt;ulink linkType="Reference" linkID="1200755"&gt;1200755&lt;/ulink&gt;]) led to an enhanced antitumor response [&lt;ulink linkType="Reference" linkID="974017"&gt;974017&lt;/ulink&gt;]. At the time of publication, several phase I protocols involving trametinib DMSO in combination with the PI3K inhibitor &lt;ulink linkType="Drug" linkID="64359"&gt;GSK-2126458&lt;/ulink&gt;, the AKT inhibitor &lt;ulink linkType="Drug" linkID="63799"&gt;GSK-2141795&lt;/ulink&gt; or the mTOR inhibitor &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;, were ongoing. These combination treatment strategies are expected to demonstrate improved efficacy compared with single-agent trametinib DMSO.&lt;/para&gt;&lt;para&gt;Furthermore, dual inhibition of the MAPK pathway with a BRAF inhibitor and a MEK inhibitor could be a successful strategy for the treatment of BRAF-mutant melanoma and other malignancies driven by abnormal MAPK signaling. MEK inhibition may be a possible solution to resistance that often develops following BRAF inhibitor therapy because resistance to BRAF inhibition is considered to at least partially depend on MEK activation. At the time of publication, clinical trials (eg, &lt;ulink linkType="Protocol" linkID="64287"&gt;NCT01072175&lt;/ulink&gt;) involving the combination of the BRAF inhibitor &lt;ulink linkType="Drug" linkID="53133"&gt;dabrafenib&lt;/ulink&gt; with trametinib DMSO were being conducted to address the possible therapeutic efficacy of dual MAPK pathway inhibition for patients with BRAF-mutant metastatic melanoma.&lt;/para&gt;&lt;para&gt;The available information on trametinib DMSO is preliminary but promising. MEK inhibition is an emerging therapeutic approach to block abnormally active MAPK pathway signaling and may ultimately be beneficial in a number of malignancies. MEK inhibitors, such as trametinib DMSO, will hopefully continue to demonstrate promising clinical results as monotherapy. Their greatest efficacy, however, will likely be as a component of combination approaches involving the concomitant inhibition of other growth-promoting signaling pathways, such as the PI3K/AKT/mTOR pathway, and in dual inhibition of the MAPK pathway. Clinical trials of trametinib DMSO in combination with other signaling inhibitors are already underway and results are eagerly anticipated. For future trials of trametinib DMSO, stratification of patients based on tumor mutational status will be essential.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016801" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-03T00:00:00.000Z</StatusDate><Source id="1913566" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-29T00:00:00.000Z</StatusDate><Source id="2067367" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-09T00:00:00.000Z</StatusDate><Source id="2136526" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-31T00:00:00.000Z</StatusDate><Source id="2073891" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-31T00:00:00.000Z</StatusDate><Source id="2073891" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-15T00:00:00.000Z</StatusDate><Source id="1938335" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-31T00:00:00.000Z</StatusDate><Source id="2073891" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-11T00:00:00.000Z</StatusDate><Source id="2056935" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-03T00:00:00.000Z</StatusDate><Source id="1913566" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-03T00:00:00.000Z</StatusDate><Source id="1913566" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-09T00:00:00.000Z</StatusDate><Source id="2136526" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3769">Anaplastic thyroid cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-04T00:00:00.000Z</StatusDate><Source id="2030753" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-08-28T00:00:00.000Z</StatusDate><Source id="1736666" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-31T00:00:00.000Z</StatusDate><Source id="1767636" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-22T00:00:00.000Z</StatusDate><Source id="1940133" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-30T00:00:00.000Z</StatusDate><Source id="2029260" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-01T00:00:00.000Z</StatusDate><Source id="1714087" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-05T00:00:00.000Z</StatusDate><Source id="1792698" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2107483" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-07T00:00:00.000Z</StatusDate><Source id="2107483" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="1999482" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-30T00:00:00.000Z</StatusDate><Source id="1742727" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-30T00:00:00.000Z</StatusDate><Source id="1742727" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3737">Germ cell and embryonic cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-21T00:00:00.000Z</StatusDate><Source id="2049230" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1516">Biliary cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-07T00:00:00.000Z</StatusDate><Source id="1742727" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3769">Anaplastic thyroid cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-04-30T00:00:00.000Z</StatusDate><Source id="1655393" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3672">Metastatic colon cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-21T00:00:00.000Z</StatusDate><Source id="2049230" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-07T00:00:00.000Z</StatusDate><Source id="1742727" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2399">Adenocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1108">Glioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3521">Neurofibromatosis type I</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-15T00:00:00.000Z</StatusDate><Source id="2055965" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3521">Neurofibromatosis type I</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-15T00:00:00.000Z</StatusDate><Source id="2055965" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3521">Neurofibromatosis type I</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-15T00:00:00.000Z</StatusDate><Source id="2055965" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3671">Metastatic rectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3521">Neurofibromatosis type I</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-15T00:00:00.000Z</StatusDate><Source id="2055965" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3521">Neurofibromatosis type I</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-15T00:00:00.000Z</StatusDate><Source id="2055965" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1134">Thyroid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="3664">Metastatic prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-31T00:00:00.000Z</StatusDate><Source id="1995660" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-31T00:00:00.000Z</StatusDate><Source id="2107483" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-09T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17327">Japan Tobacco Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-18T00:00:00.000Z</StatusDate><Source id="662918" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1134">Thyroid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3671">Metastatic rectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17327">Japan Tobacco Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-18T00:00:00.000Z</StatusDate><Source id="662918" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1161630" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-31T00:00:00.000Z</StatusDate><Source id="945050" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1161630" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-03T00:00:00.000Z</StatusDate><Source id="1313077" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1161630" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-29T00:00:00.000Z</StatusDate><Source id="1430654" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-18T00:00:00.000Z</StatusDate><Source id="1161630" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-07T00:00:00.000Z</StatusDate><Source id="1368381" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-22T00:00:00.000Z</StatusDate><Source id="1248163" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</StatusDate><Source id="1045072" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-11-15T00:00:00.000Z</StatusDate><Source id="1352404" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-06T00:00:00.000Z</StatusDate><Source id="1503966" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-22T00:00:00.000Z</StatusDate><Source id="1387848" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-22T00:00:00.000Z</StatusDate><Source id="1387848" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-11-15T00:00:00.000Z</StatusDate><Source id="1352404" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-11-15T00:00:00.000Z</StatusDate><Source id="1352404" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-11-15T00:00:00.000Z</StatusDate><Source id="1352404" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1199605" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1199605" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1141173" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-31T00:00:00.000Z</StatusDate><Source id="1440503" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-31T00:00:00.000Z</StatusDate><Source id="1440503" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-31T00:00:00.000Z</StatusDate><Source id="1660056" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-31T00:00:00.000Z</StatusDate><Source id="1440503" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-24T00:00:00.000Z</StatusDate><Source id="1456076" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-24T00:00:00.000Z</StatusDate><Source id="1456078" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-30T00:00:00.000Z</StatusDate><Source id="1576533" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-11T00:00:00.000Z</StatusDate><Source id="1585451" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-30T00:00:00.000Z</StatusDate><Source id="1518688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1199605" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-31T00:00:00.000Z</StatusDate><Source id="1576533" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-27T00:00:00.000Z</StatusDate><Source id="1654583" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-28T00:00:00.000Z</StatusDate><Source id="1746725" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1134">Thyroid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-31T00:00:00.000Z</StatusDate><Source id="1255249" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-30T00:00:00.000Z</StatusDate><Source id="1866715" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-15T00:00:00.000Z</StatusDate><Source id="1938335" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-30T00:00:00.000Z</StatusDate><Source id="1866715" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1912899" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1912899" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1912899" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1912899" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-22T00:00:00.000Z</StatusDate><Source id="1940133" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-03T00:00:00.000Z</StatusDate><Source id="1913566" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-05T00:00:00.000Z</StatusDate><Source id="1883178" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-23T00:00:00.000Z</StatusDate><Source id="2016801" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-22T00:00:00.000Z</StatusDate><Source id="1993442" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-30T00:00:00.000Z</StatusDate><Source id="2029260" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3769">Anaplastic thyroid cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-15T00:00:00.000Z</StatusDate><Source id="1910990" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3769">Anaplastic thyroid cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-04T00:00:00.000Z</StatusDate><Source id="2030753" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="1999482" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-29T00:00:00.000Z</StatusDate><Source id="2067367" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-31T00:00:00.000Z</StatusDate><Source id="2073891" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-31T00:00:00.000Z</StatusDate><Source id="2073891" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-31T00:00:00.000Z</StatusDate><Source id="2073891" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-11T00:00:00.000Z</StatusDate><Source id="2056935" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-05T00:00:00.000Z</StatusDate><Source id="2073879" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-05T00:00:00.000Z</StatusDate><Source id="2073879" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-05T00:00:00.000Z</StatusDate><Source id="2073879" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-05T00:00:00.000Z</StatusDate><Source id="2073879" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-30T00:00:00.000Z</StatusDate><Source id="2073870" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-30T00:00:00.000Z</StatusDate><Source id="2073870" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-19T00:00:00.000Z</StatusDate><Source id="2073870" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-19T00:00:00.000Z</StatusDate><Source id="2073870" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-19T00:00:00.000Z</StatusDate><Source id="2073870" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-19T00:00:00.000Z</StatusDate><Source id="2073870" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-31T00:00:00.000Z</StatusDate><Source id="2073830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-31T00:00:00.000Z</StatusDate><Source id="2073830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-31T00:00:00.000Z</StatusDate><Source id="2073830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="2073830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="2073830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="2073830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="2073830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="2073830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="2073830" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-30T00:00:00.000Z</StatusDate><Source id="1866715" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-31T00:00:00.000Z</StatusDate><Source id="2097299" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-31T00:00:00.000Z</StatusDate><Source id="2097299" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-31T00:00:00.000Z</StatusDate><Source id="2097299" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-31T00:00:00.000Z</StatusDate><Source id="2097299" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1955309" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3671">Metastatic rectal cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-30T00:00:00.000Z</StatusDate><Source id="2102050" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1199605" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-30T00:00:00.000Z</StatusDate><Source id="1199605" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-03T00:00:00.000Z</StatusDate><Source id="1913566" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-02T00:00:00.000Z</StatusDate><Source id="1637483" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-03T00:00:00.000Z</StatusDate><Source id="1913566" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-09T00:00:00.000Z</StatusDate><Source id="1742448" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-13T00:00:00.000Z</StatusDate><Source id="2010290" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-31T00:00:00.000Z</StatusDate><Source id="945050" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-31T00:00:00.000Z</StatusDate><Source id="945050" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1110286" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-31T00:00:00.000Z</StatusDate><Source id="945050" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>In combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-01-08T00:00:00.000Z</MileStoneDate><Source id="1514730" type="PR"></Source></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>In combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-08T00:00:00.000Z</MileStoneDate><Source id="1449851" type="PR"></Source></Row><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3769">Anaplastic thyroid cancer</Indication><AwardedIndication>In combination with dabrafenib for the treatment of BRAF V600E mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-04T00:00:00.000Z</MileStoneDate><Source id="2030753" type="PR"></Source></Row><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3256">Stage III melanoma</Indication><AwardedIndication>The adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-23T00:00:00.000Z</MileStoneDate><Source id="1973359" type="PR"></Source></Row><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="1262">Non-small-cell lung cancer</Indication><AwardedIndication>BRAF V600E mutation-positive non-small-cell lung cancer (NSCLC)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-21T00:00:00.000Z</MileStoneDate><Source id="1678993" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="JP">Japan</Country><Indication id="1262">Non-small-cell lung cancer</Indication><AwardedIndication>BRAF-positive unresectable advanced or recurrent non-small cell lung cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-27T00:00:00.000Z</MileStoneDate><Source id="1804290" type="SERIAL"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3769">Anaplastic thyroid cancer</Indication><AwardedIndication>In combination with dabrafenib  for the treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-01T00:00:00.000Z</MileStoneDate><Source id="1796564" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28355">GlaxoSmithKline plc</OwnerCompany><Country id="JP">Japan</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>Malingnant melanoma with BRAF-V600 mutation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-23T00:00:00.000Z</MileStoneDate><Source id="1654850" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="JP">Japan</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>Malingnant melanoma with BRAF-V600 mutation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-13T00:00:00.000Z</MileStoneDate><Source id="1479034" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28355">GlaxoSmithKline plc</OwnerCompany><Country id="JP">Japan</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>Malignant melanoma with BRAF-V600 mutation BRAFV600遺伝子変異を有する悪性黒色腫</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-13T00:00:00.000Z</MileStoneDate><Source id="1479034" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>Treatment of Stage IIb through Stage IV melanoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-20T00:00:00.000Z</MileStoneDate><Source id="1334880" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28355">GlaxoSmithKline plc</OwnerCompany><Country id="AU">Australia</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>For the treatment of the patients with BRAF V600 mutation positive unresectable or metastatic (Stage IV) melanoma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-01T00:00:00.000Z</MileStoneDate><Source id="1337011" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28355">GlaxoSmithKline plc</OwnerCompany><Country id="AU">Australia</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>For the treatment of the patients with BRAF V600 mutation positive unresectable or metastatic (Stage IV) melanoma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-01T00:00:00.000Z</MileStoneDate><Source id="1337011" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>Treatment of Stage IIb through Stage IV melanoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-20T00:00:00.000Z</MileStoneDate><Source id="1334884" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3769">Anaplastic thyroid cancer</Indication><AwardedIndication>In combination with dabrafenib for the treatment of BRAF V600E mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-04T00:00:00.000Z</MileStoneDate><Source id="2030753" type="PR"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3256">Stage III melanoma</Indication><AwardedIndication>Adjuvant treatment in combination with dabrafenib of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, following complete resection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-22T00:00:00.000Z</MileStoneDate><Source id="1993442" type="PR"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="AU">Australia</Country><Indication id="3256">Stage III melanoma</Indication><AwardedIndication>In combination with dabrafenib, for the adjuvant treatment of patients with Stage III melanoma with a BRAF V600 mutation, following complete resection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-13T00:00:00.000Z</MileStoneDate><Source id="2010290" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="EU">EU</Country><Indication id="3665">Metastatic non small cell lung cancer</Indication><AwardedIndication>Treatment of patients with BRAF V600-positive advanced or metastatic NSCLC </AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-11-30T00:00:00.000Z</MileStoneDate><Source id="1895140" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01286"><Name>MEK-1 protein kinase</Name><SwissprotNumbers><Swissprot>P29678</Swissprot><Swissprot>P31938</Swissprot><Swissprot>Q01986</Swissprot><Swissprot>Q02750</Swissprot><Swissprot>Q05116</Swissprot><Swissprot>Q63980</Swissprot><Swissprot>Q91447</Swissprot><Swissprot>Q9XT09</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01287"><Name>MEK-2 protein kinase</Name><SwissprotNumbers><Swissprot>P36506</Swissprot><Swissprot>P36507</Swissprot><Swissprot>Q07192</Swissprot><Swissprot>Q63932</Swissprot><Swissprot>Q90321</Swissprot><Swissprot>Q90891</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2156160" linkType="reference" linkID="2156160"&gt;2156160&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1020515">ACCRA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="1041750">National Comprehensive Cancer Network</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1047565">Clovis Oncology Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17327">Japan Tobacco Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>8</CountTotal></Company><Company><Company id="28443">The University Health Network</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000590">Quest Diagnostics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5</Smiles><Smiles>Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5.CS(=O)C</Smiles></StructureSmiles><Deals><Deal id="108808" title="GSK to develop Japan Tobacco's MEK inhibitor worldwide"></Deal><Deal id="135547" title="NCCN to evaluate GlaxoSmithKline's oncology products, including pazopanib, GSK-1120212 and GSK-2118436      "></Deal><Deal id="140813" title="GSK and bioMerieux to codevelop molecular theranostic test to detect BRAF V600 gene mutations   "></Deal><Deal id="147456" title="Pfizer and GSK to conduct study of trametinib combined with palbociclib for advanced or metastatic melanoma"></Deal><Deal id="148284" title="GlaxoSmithKline and MedImmune to codevelop MEDI-4736 + dabrafenib + trametinib combination drug against melanoma"></Deal><Deal id="149176" title="Novartis acquires GlaxoSmithKline's oncology portfolio"></Deal><Deal id="149688" title="Quest Diagnostics to distribute bioMerieux's THxID-BRAF companion diagnostic to dabrafenib and trametinib for melanoma "></Deal><Deal id="151702" title="Clovis and GlaxoSmithKline to evaluate rociletinib and trametinib drug combination in EGFR NSCLC patients    "></Deal><Deal id="154294" title="The University Health Network to conduct phase II study for GSK's GSK-2256098 or in combination with Trametinib against advanced pancreatic cancer         "></Deal><Deal id="240540" title="Novartis and BMS to evaluate Mekinist with Opdivo and (Opdivo + Yervoy) for metastatic colorectal cancer    "></Deal><Deal id="241690" title="Molecular theranostic test for metastatic melanoma treatment selection  "></Deal></Deals><PatentFamilies><PatentFamily id="1041207" number="WO-2011146712" title="Combination"></PatentFamily><PatentFamily id="1412539" number="WO-2011062930" title="Combination"></PatentFamily><PatentFamily id="1636643" number="WO-2012088033" title="Novel pharmaceutical composition"></PatentFamily><PatentFamily id="1710347" number="WO-2012088030" title="Combination"></PatentFamily><PatentFamily id="1847059" number="WO-2011047238" title="Combination"></PatentFamily><PatentFamily id="2006095" number="WO-2012061683" title="Methods for treating cancer"></PatentFamily><PatentFamily id="2375487" number="WO-2011038082" title="Combination"></PatentFamily><PatentFamily id="2466135" number="WO-2013019620" title="Combination of BRAF inhibitor, MEK inhibitor, and anti-CTLA-4 antibody"></PatentFamily><PatentFamily id="2553416" number="WO-2013096430" title="Method of treating cancer with MAGEA3 immunotherapeutic with BRAF inhibitor and/or MEK inhibitor"></PatentFamily><PatentFamily id="2696532" number="WO-2014039375" title="Method of adjuvant cancer treatment"></PatentFamily><PatentFamily id="2717370" number="WO-2014059095" title="Combinations"></PatentFamily><PatentFamily id="2725904" number="WO-2014066606" title="Combination"></PatentFamily><PatentFamily id="2752022" number="WO-2014085371" title="Novel pharmaceutical composition"></PatentFamily><PatentFamily id="2770811" number="WO-2014108837" title="Combination"></PatentFamily><PatentFamily id="2805037" number="WO-2014152377" title="Methods for classifying and treating adenocarcinomas"></PatentFamily><PatentFamily id="2836367" number="WO-2014193589" title="Cancer treatment method"></PatentFamily><PatentFamily id="2836387" number="WO-2014191920" title="N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide for use in the treatment of cancer"></PatentFamily><PatentFamily id="2836478" number="WO-2014193898" title="Combination therapies for cancer"></PatentFamily><PatentFamily id="2839902" number="WO-2014195852" title="Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a Braf inhibitor"></PatentFamily><PatentFamily id="2911171" number="WO-2015041534" title="p90RSK in combination with RAF/ERK/MEK"></PatentFamily><PatentFamily id="2911314" number="WO-2015041533" title="ROCK in combination with MAPK-pathway"></PatentFamily><PatentFamily id="2925441" number="WO-2015059677" title="Methods of treating cancer"></PatentFamily><PatentFamily id="2928942" number="WO-2015066439" title="Methods of treating hematological malignancies"></PatentFamily><PatentFamily id="2929303" number="WO-2015066432" title="Method of treating post-myeloproliferative neoplasms (mpns) and post-mpn acute myeloid leukemia"></PatentFamily><PatentFamily id="2934494" number="CN-104434924" title="Application of trametinib in preparing medicine for reversing multi-medicine resistance of tumors"></PatentFamily><PatentFamily id="2952037" number="WO-2015081566" title="Crystalline forms of trametinib and solvate thereof, preparation method therefor, pharmaceutical composition comprising same and use thereof"></PatentFamily><PatentFamily id="2952428" number="WO-2015085097" title="Compositions and methods for identifying and treating cachexia or pre-cachexia"></PatentFamily><PatentFamily id="2958280" number="WO-2015087279" title="Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer"></PatentFamily><PatentFamily id="2960837" number="WO-2015095825" title="Cancer treatments using combinations of type 2 MEK and ERK inhibitors"></PatentFamily><PatentFamily id="2974336" number="WO-2015105822" title="Cancer treatment method"></PatentFamily><PatentFamily id="3010087" number="WO-2015128298" title="Pharmaceutical composition"></PatentFamily><PatentFamily id="3045599" number="WO-2015149720" title="HNF4G-RSPO2 fusion gene and use thereof in treatment of cancer"></PatentFamily><PatentFamily id="3055991" number="WO-2015160975" title="Combination therapies"></PatentFamily><PatentFamily id="3056018" number="WO-2015161230" title="Methods of reducing kinase inhibitor resistance"></PatentFamily><PatentFamily id="3067769" number="WO-2015175846" title="Treating chronic myelogenous leukemia (CML)"></PatentFamily><PatentFamily id="3071520" number="WO-2015179075" title="Treatment for melanoma"></PatentFamily><PatentFamily id="3092336" number="US-20150361503" title="Methods for selecting therapeutics for treatment of Her2+ cancers"></PatentFamily><PatentFamily id="3152447" number="WO-2016047738" title="Method for screening for anticancer agent"></PatentFamily><PatentFamily id="3198858" number="WO-2017158358" title="Gene signatures for cancer detection and treatment"></PatentFamily><PatentFamily id="3209236" number="WO-2016098873" title="Method for determining risk of developing primary central nervous system lymphoma, and composition for treating primary central nervous system lymphoma"></PatentFamily><PatentFamily id="3216980" number="CN-105646478" title="Crystalline form of trametinib"></PatentFamily><PatentFamily id="3227277" number="WO-2016109452" title="Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results"></PatentFamily><PatentFamily id="3262796" number="WO-2016123378" title="Cancer therapy using JAK inhibitor in combination with MAPK inhibitors"></PatentFamily><PatentFamily id="3295510" number="WO-2016130917" title="Synergistic cancer treatment"></PatentFamily><PatentFamily id="3359896" number="WO-2016141492" title="Markers for MLL-rearranged acute myeloid leukemias and uses thereof"></PatentFamily><PatentFamily id="3416918" number="WO-2016168634" title="Biomarkers related to treatment of cancer with HER3 and EGFR inhibitors"></PatentFamily><PatentFamily id="3427250" number="WO-2016169532" title="Crystalline forms of trametinib"></PatentFamily><PatentFamily id="3479020" number="WO-2016200726" title="Inhibitors of Mcl-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors"></PatentFamily><PatentFamily id="3533688" number="WO-2017019279" title="Methods and compositions to treat cancers involving EGFR"></PatentFamily><PatentFamily id="3562818" number="WO-2017037574" title="Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer"></PatentFamily><PatentFamily id="3562823" number="WO-2017037579" title="MDM2 Inhibitors and combinations thereof"></PatentFamily><PatentFamily id="3594933" number="WO-2017059173" title="Methods and apparatus for modeling cancer metastasis in vitro"></PatentFamily><PatentFamily id="3604632" number="WO-2017065277" title="Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used"></PatentFamily><PatentFamily id="3606103" number="WO-2017062426" title="Methods and compositions for treatment of metastatic and refractory cancers and tumors"></PatentFamily><PatentFamily id="3610518" number="WO-2017070475" title="Methods of treating cancer by administering a MEK inhibitor and a combination of anti-EGFR antibodies"></PatentFamily><PatentFamily id="3660845" number="WO-2017096150" title="Methods of treatment of malignancies"></PatentFamily><PatentFamily id="3668667" number="WO-2017086332" title="Therapeutic agent for mesenchymal KRAS mutation–type cancers"></PatentFamily><PatentFamily id="3669361" number="WO-2017091865" title="Monitoring treatment or progression of myeloma"></PatentFamily><PatentFamily id="3691488" number="WO-2017106189" title="Compositions and methods for treating RAS/MAPK mutant lung cancer"></PatentFamily><PatentFamily id="3691592" number="WO-2017106492" title="Combinations for the treatment of cancer"></PatentFamily><PatentFamily id="3705814" number="WO-2017117386" title="Methods of treating cancer using network brakes"></PatentFamily><PatentFamily id="3745200" number="WO-2017132518" title="Combination therapy for treating cancer"></PatentFamily><PatentFamily id="3745281" number="WO-2018234404" title="Stratification of acute myeloid leukemia patients for sensitivity to kinase pathway inhibitor therapy"></PatentFamily><PatentFamily id="3751573" number="IN-201503773" title="New amorphous form of trametinib used in pharmaceutical composition for treating unresectable or metastatic melanoma having val600glu or val600lys mutations in braf gene"></PatentFamily><PatentFamily id="3781622" number="IN-201641005975" title="Process for the preparation of trametinib dimethyl sulfoxide"></PatentFamily><PatentFamily id="3795860" number="WO-2017160983" title="Compositions and methods for the treatment of a beta-catenin-associated disease or disorder"></PatentFamily><PatentFamily id="3821235" number="WO-2017180581" title="Diagnostic and therapeutic methods for cancer"></PatentFamily><PatentFamily id="3841208" number="WO-2017192928" title="Treatment of rosacea with p38 and Erk kinase pathway inhibitors"></PatentFamily><PatentFamily id="3841286" number="WO-2017193086" title="Therapeutic compounds and methods"></PatentFamily><PatentFamily id="3855769" number="WO-2017200325" title="Pharmaceutical composition containing keratin 8 phosphorylation inhibitor for preventing or treating macular degeneration, and method for screening macular degeneration medicine"></PatentFamily><PatentFamily id="3913379" number="WO-2018183065" title="Methods of treating melanoma"></PatentFamily><PatentFamily id="3975271" number="WO-2018045078" title="Compositions and methods for the diagnosis and treatment of lymphatic system disorders"></PatentFamily><PatentFamily id="4029259" number="WO-2018072269" title="Application of nonsteroidal anti-inflammatory drug for increasing sensitivity of tumor cell to tyrosine kinase inhibitor"></PatentFamily><PatentFamily id="4060229" number="WO-2018092064" title="Combinations of MDM2 inhibitors and Bcl-xL inhibitors"></PatentFamily><PatentFamily id="4071030" number="WO-2018097628" title="Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same"></PatentFamily><PatentFamily id="4088408" number="WO-2018107146" title="Methods and compositions for treatment of BRAF mutant cancers"></PatentFamily><PatentFamily id="4113736" number="WO-2018126192" title="MAP2K1 (MEKl) as a therapeutic target for arteriovenous malformations and associated disorders"></PatentFamily><PatentFamily id="4146622" number="WO-2017058007" title="Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma"></PatentFamily><PatentFamily id="4200282" number="WO-2018167519" title="Biomarker for identifying responders to cancer treatment"></PatentFamily><PatentFamily id="4240330" number="WO-2018195392" title="Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation"></PatentFamily><PatentFamily id="4256809" number="WO-2018203219" title="Combination therapy"></PatentFamily><PatentFamily id="4292324" number="WO-2018218633" title="Combination therapies for treating cancers"></PatentFamily><PatentFamily id="4388978" number="US-20190041401" title="Methods of treating subjects having severe and/or persistent asthma"></PatentFamily><PatentFamily id="4391595" number="WO-2019033123" title="Drug combinations for targeting multiple mutations in cancer"></PatentFamily><PatentFamily id="4400105" number="CN-109320513" title="A method of synthesizing guanidine-trimetazidine"></PatentFamily><PatentFamily id="4412087" number="CN-109336884" title="A method for synthesizing key intermediate of guanidine-trimetazidine"></PatentFamily><PatentFamily id="4429234" number="WO-2019049891" title="Method for treating cancer by combination of trk inhibitor and kinase inhibitor"></PatentFamily><PatentFamily id="4429480" number="WO-2019051084" title="SHP2 inhibitor compositions and methods for treating cancer"></PatentFamily><PatentFamily id="4496592" number="US-20190136212" title="Combination chemotherapy for the treatment of cancer"></PatentFamily><PatentFamily id="4525673" number="WO-2019103984" title="Compositions including FATP1, FATP3, FATP4, FATP5, and/or FATP6 inhibitors and uses thereof"></PatentFamily><PatentFamily id="4542656" number="WO-2019112519" title="Photodynamically active organosilica nanoparticles and medical uses thereof"></PatentFamily><PatentFamily id="518362" number="WO-2012027438" title="Pharmaceutical combination of a VEGFR inhibitor and a MEK inhibitor useful for treating cancer"></PatentFamily><PatentFamily id="643466" number="WO-2005121142" title="5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido-[2,3-d]-pyrimidine derivatives and related compounds for the treatment of cancer"></PatentFamily><PatentFamily id="81040" number="WO-2012068468" title="Method of treatment with BRAF inhibitor"></PatentFamily><PatentFamily id="894799" number="WO-2011038085" title="Combination"></PatentFamily><PatentFamily id="963662" number="WO-2012068339" title="Methods of treating cancer"></PatentFamily><PatentFamily id="972274" number="WO-2011038380" title="Combination"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>63</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>13</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>17</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanyang Technological University" id="1002386"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Yat-Sen University" id="1004360"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Konkuk University" id="1008802"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kyorin University" id="1009840"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hopital Maisonneuve-Rosemont" id="1014786"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jinan University (Guangdong)" id="1019449"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Almac Group" id="1026177"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Technion - Israel Institute of Technology" id="1030571"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Broad Institute Inc" id="1031693"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Thermo Fisher Scientific Inc" id="1032764"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rsem Ltd Partnership" id="1039697"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dicerna Pharmaceuticals Inc" id="1040605"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agios Pharmaceuticals Inc" id="1040627"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis" id="1046025"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alfred Health" id="1047109"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Epizyme Inc" id="1048714"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Foundation Medicine Inc" id="1056444"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioMed Valley Discoveries" id="1063567"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Hankang Pharmaceutical Biotechnology" id="1065273"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute for Research in Immunology and Cancer" id="1067253"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emeritus Research" id="1082916"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guardant Health Inc" id="1093870"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hangzhou Pushai Pharmaceutical Technology Co Ltd" id="1101963"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="REVOLUTION Medicines Inc" id="1105504"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advent International" id="1123769"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="KSQ Therapeutics" id="1129349"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alphabet Inc" id="1129360"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Artios Pharma Ltd" id="1130201"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Percans Oncology Co Ltd" id="1153800"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tarrex Biopharma Inc" id="1156367"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vivo Development Ltd" id="1156541"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wake Forest University Health Sciences, US" id="1158032"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Curematch Inc" id="1161849"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shine Biopharma Inc" id="1165403"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ubrx Inc" id="1169065"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anqing QiChuang Pharmaceutical Co Ltd" id="1171335"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Japan Tobacco Inc" id="17327"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanford-Burnham Medical Research Institute" id="17746"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Massachusetts Institute of Technology" id="18225"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Jewish Health" id="18461"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nissan Chemical Corp" id="18563"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ono Pharmaceutical Co Ltd" id="18681"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Southern Research Institute" id="20226"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Edinburgh" id="20572"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of London" id="20607"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Massachusetts" id="20615"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mount Sinai School of Medicine" id="20631"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pennsylvania" id="20658"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas Tech University" id="20684"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Thomas Jefferson University" id="20685"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Tokyo" id="20686"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vanderbilt University" id="20693"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wake Forest University" id="20699"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wistar Institute of Anatomy &amp; Biology" id="20944"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Childrens Hospital of Philadelphia" id="21052"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Howard Hughes Medical Institute" id="21084"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite De Montreal" id="21280"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Memorial Sloan-Kettering Cancer Center" id="22122"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nitto Boseki Co Ltd" id="22237"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>17</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>18</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agenus Inc" id="23221"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Albany Medical College" id="24139"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boston Children's Hospital" id="24334"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wellcome Trust Sanger Institute" id="24961"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yonsei University" id="25184"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Japanese National Cancer Center" id="25425"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kanazawa University" id="25555"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celldex Therapeutics Inc" id="25726"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Saitama Medical University" id="25996"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Genmab A/S" id="26469"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Queens University of Belfast" id="27130"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merrimack Pharmaceuticals Inc" id="27954"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>27</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>27</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Infinity Pharmaceuticals Inc" id="29753"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="VU University Medical Center" id="30810"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="JSR Corp" id="CM28169"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Wisconsin-Madison" id="DOL1000742"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>